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Abstract 
Gestational diabetes mellitus (GDM) is characterized by high blood glucose levels that first 
develop during pregnancy. GDM has been linked with many adverse short and long term 
health outcomes for the developing foetus as well as for the mother. The Developmental 
Origins of Health and Disease (DOHaD) concept suggests that in the presence of adverse 
stimuli, the foetus will adapt, through epigenetic mechanisms, to ensure its immediate 
survival.  For this reason, epigenetic modifications are emerging as mediators linking early 
environmental exposures during pregnancy with programmed changes in gene expression 
that alter offspring growth and development. The objective of this research study was to 
explore the role of altered gene expression and methylation in the development of GDM and 
determine whether these alterations are inherited by the exposed foetus. 
Transcriptome sequencing was performed on mRNA extracted from blood samples collected 
from six women with GDM and from six controls; as well as from exposed (N=6) and 
unexposed placenta (N=6). Genes that displayed significant (p<0.005) differential expression 
(log2 fold change >2 and <-2) between cases and controls were identified from the blood 
(N=60) and placenta (N=56) datasets. Gene ontology and enrichment was performed using 
DAVID and PANTHER with the aim to narrow down the candidate gene lists.  
The ten most likely candidate genes for differential gene expression from the blood dataset 
were G6PD, DCXR, TKT, ALDOA, PGLS, KCNQ1, C14orf80, KCNQ1, SLC25A22 and GSK3A. Gene 
enrichment revealed that five of these significantly under-expressed genes (G6PD, DCXR, TKT, 
ALDOA and PGLS) encode enzymes in the pentose phosphate pathway (PPP). In the placental 
dataset the top ten candidate genes were CXCR1, CXCR2, G6PD, TKT, IGFBP-1, IGFBP-2, IGFBP-
6, GGT3P, MMP12 and GLT1D1. The direction and fold change of differential expression of all 
twenty genes were validated using TaqMan qPCR probes. Of these twenty genes, the five most 
promising biological candidates (G6PD, TKT, IGFBP-1, IGFBP-2 and IGFBP-6) were identified 
and the level of promoter region methylation was assessed using EpiTech Methyl II PCR 
Assays. The level of methylation in the promoter region of G6PD in both blood and placenta 
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tissue was found to be significantly higher (p=1.90 x 10-5 and p=1.2 x 10-11 respectively) in the 
case groups, correlating with decreased mRNA expression levels. There was a significant 
negative correlation between G6PD mRNA expression in the blood and placenta with the level 
of maternal glucose at fasting (p=0.006 and p=0.001, respectively), 1-hr (p=0.016 and p=0.007, 
respectively) and 2-hr post OG (p=0.045 in placenta). We observed a significant positive 
correlation between G6PD promoter region methylation in both blood and placental tissues 
with maternal glucose levels at fasting (p=0.023 and p=0.001, respectively) and at 1-hr post 
OG (p=0.001 and p=0.004, respectively). IGFBP-1 was found to be significantly under-
expressed in exposed placental tissue and hypermethylated (p=1.1 x 10-6) at the promoter 
region when compared to unexposed samples. There was a significant negative correlation 
between the expression of IGFBP-1 mRNA in the blood and placenta with foetal birth weight 
(p=0.005 and p=0.017, respectively).  
Our results suggest that high glucose levels, an important characteristic of GDM, result in the 
disturbance of the pentose phosphate pathway, a pathway linked closely to glycolysis, and the 
IGF-axis, which is important in foetal growth and development. In GDM there is suppression 
of G6PD mRNA expression in both the blood and placental tissue which influences the pentose 
phosphate pathway. We hypothesize that this is mediated through an epigenetic mechanism 
since it is correlated with increased methylation of the G6PD promoter region. Down 
regulation of G6PD would suppress the PPP and reduce the levels of NADPH production, which 
may in turn lead to an increase in oxidative stress and an adverse outcome in the mother and 
foetus. With regard to the IGF-axis, our results demonstrated that IGFBP-1 and IGFBP-2 mRNA 
expression in the placenta may be inhibited due to the presence of high glucose and insulin 
levels and this decrease in mRNA expression is likely implicated in the abnormal foetal growth 
which is often associated with GDM.  
This study has provided novel insights into gene expression and DNA methylation changes in 
the blood of women with GDM and the placenta of their female offspring that involve genes 
in the PPP and the IGF-axis.  
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CHAPTER ONE 
1. INTRODUCTION 
1.1 Diabetes Mellitus in Sub-Saharan Africa (SSA) 
The incidence of diabetes, especially type 2 diabetes (T2D), is rapidly growing worldwide. In 
1980, an estimated 108 million people suffered with this chronic disease, which by year 2014, 
had increased to an estimated 422 million, representing 8.5 % of the worlds adult  population. 
Of this number, 80 % of these individuals live in developing countries (Roglic et al., 2005, 
Azevedo and Alla, 2008). Diabetes was once considered a rare disease in SSA however, like 
the rest of the world, SSA is experiencing an increasing prevalence of this disease. It is 
predicted that SSA will have the highest growth in the number of people affected by diabetes 
over the next 20 years. The prevalence of diabetes in SSA is projected to rise from 12.1 million 
in 2010 to an estimated 23.9 million in 2030, representing a 98 % increase in the number of 
individuals affected by the disease (Shaw et al., 2010, Tekola-Ayele et al., 2013). This 
proportion is more than double the predicted global increase of 37 % (Mbanya et al., 2011). 
Assessing the prevalence and incidence of diabetes in SSA is challenging because of the lack 
of data from many countries (Mbanya et al., 2011). The majority of the African diabetes is of 
type 2 (70 %–90 %), with only 25 % showing the complications of type 1 (Mufunda et al., 2006, 
Osei et al., 2003). Although there is a strong genetic predisposition to developing T2D, the 
alarming increase in its prevalence in SSA is mainly attributed to changes in lifestyle and diet 
with increased food intake and reduced energy expenditure (Alfaradhi and Ozanne, 2011, 
Mbanya et al., 2011). The process of urbanisation is occurring at a rapid rate in SSA and has a 
large influence on the prevalence of diabetes. The relocation to urban areas results in lifestyle 
changes as well as changes in dietary habits (Beaglehole and Yach, 2003). The prevalence of 
diabetes in urban residents is almost 4 times higher than in rural dwellers (Jamison et al., 2006) 
and this number is expected to increase substantially due to a high rate of urbanisation.  
 
Diabetes is a chronic disease that requires life-long treatment and significantly increases the 
risk of serious, long-term complications (Hall et al., 2011, Mossie et al., 2017). The rapid 
increase in the prevalence of diabetes in SSA poses a major and costly public health and 
socioeconomic burden. Offering the long-term monitoring and treatment needed is not easy 
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for the healthcare systems of SSA which are more concerned with managing severe infections 
(Azevedo and Alla, 2008). There are many factors which limit the appropriate diabetes care in 
SSA, namely inadequate healthcare systems, the shortage of adequately trained doctors and 
nurses and the unaffordability of medication (Mbanya et al., 2011). On an individual level, 
those affected with diabetes face many practical and financial problems. Not only is it difficult 
to reach treatment centres, but the necessary medication is expensive and often not 
affordable to many families affected with diabetes. With the double burden of both infectious 
and non-communicable disease in the SSA region, diabetes must compete for political 
attention and financial investment (WHO, 2013). It is possible to prevent this burden if 
effective interventions are implemented. Although the incidence of diabetes can be reduced 
by primary prevention and treatment, establishing effective diabetes programs in SSA, a 
region that requires a shift in the current public health priority, requires a larger amount of 
evidence to highlight the magnitude of the problem as well as the areas for intervention (Hall 
et al., 2011). Based on aetiology, diabetes mellitus has been classified into type 1 diabetes 
(T1D), type 2 diabetes (T2D) and gestational diabetes mellitus (GDM). T1D is the most studied 
type of diabetes and is characterised by the autoimmune destruction of pancreatic B-cells 
leading to insulin deficiency (Evangelista et al., 2014). Macrophages, dendritic cells and 
lymphocytes are involved in this pathogenic process through a complex interplay of 
mechanisms implicated in the loss of immune tolerance to autoantigens. T2D, a genetically 
heterogeneous disease with several rare monogenic forms and a number of common forms 
resulting from a complex interaction of genetic and environmental factors, is characterised by 
insulin resistance and pancreatic ß-cell dysfunction (Doria et al., 2008). T2D arises from an 
impairment in the ability of muscle, fat and liver to respond to insulin, combined with an 
inability of the ß-cells to respond normally to glucose by increasing insulin secretion (Kahn, 
1994). GDM is a complication of pregnancy that is characterised by impaired glucose tolerance 
with the onset or first recognition during pregnancy (Al-Badri et al., 2015). 
1.2 Gestational diabetes mellitus (GDM) 
1.2.1 Definition 
 
Diabetes can affect pregnancy in two ways; pre-gestational and gestational diabetes. Women 
diagnosed with type 1 diabetes (T1D) or T2D prior to conception are referred to as having pre-
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gestational diabetes but when pregnant women exhibit high fasting blood glucose levels first 
observed during pregnancy, it is referred to as gestational diabetes mellitus (Ben-Haroush et 
al., 2004, Jawad and Ejaz, 2016). GDM is defined as “any degree of glucose intolerance with 
onset or first recognition during pregnancy” (Durnwald, 2015, Karagiannis et al., 2010). GDM 
is characterized by β-cell function that is insufficient to meet the increased demand for insulin 
during pregnancy. The severity and prevalence of GDM, a heterogeneous disorder, is 
influenced by a number of different factors including genetic background, obesity and age 
(Butte, 2000). Although GDM resolves after delivery, uncontrolled GDM is associated with an 
increased risk of maternal and neonatal morbidity and predisposes the mother as well as the 
foetus to a higher risk of developing T2D, obesity and metabolic syndrome later in life. There 
are some striking parallels between GDM and T2D; GDM shares several risk factors with T2D 
and the pathophysiological changes of GDM and T2D are similar, both resulting by insulin 
resistance accompanied by an insulin-secretory defect (Buchanan, 2001). There is an observed 
association between GDM and the risk of developing T2D later in life (Eades et al., 2015, Kaaja 
and Ronnemaa, 2008, Kim et al., 2012, Noctor and Dunne, 2015). This suggests that GDM may 
serve as a window for determining predisposition to T2D (Robitaille and Grant, 2008).  
 
1.2.2 Pathophysiology 
Insulin resistance is one of the pathophysiological mechanisms which underlie the 
development of GDM (Catalano et al., 2003). The specific mechanisms underlying the 
development of the disease are unknown. It is believed that the secretion of pregnancy 
hormones (specifically, estrogen, human placental lactogen, cortisol and progesterone) 
(Figure 1.1) interferes with the action of insulin as it binds to the insulin receptor. This 
interference will result in a state of insulin resistance and an accumulation of glucose in the 
blood. Insulin resistance is a natural phenomenon occurring in all pregnancies to ensure that 
a sufficient amount of glucose reaches the developing foetus. To overcome this increase of 
glucose, more insulin secretion is required. However, in a certain percentage of women, the 
up-regulation of insulin secretion does not occur and glucose accumulation will continue to 
levels seen in non-pregnant T2D individuals (Gabbe, 1986, Poulakos et al., 2015). Maternal 
hyperglycaemia, foetal hyperinsulemia and foetal over nutrition is the result of this imbalance 
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between increased insulin resistance and maternal insulin production observed in GDM 
pregnancies. Although a number of explanations regarding the inability to regulate insulin 
needs during pregnancy have been proposed, the reason remains unknown. The clinical 
presentation of GDM is well defined however, the mechanism underlying the development of 
this disease is still not well understood (Catalano et al., 2003; Hajj et al., 2014).  
                     
Figure 1.1. The proposed pathophysiology of gestational diabetes. Placental hormones partially block the action 
of insulin which results in insulin resistance in pregnant women. Normally, there is an up-regulation of insulin 
secretion from ß-cells to restore this insulin resistance, however in a certain percentage of women, this up-
regulation does not occur and glucose will accumulate, resulting in GDM.  
 
1.2.3 Prevalence 
Gestational diabetes mellitus is characterized by glucose intolerance that first becomes 
apparent during pregnancy. GDM is becoming a major public health concern as its prevalence 
has doubled over the past 20 years, affecting approximately 16.9 % of pregnancies worldwide 
(Arora et al., 2013, Gilmartin et al., 2008, Robitaille and Grant, 2008). Macaulay et al. (2014) 
reviewed data from 14 studies conducted in six African countries and reported the prevalence 
of GDM to range from 0 % in Tanzania to 13.9 % in women from Nigeria (Macaulay et al., 
2014). A more recent review reported data from 22 studies in six African countries and 
observed that, regardless of the diagnostic criteria and study setting, the prevalence of GDM 
in SSA is in a range comparable to the 2-6 % reported for European countries (Mwanri et al., 
2015). These data show that the prevalence of GDM varies depending on the diagnostic 
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criteria used and also between racial and ethnic groups (Buchanan, 2001, Buchanan and Xiang, 
2005, Noctor and Dunne, 2015). Studies that compared different diagnostic criteria found that 
there were significant differences in the reported prevalence of GDM in SSA (Mwanri et al., 
2015), however, in line with an increasing prevalence of T2D, the incidence of GDM in SSA is 
also on the rise (Petry, 2010).  
1.2.4. Risk Factors  
There are a number of different factors that will increase a woman’s risk of developing GDM 
(Bottalico, 2007, Zhang et al., 2016). The risk factors for GDM share similarities with those for 
T2D with the common factors including a previous history of GDM or impaired glucose 
tolerance (Zhang and Ning, 2011), obesity, ethnicity (higher risk for those of African, Asian, 
Hispanic, and Native American descent), advanced maternal age (older than 35 years), a family 
history of T2D (Zhang and Ning, 2011), a history of spontaneous abortions and unexplained 
stillbirths as well as polycystic ovarian syndrome and pregnancy related hypertension 
(Gilmartin et al., 2008, Petry, 2010).  
The presence of GDM has been linked with short and long term risk factors for both the 
mother and her offspring (Enquobahrie et al., 2009). Short-term risks associated with GDM in 
the mother include a higher incidence of pre-eclampsia (Oats and Beischer, 1986), 
unexplained stillbirths and spontaneous abortions, urinary tract infections, increased risk of 
congenital abnormalities as well as an increased risk of postpartum bleeding, pregnancy-
induced hypertension and abnormal weight gain. GDM has long been known to increase the 
risk of macrosomia (birth weight > 4 kg) in the offspring (Petry, 2010). GDM-associated 
macrosomia is linked to increased rates of a variety of complications, including shoulder 
dystocia, brachial plexus injuries and clavical fractures which occur during natural birth, 
leading to a higher requirement for Caesarean section (Catalano et al., 2003, Petry, 2010, 
Watanabe, 2011). Diabetic pregnancy induces marked abnormalities in glucose homeostasis 
and insulin secretion in the foetus, resulting in foetal hyperglycaemia and abnormal foetal 
growth (Lehnen et al., 2013, Pinney and Simmons, 2012, Vambergue and Fajardy, 2011). 
Short-term risks for the baby include neonatal hypoglycaemia (Watanabe, 2011); neonatal 
cardiac dysfunction; respiratory stress disorder; hyperbilirubinemia and hypocalcaemia 
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(Petry, 2010, Robitaille and Grant, 2008). Other early effects of GDM on the foetus include 
jaundice, polycythemia, hypocalcemia, hypomagnesemia, and prematurity (Yang et al., 2002). 
Women who develop GDM have an increased risk (ranging from 17 % - 63 %) of developing 
T2D, within 5 - 16 years after pregnancy, depending on population group and other risk factors 
(Robitaille and Grant, 2008). As well as long-term risks for herself, her offspring will have 
increased risk of developing childhood obesity, T2D and hyperlipidaemia in adolescence as 
well as developing adult onset disease such as cardiovascular disorders (Law et al., 2015, 
Pettitt et al., 2008). When the offspring is female, exposure to maternal diabetes in utero 
increases their risk of developing GDM in their own pregnancies (Claesson et al., 2007). This 
metabolic programming by in utero exposure to hyperglycaemia is a transgenerational effect 
that may contribute to the large increase in the prevalence of T2D worldwide (Petry, 2010).  
 
1.2.5 Screening and Diagnosis 
Gestational diabetes mellitus, a condition that is generally asymptomatic, is only diagnosed if 
screening is done during pregnancy (Buchanan et al., 2012). Despite the increasing evidence 
showing that untreated GDM is associated with short and long term risks to the mother and 
her offspring, controversy remains regarding screening tests, diagnostic tests and the level of 
hyperglycaemia that is diagnostic of GDM (Gilmartin et al., 2008). There are two primary 
methods used to screen for GDM, a universal approach method and a risk factor based 
method (Figure 1.2)(Gilmartin et al., 2008, Rani and Begum, 2016). The universal screening 
approach maximizes sensitivity and will identify women with GDM who have no risk factors 
whereas the risk factor based approach is more cost effective due to its selective screening of 
women who have the most common GDM risk factors (Berger and Sermer, 2009).                 
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Figure 1.2: Universal and risk factor based strategies for screening pregnant women for GDM. The most 
common risk factors include family history of the disease, excess weight, ethnic groups and age greater than 25 
years.  
 
Diagnostic tests differ from the above-mentioned screening tests. GDM is usually diagnosed 
using some kind of Oral Glucose Tolerance Test (OGTT). During the years there have been 
different diagnostic criteria for the diagnosis of GDM but all provide diagnostic cut-off levels 
for diabetes using blood glucose concentrations (Schneider et al., 2003). There are a number 
of different diagnostic criteria used to classify diabetes during pregnancy. O’Sullivan and 
Mahan proposed the first criteria for the diagnosis of GDM in 1964 (O'Sullivan and Mahan, 
1964). These criteria were later modified by Carpenter and Couston (Carpenter and Coustan, 
1982). Both these early criteria focused mainly on the mother’s postpartum risk of developing 
diabetes because the adverse risk to the foetus was not yet known. The World Health 
Organization (WHO) criteria from 1985 are still widely used throughout the world for the 
diagnosis of GDM (WHO, 2013), however the more recently published guidelines have revised 
the diagnostic value thresholds that are indicative of GDM. The American Diabetes Association 
(ADA) recommendations are based on the Carpenter-Couston 100 g OGTT criteria (Karagiannis 
et al., 2010) and are used to screen all pregnant women in the USA. Based on the 
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study published in 2008 (Metzger 
et al., 2008), new recommendations were made by the ADA (Couston et al., 2010). This 
multicentre, multinational observational study of 25,000 pregnant women aimed to identify 
a relationship between maternal hyperglycaemia (less severe than overt diabetes) and 
adverse pregnancy outcomes. They found that the risk for macrosomic babies, neonatal 
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hypoglycaemia, increased C-peptide levels and caesarean delivery increased with an increase 
in the mother’s glucose levels, even if they were below the value for GDM (Lowe et al., 2012, 
Metzger et al., 2008). Since this study, the International Association of Diabetes and Pregnancy 
Study Group (IADPSG) recommended that all pregnant women without known diabetes 
undergo a 75 g OGTT at 24 - 28 weeks gestation and that their fasting glucose, 1-hour and 2-
hour glucose levels be considered important in the diagnosis of GDM (Bernasko, 2016). Using 
HbA1c in screening for GDM (instead of an OGTT) has been studied but was found to be 
controversial and resulted in misclassification and misdiagnosis (Salmeen, 2016). However, 
recent studies have confirmed that the HbA1c test can be used for the diagnosis of GDM but 
in conjunction with the OGTT (Aldasouqi et al., 2008, Soumya et al., 2015). Therefore, the 
OGTT remains the gold standard for GDM diagnosis. However, there are still no universal 
recommendations for the ideal approach for the screening and diagnosis of GDM today. With 
the number of women who develop GDM during pregnancy increasing at an alarming rate 
(Liao et al., 2012) and the increasing evidence that GDM is associated with adverse pregnancy 
outcomes for mothers and their offspring (Kalter-Leibovici et al., 2012), screening of all 
pregnant women should be done routinely. 
1.2.6 Treatment and prevention 
Although there are no evidence-based studies which indicate that the prevention or treatment 
of GDM minimize maternal or foetal complications (Jovanovic, 2001, Jovanovic and Pettitt, 
2001), there have been a number of studies done which aim to demonstrate the effect 
treatment has on GDM (Bancroft et al., 2000, Elnour et al., 2008, Nachum et al., 1999). 
Nutritional intervention for women with GDM has been recognised as the cornerstone of 
management therapy (Funnell et al., 2007), although other treatment types include 
interventions to control blood glucose, diet control, glucose monitoring, insulin use and 
pharmaceutical intervention (Horvath et al., 2010, Kalter-Leibovici et al., 2012). These studies 
demonstrated that these treatment types did significantly reduce the risk of adverse perinatal 
and neonatal outcomes (Kalra et al., 2016, Tobias et al., 2011, Tobias, 2011) and highlight that 
the prevention of GDM is crucial in avoiding the adverse outcomes often associated with 
GDM. Physical activity is known to improve glucose homeostasis through its direct and indirect 
effects on insulin sensitivity (Colberg et al., 2013). Physical activity has independent effects on 
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glucose disposal by increasing insulin mediated and non-insulin mediated glucose disposal 
(Tobias et al., 2011, Tobias, 2011). The long-term effects of physical activity include a 
significantly improved insulin sensitivity through increased fat free mass. However, more data 
are required to significantly show the impact physical activity in women with GDM has in the 
prevention of, or delay in, the development of T2D (Colberg et al., 2013, Tobias et al., 2011). 
A review written in 2015 (Sanabria-Martinez et al., 2015) found that moderate physical 
exercise done during pregnancy was effective for the prevention of GDM, however, a study 
done by Yin et al. (2014) did not find a significant effect (Yin et al., 2014) suggesting that the 
effect physical activity has on GDM and the consequent development of T2D remains 
controversial.  
1.3.  Developmental programming of adult disease 
Diabetes is a complex trait that results from interactions between genes, dietary intake, 
physical inactivity and other environmental factors. Although a number of genes have been 
known to play a role in the development of diabetes, the genetic component alone cannot 
account for the dramatic increase in the prevalence of this disease and environmental factors 
must be important triggers (Vickers, 2011). Therefore, the development of diabetes, a 
multifactorial disease, is influenced by genetic and environmental factors. Environmental 
factors which have the ability to modify genetic risk are important in the development of 
diabetes (Murea et al., 2012). Epigenetics may be the molecular link between environmental 
factors and diabetes.  These environmental factors may cause epigenetic changes that can 
persist into adulthood. Relevant epidemiological studies have observed an association 
between the in utero environment and the subsequent development of adult disease. The 
terms “developmental programming” and the “developmental origins of adult health and 
disease (DOHaD)” are used to describe these associations (Charles et al., 2016).  
1.3.1 The theories of developmental programming 
It is now well recognized that the in utero environment influences key developmental 
processes and has long-lasting effects on health and disease (Hajj et al., 2014). In 1986, 
Freinkel proposed the ‘fuel-mediated teratogenesis’ concept which postulates that foetal 
hyperinsulemia in pregnancies affected by GDM, is a result of the increase in glucose (Freinkel 
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et al., 1986). This has immediate as well as long-lasting consequences for the offspring (Hajj 
et al., 2014). In the early 1990s, Barker and Hales (1992) proposed the concept of foetal 
metabolic programming which stated that “foetal and perinatal events, such as maternal over 
and under-nutrition, were crucial in determining the risk of developing chronic metabolic 
diseases in adulthood” (Hales and Barker, 1992).  
The thrifty hypothesis describes how intrauterine malnutrition influences foetal development 
and increases the offspring’s risk of developing adult disease (Chen and Zhang, 2011). This 
hypothesis suggests that the exposure to a nutritionally suboptimal in utero environment will 
result in a permanent alteration of glucose metabolism, thereby increasing the risk of 
developing T2D in adulthood. In 1993, Barker et al. (1993) hypothesized that neonates born 
with low birth weight, a marker for an adverse in utero environment, had increased 
susceptibilities for developing metabolic diseases in adulthood (Barker et al., 1993, El Hajj et 
al., 2014b, Hanson et al., 2004). This hypothesis is commonly referred to as the DOHaD 
hypothesis and is referred to in more detail in Section 1.3.2. Keeping the perspective of DOHaD 
in mind, Hanson and Gluckman (2004) proposed the Predictive Adaptive Response hypothesis, 
which states that “foetal reprogramming, induced by in utero exposures, is a short term 
adaption to the predicted environment in order to enhance the survival of the individual”. It 
is hypothesized that these adaptions may occur through epigenetic changes (Gluckman and 
Hanson, 2004, Ueda, 2013). In this way, the foetus is predicting what its early life nutritional 
environment will be like based on its in utero exposure. Although this adaption may improve 
the chances of survival in the short term, they may be deleterious to long term health given a 
more nutrient rich environment (Hales and Barker, 1992, Ueda, 2013). The problem of 
“mismatch” occurs when individuals adapt to one environment during development and are 
then exposed to another after birth. The association observed between increased 
susceptibility to developing adult onset diseases and nutritionally adverse in utero 
environments is of particular interest in low and middle income African countries (Hobbs and 
Ramsay, 2015). In these countries, people are born into rural environments that are nutrient 
scarce and move to urban areas where they are exposed to unhealthy diets, smoking, drinking, 
and become less active (all NCD risk factors). The rapidly increasing burden of disease in these 
developing economies may be underpinned by in utero exposure to nutrient poor 
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environment (Puoane, 2008, Ueda, 2013). This phenomenon is thought to be involved in the 
current T2D epidemic (Brenseke et al., 2013). The current surge in metabolic and 
cardiovascular disease in SSA may be fueled by a combination of under-nutrition in early life 
and over-nutrition in later life.  
1.3.2 The DOHaD hypothesis 
It is well known that the phenotype of an individual can be determined by both the in utero 
and early postnatal environmental conditions such as the nutritional state of the mother 
(Alfaradhii et al., 2011). Barker and colleagues observed that the starvation of pregnant 
women during the Dutch ‘hunger winter’ of the second world war correlated with an increased 
risk of cardiovascular and metabolic diseases in their offspring later in life (Barker et al., 1993, 
Heindel and Vandenberg, 2015). Hence, a link between early life environmental factors and 
later life diseases was observed. These observations opened a new and exciting area of 
research. DOHaD is a multi-disciplinary field that studies how “environmental factors acting 
during the phase of developmental plasticity interact with genotypic variation to change the 
capacity of the organism to cope with its environment in later life” (Gluckman and Hanson, 
2004, Uauy et al., 2011). Substantial experimental evidence from different mammalian species 
has supported the hypothesis that an adverse intrauterine environment may alter the 
embryo’s development through predictive adaptive responses. It is believed that these 
responses are adaptations made by the embryo in response to a particular maternal 
environment to ensure its immediate survival in utero and to prepare itself for postnatal life. 
It is likely that a disease phenotype will arise if there is a mismatch between the in utero diet 
and postnatal diet (Trussler, 2010). Evidence from epidemiological studies as well as animal 
models suggest that the intrauterine environment does play a role in the development of 
metabolic disorders. A suboptimal maternal nutrition, whether under- or over-nutrition, has 
negative effects on the offspring (Williams et al., 2014). 
1.3.2.1 Evidence from human epidemiological studies for maternal nutrition 
influencing early life exposure to disease risk  
Two separate studies examined the relationship between glucose concentrations at 28 weeks 
gestation and the development of early childhood obesity. Deierlein et al. (2011) observed a 
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two-fold greater risk of childhood overweight/obesity at 3 years of age when comparing 
maternal glucose concentrations ≥130 mg/dL to maternal glucose concentrations less than 
100 mg/dL during GDM testing. These results indicate that foetal exposure to high glucose 
concentrations may contribute to the development of overweight/obesity in the offspring 
(Deierlein et al., 2012, Kim et al., 2012). Pettit et al. (2010) evaluated the relationship of 
glycemic levels during pregnancy with anthropometric data of the offspring from diabetic and 
nondiabetic mothers of the HAPO study. They found a significant association with maternal 1-
hour blood glucose levels and offspring BMI at two years of age. Crume et al. (2011) examined 
the association between exposure to maternal diabetes in utero and BMI growth trajectories 
from birth through age 13 years. After adjusting for sex and ethnicity, they observed that the 
overall BMI growth trajectory was not significantly different between exposed and unexposed 
offspring from birth to 26 months. However, from the age of 27 months to 13 years, the BMI 
growth trajectory for exposed offspring was significantly greater than that of unexposed 
offspring (Crume et al., 2011). 
Following the initial work of Barker et al. (1993) that demonstrated a relationship between 
low birth weight and an increased risk of adult disease, the importance of maternal nutrition 
was addressed in studies of famine exposure (Vickers, 2011). The Dutch Hunger Winter study 
demonstrates the long-lasting effects that nutritionally adverse in utero and/or neonatal 
environments have on health and disease (Lehnen et al., 2013). This Dutch Hunger Winter 
cohort included men and women who were exposed in utero to the Dutch famine of 1944-
1945 (Heijmans et al., 2008, Lehnen et al., 2013). Individuals exposed to a nutritionally adverse 
(under-nutrition) in utero environment exhibited an increased risk for metabolic diseases (El 
Hajj et al., 2014a). They also observed that women who were pregnant during this period and 
therefore exposed to environmental stress and nutrient restriction throughout their 
pregnancy, gave birth to infants who had a decreased birth weight and increased insulin 
resistance (Lumey et al., 2007) when compared to their unexposed siblings.  
 
In rural Gambia, there is seasonal variation in the availability of micronutrients with an 
alternation between the dry season (when food is plentiful) and the wet season (when there 
is less food available and therefore poorer nutrition) (Waterland et al., 2010). During the 
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nutritionally poor rainy season, a high incidence of deficiencies in several essential 
micronutrients has been observed in pregnant women (Waterland et al., 2010). This seasonal 
deficiency is associated with an increased incidence of low birth weight, as well as childhood 
morbidity and mortality (Khulan et al., 2012, Waterland et al., 2010). Another famine study 
which demonstrates the long-lasting effects nutritionally adverse in utero and/or neonatal 
environments have on health and disease is the Nigerian (Biafran) famine of 1967 – 1970 (Hult 
et al., 2010). The Biafran famine cohort consists of 1,339 Igbo individuals who were born 
before, during and after the Biafran famine (between 1965 and 1973). Hult et al. (2010) 
observed an increased risk of adult hypertension, glucose intolerance and obesity in 
individual’s exposed to the famine in utero or in infancy (Hult et al., 2010). This study highlights 
that the prevention of under-nutrition during pregnancy and in infancy must become a high 
priority in health, education, and economic agendas (Hult et al., 2010, Ueda, 2013).  
1.3.2.2. Evidence from animal studies  
Animal models have been used extensively to study the physiological principles of the DOHaD 
hypothesis and are essential in studying the mechanistic links between prenatal and postnatal 
influences and the risk for developing the metabolic syndrome in later life (Vickers, 2011). A 
large number of studies have used dietary restriction (such as a protein and/or calorie 
restriction) as a model for observing the effects of maternal under-nutrition. A study 
performed by Yura et al. (2005) showed that offspring of dams fed a relatively modest 70 % 
nutrient restricted diet developed obesity and adiposity when compared to controls. In 2004, 
Bellinger and colleagues observed that the offspring of dams fed a 50 % protein restricted diet 
showed an increased appetite for energy dense food in early life when compared to controls 
(Bellinger et al., 2004). Although initial studies focused mainly on the effects of maternal under 
nutrition such as diet low in protein or calories, recent studies have focused on the effects of 
maternal over-nutrition (maternal high fat diet). In one such study, Samuelsson et al. (2008). 
Observed that the offspring of dams fed a palpable obesogenic diet exhibited increased 
adiposity as well as cardiovascular and metabolic dysfunction when compared to controls 
(Samuelsson et al., 2008). A study done later by the same researchers found that feeding 
sucrose to a mouse during pregnancy leads to hypertension and insulin resistance in female 
offspring (Samuelsson et al., 2013). These studies suggest that an adverse in utero nutritional 
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environment programs the development of a metabolic syndrome-like phenotype (Rinaudo 
and Wang, 2012).   
1.4. Epigenetic mechanisms in developmental programming of adult disease 
Although there have been several hypotheses proposed to explain the associations between 
in utero environment and adult health (Rinaudo and Wang, 2012), it is still is not well 
understood how foetal developmental plasticity enables organisms to make adaptive 
responses to the foetal environment that can result in permanent adverse effects later in life 
(Koukoura et al., 2012). Recent studies have suggested that the environment influences 
epigenetic processes that regulate gene expression patterns, and might play key roles in the 
developmental programming of adult disease (Chen and Zhang, 2011). The ability of the 
organism to change its structure and cellular function in response to the environment is 
known as developmental plasticity which, in turn, is known to act through epigenetic changes 
in gene transcription, alterations in tissue differentiation and changes in homeostatic 
processes (Gluckman and Hanson, 2004, Liguori et al., 2010). These epigenetic changes are 
established early on in life and control the expression of certain genes during development. 
Disease arises from a mismatch between deprived in utero environment (for which epigenetic 
adaptions have been imposed in early development) and a comparatively rich postnatal 
environment (Rinaudo and Wang, 2012). The plasticity of the developmental process allows 
the organism to respond to the surrounding environment during early development when 
cells are differentiating and tissues developing. Although this plasticity allows the organism to 
adapt to changing environments, interference with these developmentally adaptive processes 
may have adverse effects on functions and increase risk for disease later in life (Barouki et al., 
2012). It is during the developmental stage that epigenetic marks undergo critical 
modifications. Once a tissue or biological system is fully developed, it is less sensitive to 
environmental stimuli. Therefore the most sensitive period for epigenetic effects is different 
for each tissue and may extend into childhood or perhaps puberty or beyond (Barouki et al., 
2012). Epigenetic changes that occur as a result of maternal diabetes may predispose the 
offspring to develop metabolic disease in adulthood. These epigenetic signatures of adverse 
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environmental exposure may be transmitted to successive generations. This cycle could 
contribute to the worldwide metabolic disease epidemic. 
 (El Hajj et al., 2014).  
 
1.4.1 Introduction to epigenetics 
The term epigenetics refers to the “stable and heritable patterns in gene expression that do 
not involve alterations in DNA sequence” (Cazaly et al., 2015). There are three main epigenetic 
mechanisms, namely, DNA methylation, histone modification and RNA interference (Moore 
et al., 2013). These epigenetic modifications are important for normal development and 
differentiation of distinct cell lineages in the adult organism (Handy et al., 2011). DNA 
methylation is a post-replication modification that is predominantly found in the cytosines of 
the dinucleotide sequence cytosine-phosphate-guanine (CpG) (Brenseke et al., 2013). In 
addition to DNA methylation, there are proteins which are associated with the organisation 
of DNA into nucleosomes. These proteins are known as histones and are subject to a large 
number of post-translational modifications (methylation, acetylation and/or phosphorylation) 
which control the structure and/or function of the chromatin (Brenseke et al., 2013, 
Sadakierska-Chudy and Filip, 2015).  
Epigenetic modifications are flexible and can be modified by external influences (Handy et al., 
2011). They also provide a mechanism that ensures the stable propagation of gene activity 
from one generation of cells to the next (Bollati and Baccarelli, 2010). Failure and/or improper 
reprogramming of the epigenetic machinery has been implicated in a broad range of diseases. 
Epigenetic modifications can be cell, tissue and sex specific as well as time dependant (Barouki 
et al., 2012). Each of the >200 cells types in the body have a specific combination of silenced 
and expressed genes, which are established during development and differentiation and 
stably inherited during cell divisions (Lehnen et al., 2013). Epigenetic modifications are 
influenced by several factors such as the environment, lifestyle, age and disease state and are 
not only sensitive to nutrients and physiological factors, but also to drugs, tobacco smoke, 
alcohol, industrial chemicals and other environmental exposures (Figure 1.3) (Barouki et al., 
2012).  
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Figure 1.3: The link between an adverse in utero environment and epigenetic modifications. These epigenetic 
modifications take place in the developing foetus and may have lifelong consequences (taken from (Hobbs and 
Ramsay, 2015)). 
 
1.4.2 DNA methylation 
Since DNA methylation has the ability to modulate gene expression, which is a major 
determinant of many diseases, it has been suggested as a possible mechanism through which 
the exposure to an adverse in utero environment translates into the development of diseases 
(Alfaradhi and Ozanne, 2011, Waterland et al., 2010). DNA methylation appears to be the most 
dominant and best-studied epigenetic modification (Chen and Zhang, 2011) and is a heritable 
yet reversible epigenetic mark that can be stably propagated following DNA replication (Jin et 
al., 2011). DNA methylation involves the addition of a methyl group to the fifth carbon in CpG 
sites (Moore et al., 2013). The process of donating a methyl group to the 5-cytosine residue is 
catalysed by several enzymes known as DNA methytransferases (DNMTs). In humans, DNA 
methylation patterns are “established by the DNA methyltransferase DNMT3 family of de 
novo methyltransferases and maintained by DNMT1” (Law and Jacobsen, 2010). 
 
In the non-coding regions of the genome, the majority of CpG dinucleotides are methylated 
in order to prevent retrotransposition activity. Unmethylated CpGs are usually clustered 
together in ‘CpG islands’, which are located within the promoter region of genes (Bird, 2002, 
Hill et al., 2011). In normal cells, the promoter CpG islands are typically unmethylated and are 
associated with active gene expression during differentiation and development. The 
methylation of these CpG islands during development or disease processes is associated with 
post-translational histone modifications. This modification results in a condensed inactive 
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chromatin structure and ultimately gene silencing (Lehnen et al., 2013). There are other 
regions of DNA methylation and intermediate CpG densities which exist across the genome, 
often in the body of genes. CpG island ‘shores’ are regions of comparatively low CpG density, 
located approximately 2 kb from CpG islands and exhibit tissue- and cancer-specific 
differential methylation (Fan and Zhang, 2009, Fernandez et al., 2012). Beyond CpG islands 
and shores, the remainder of genome displays a lower frequency of CpG sites (Stirzaker et al., 
2014). 
 
DNA methylation is crucial for normal mammalian development and is an important 
component for many cellular processes such as “embryonic development, genomic 
imprinting, X-chromosome inactivation and preservation of chromosome stability” (Sadikovic 
et al., 2008). DNA methylation typically represses transcription by inhibiting the binding of 
transcription factors or by recruiting DNA binding proteins that remodel chromatin structure 
(Gaunt et al., 2016). For this reason, the establishment and maintenance of DNA methylation 
patterns are crucial for normal cellular function. Methylation patterns are established during 
embryogenesis in a spatiotemporal manner and are dynamic across an individual’s lifetime 
(Hirasawa et al., 2008). The erasure of DNA methylation patterns of the gametes in the zygote 
occur immediately after fertilization (Trerotola et al., 2015) and are re-established as 
embryonic implantation occurs (Messerschmidt et al., 2014). This implicates this early stage 
of development as a critical window in the regulation of methylation and therefore gene 
expression and developmental programming (Ho et al., 2012). Any alteration to the in utero 
environment during early development can lead to permanent changes in the pattern of DNA 
methylation (Bollati and Baccarelli, 2010). Changes in methylation status (hyper- or 
hypomethylation) have been implicated in the development of certain disorders and disease 
(Jaffe and Irizarry, 2014) and may be a potential link between genome, environment and 
disease (Barfield et al., 2014, Relton et al., 2012). 
 
1.4.2.1 Epigenetic multigenerational inheritance 
One of the more fascinating and significant findings related to the DOHaD paradigm is that 
disease risk can be transmitted across generations. This indicates that not only are the somatic 
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cells perturbed but so are the gametes which will give rise to the next generation. 
Multigenerational inheritance is when genetic information is inherited from the F0 generation 
(mother) by the F1 (child) or F2 (grandchild) generation. Epigenetic inheritance is therefore 
the transmission of epigenetic marks from one generation to the next (Jirtle and Skinner, 
2007). These epigenetic marks can be induced by environmental factors such as nutrition, 
temperature, stress and environmental toxicants (Hanson and Skinner, 2016). Epigenetic 
multigenerational inheritance occurs at a critical window of exposure linked to the 
development of the germ cells (sperm and egg)(Hanson and Skinner, 2016). When germ cells 
are developing, all epigenetic marks are erased through the process of reprogramming, 
allowing them to become pluripotent cells (Heard and Martienssen, 2014). Epigenetic marks 
are added back in a time- and sex-specific manner. Thus if germline reprogramming fails, these 
epigenetic marks can be retained and transmitted from one generation to the next. At 
fertilization, the sperm and egg provide their epigenome which has been modified during 
spermatogenesis and oogenesis, respectively.  Even the smallest change to the epigenomes 
by various environmental factors can have significant effects on the developing offspring.  The 
exposure of maturing oocytes and developing pre-implantation embryos to maternal diabetes 
is sufficient to re-program the foetal epigenome permanently, resulting in significant 
morphological changes (Hanson and Skinner, 2016).  
 
1.4.2.2 Evidence for DNA methylation influencing early life exposure to disease 
risk in animal studies  
There is an increasing amount of evidence that supports the role of environmentally-induced 
epigenetic changes in disease susceptibility. Animal studies have demonstrated that 
nutritional factors can modify the epigenome of the developing offspring (Lehnen et al., 2013, 
Brenseke et al., 2013, Plagemann et al., 2009).  One of the most impressive animal model 
examples of the epigenetic effects of maternal nutrition on the foetus is the viable yellow 
agouti (Avy) mouse model, in which coat colour variation is correlated to epigenetic marks 
established in early development (Dolinoy, 2008, Dolinoy and Jirtle, 2008, Vickers, 2011). The 
agouti gene is present in all mammals and functions in the determination of coat colour. 
Transcription of this gene occurs in the skin only for a short period, after which it is silenced 
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through DNA methylation (Blewitt and Whitelaw, 2013). A transposable intracisternal A 
particle (IAP) element was inserted upstream of the agouti gene transcription start site. This 
created a metastable epiallele that could be switched on or off during early development 
(Kanherkar et al., 2014). The degree of methylation that occurs at this IAP element correlates 
inversely with agouti gene expression and hence the phenotype of the mouse (Dolinoy and 
Jirtle, 2008, Lehnen et al., 2013). When the degree of methylation at the epiallele was 
increased by adding methyl donors to the mother’s diet (Daxinger and Whitelaw, 2010), the 
offspring appeared healthy and displayed a brown coat.  This brown coat colour or wild type 
phenotype is the result of hypermethylation at the IAP element which suppresses agouti gene 
expression. Hypomethylation of the IAP element increases agouti expression and results in a 
yellow coat phenotype which is correlated with the susceptibility to metabolic diseases, 
cancers and obesity (Lehnen et al., 2013).   
In a study done by Plagemann et al. (2009), epigenetic changes in the hypothalamic 
proopiomelanocortin (Pomc) and insulin receptor (Insr) genes were associated with neonatal 
over feeding of rats (Plagemann et al., 2009). The level of DNA methylation was directly 
dependant on the amount of glucose given to the rats. Another example of environmentally-
induced epigenetic changes is reduced pancreatic and duodenal homeobox 1 (Pdx1), also 
known as insulin promoter factor 1, gene expression in a rat model of intrauterine growth 
restriction (Brenseke et al., 2013). A reduced expression of the Pdx1 gene (transcription factor 
necessary for the development and function of the insulin producing pancreatic 𝛽-cell) was 
observed in the 𝛽-cells of the rats experiencing intrauterine growth restriction. These rats 
went on to develop T2D in adulthood. A cascade of epigenetic modifications mediates the 
reduced Pdx1 expression (Park et al., 2008).  
1.4.2.3 Evidence from human studies 
Although data from humans is still limited, the Dutch Hunger Winter famine of 1944-1945 has 
been used by various investigators as an equivalent to an experimental study to investigate 
the long-lasting effects that an nutritionally adverse in utero environment has on health and 
disease in humans (Hanson and Gluckman, 2014). Heijmans et al. (2008) showed that exposed 
individuals had, almost 60 years later, less DNA methylation at the imprinted insulin growth 
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factor 2 (IGF2) gene when compared to their same-sex, unexposed siblings (Heijmans et al., 
2008). This finding reinforced the idea that early life exposures can cause epigenetic changes 
that persist throughout a person’s life (Ruchat et al., 2013a, Ruchat et al., 2013b). In 2009, 
Tobi et al, investigated the methylation levels of 15 genes implicated in growth and metabolic 
disease in exposed and unexposed individuals from the Dutch Hunger Winter Cohort. They 
observed that the methylation of the insulin induced protein factor gene (INSIGF) was lower 
and methylation of interleukin-10 (IL10), leptin gene (LEP), ATP-binding cassette, sub-family A 
(ABCA1), GNAS antisense RNA (GNASAS) and maternally expressed gene 3 (MEG3) was higher 
among exposed individuals when compared with their unexposed same-sex siblings. They also 
observed a significant interaction between the sex of the individuals and level of methylation 
in INSIGF, LEP and GNASAS. Exposed individuals had significantly altered levels of DNA 
methylation in a number of genes as well as a higher incidence of chronic diseases such as 
obesity, cardiovascular disease and diabetes when compared to unexposed siblings. The 
findings from these studies support the hypothesis that DNA methylation changes that occur 
in certain genes may be the result of exposure to prenatal famine and that the level of 
methylation change depends on the sex of the exposed individual (Tobi et al., 2009).  
In a study of two prospective cohorts, Godfrey and colleagues measured the methylation 
status of CpGs in the promoters of candidate genes using DNA extracted from umbilical cord 
tissue obtained at birth in children who were later assessed for adiposity at 9 years of age  
(Brenseke et al., 2013, Godfrey et al., 2011). They found a correlation between the 
methylation status of the retinoid X receptor-𝛼 (RXRA) (in cohort 1 and 2) and endothelial 
nitric oxide synthase (eNOS) (in cohort 1 only) gene at birth with greater adiposity in later 
childhood. This observation suggests that epigenetics is involved in foetal programming of 
later obesity (Brenseke et al., 2013). In 2013, Ruchat et al, reported on the impact of GDM 
exposure on offspring DNA methylation levels across the genome in placental and cord blood 
samples (Ruchat et al., 2013a). They observed that a large number of genes in the placenta 
and cord blood are differentially methylated between samples from foetuses exposed or not 
exposed to GDM and these genes are predominantly involved in metabolic disease pathways. 
They also observed a correlation between the level of DNA methylation at 326 genes in the 
placenta and 117 genes in cord blood with neonate birth weight. In a more recent study, the 
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DNA methylation profiles of 14 metabolic programming candidate genes were analyzed in 
cord blood and placental samples (El Hajj et al., 2013). The maternally imprinted MEST gene 
and non-imprinted glucocorticoid receptor (NR3C1) gene showed a significant decrease in the 
DNA methylation levels in GDM samples when compared to controls in both tissue types 
(Bouchard, 2013, Ruchat et al., 2013a).  
In 2012, Khulan et al, aimed to determine whether periconceptional maternal micronutrient 
supplementation affects genome-wide methylation within gene promoters in the foetus. They 
took cord blood samples from offspring of Gambian mothers who were taking micronutrient 
supplementations, or placebos, during the pre- and periconceptional period. They observed a 
significant association between micronutrient supplementation and changes in DNA 
methylation of CpG loci.  These significant changes in the epigenome in cord blood DNA were 
also present in infant blood DNA samples taken at 9 months, proving that a majority of these 
changes are persistent. These results not only highlight the importance of micronutrient 
supplementation during the rainy season and around the time of conception in Gambia but 
also support the idea that the nutritional environment in which a foetus develops can 
influence the epigenetic programming of gene activity later in life (Khulan et al., 2012). 
1.4.2.4 Factors causing DNA methylation variation 
When interpreting the role of epigenetic variation in a complex disease, it is important to 
consider all the factors that may be a source of epigenetic variation (Figure 1.4). It is well 
known that environmental and fixed genetic factors are a source of epigenetic variation 
observed between individuals (Teh et al., 2014). There is also a large amount of 
epidemiological data that links disease risk directly to the in utero environment which affects 
the epigenome through stable epigenetic modifications. These epigenetic modifications may 
alter the physiology to influence disease risk in adulthood (McRae et al., 2014, Teh et al., 
2014). It has been shown that DNA methylation is highly divergent between different 
population groups, and that this divergence may be due in large part to a combination of 
differences in allele frequencies and complex epistasis or gene-environment interactions 
(Fraser et al., 2012). DNA methylation patterns have been shown to vary between sexes 
depending on disease and tissue studied. 
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Figure 1.4: Factors influencing DNA methylation variation. The level of DNA methylation observed between 
individuals may vary due to a number of different factors. 
1.4.2.4.1 Fixed genetic variation 
Recent studies have shown that a large proportion of DNA methylation variability across 
individuals and populations is a result of underlying genetic variability (McRae et al., 2014, Teh 
et al., 2014, Wagner et al., 2014). McRae et al. (2014) found that the majority of the similarity 
in DNA methylation levels between relatives is due to genetic effects. This means  that 20 % 
of DNA methylation variation that exists between individuals in a population is due to 
sequence-based DNA variants (SNPs) that are not located within the CpG sites. These 
identified SNPs, whose genotypes correlate with levels of DNA methylation, are termed 
methylation quantitative trait loci, or meQTLs (McRae et al., 2014). Therefore the inter-
individual variation in DNA methylation is, in part, a result of nucleotide polymorphisms (Teh 
et al., 2014).  Bell et al. (2011) utilized the Illumina HumanMethylation27 BeadChip to map 
associations between SNPs and methylation levels at 22,290 CpG dinucleotides in 
lymphoblastoid cell lines (LCLs). They found 180 CpG sites associated with nearby SNPs (Bell 
et al., 2011, El Hajj et al., 2014a).  In a similar study using the same DNA methylation platform, 
Gibbs et al. (2010) studied samples from four human brain regions in 150 individuals and 
reported hundreds of SNP-associated CpG sites in each brain sample, with meQTLs typically 
located very close to the associated CpG site (Gibbs et al., 2010, Wagner et al., 2014). Although 
the influences of prenatal environment on future disease risk are intensively studied, it is 
important to address the degree to which the environmental influences are moderated by 
genotype. Therefore any study aiming to explore the role of DNA methylation variation to a 
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complex disease should carry out a parallel analysis of underlying genetic variation. These 
findings highlight the importance of understanding the genetic diversity of target populations. 
 
1.4.2.4.2 Population specificity 
Recent advances in high throughput technologies for measuring quantitative locus specific 
and genome-wide DNA methylation have provided an opportunity to characterize 
methylation patterns in the context of human genome variation. DNA methylation can differ 
in diseases and cell types, or even between monozygotic twins, but while most research has 
focused on variation at the cellular level, relatively little research has been done to examine 
how epigenetic variation affects humans at the population level. DNA methylation patterns 
are important for establishing cell, tissue and organism phenotypes, but very little is known 
about their contribution to natural human variation (Heyn et al., 2013). As the scale of DNA 
methylation association studies approaches that of genome-wide association studies, issues 
such as population stratification have to be addressed. In 2012 Fraser et al, demonstrated a 
wide range of within population variability in the methylation of individual CpG sites. In 
addition to the variation within each population, they observed that a third of the genes they 
studied showed differences in the DNA methylation patterns between the populations. These 
results suggest that DNA methylation is highly divergent between populations and this is due 
to a combination of genetic factors and complex gene-environment interactions. It has also 
been observed that distinct epigenetic and genetic signatures in certain diseases are 
dependent on the ethnicity of the patient (Nieminen et al., 2012). These small but extensive 
epigenetic differences observed between populations are most likely the result of both 
genetic (Barfield et al., 2014) and environmental factors (Fraser et al., 2012).  
1.4.2.4.3 Environmental factors  
With regard to the environment, population specific environmental factors such as socio-
economic status (SES), infections and lifestyle may also contribute to differences in DNA 
methylation. SES is a measure of an individual’s or family’s economic and social position based 
on education, income, and occupation and has long been a strong predictor of health. In many 
African countries, there exist inequalities in SES and the burden of infectious and non-
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communicable disease is greater among individuals of lower SES (Ataguba et al., 2011). In a 
preliminary study, Borghol et al. (2012) revealed an association between exposure to a low 
SES in childhood and differential DNA methylation in adulthood (Borghol et al., 2012). Forty 
adult males from the 1958 British Birth Cohort were selected according to their SES at 
childhood and in mid adulthood. The SES scores were determined using specific criteria, 
dividing the men into the most disadvantaged and the least disadvantaged. The DNA 
methylation profiles in adult blood indicated greater association with childhood SES than with 
adult SES. In a separate study, McGuinness et al. (2012), investigated the relationship between 
SES and DNA methylation in a subset of individuals from the Psychological, Social and 
Biological Determinants of Health (pSoBid) cohort. This cohort is characterized by an extreme 
socio-economic and health gradient. They observed global DNA hypomethylation in the 
individuals classified as the ‘most socio-economically deprived’. They also found an 
association between global DNA methylation and biomarkers of cardiovascular disease (CVD) 
and inflammation, after adjustment for socio-economic factors. Both these studies showed 
that there is an association between epigenetic modifications and SES. This relationship has 
direct implications for population health and is reflected in further associations between 
global DNA methylation content and emerging biomarkers of non-communicable disease 
(McGuinness et al., 2012). Another example of an environmental stress factor that influences 
epigenetic modifications in humans is that of bacterial infections, a common cause of illness 
and death in SSA.  Studies have shown that bacteria have the ability to change the chromatin 
structure and transcriptional activity of their host cells. This is achieved through epigenetic 
modifications such as DNA methylation. These bacterial induced epigenetic modifications may 
affect the host cell function either to promote host defense or to allow pathogen persistence 
(Bierne et al., 2012). 
 
1.4.2.4.4 Sex  
In a number of epigenetic studies, it has been shown that epigenetic modifications are largely 
sex-specific (Boks et al., 2009, Hannum et al., 2013). Khulan et al. (2014), observed a difference 
in the genes that were methylated in female and male foetuses exposed to an asthma 
environment (mothers had asthma). This emphasizes that different developmental 
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trajectories are followed by males and female under adverse intrauterine environments. The 
greater number of loci undergoing differential methylation in males indicated that they are 
impacted more than loci in females during early postnatal development. In a study done by 
El-Maarri et al. (2007), they measured DNA methylation in total blood in 96 healthy human 
males and 96 healthy human females. Global methylation was estimated by studying two 
repetitive DNA elements (Line-1 and Alu repeats) while single loci were investigated for three 
differentially methylated regions (DMRs) at PEG3, NESP55 and H19 imprinted genes and two 
additional loci at Xq28 (F8 gene) and at 19q13.4 (locus between PEG3 and USP29). They found 
that in all the studied CpGs there was slightly higher methylation in males than observed in 
females (El-Maarri et al., 2007). Hall et al. (2014) aimed to investigate the impact of sex on the 
genome-wide DNA methylation pattern in human pancreatic islets from 53 males and 34 
females using the Infinium HumanMethylation450 Bead-Chip. They aimed to describe sex 
differences in the methylome and transcriptome in human pancreatic islets. They identified 
both chromosome-wide and site-specific sex differences in DNA methylation on the X- 
chromosome of human pancreatic islets. They also observed a higher insulin secretion in the 
pancreatic islets from females when compared with males (Hall et al., 2014). The observed 
sex differences in levels of methylation could be due to the process of X-chromosome 
inactivation, the presence of an additional X-chromosome in female cells or the result of 
downstream effects of sex determination (El-Maarri et al., 2007).  
1.4.3 The role of DNA methylation in gene expression 
For gene transcription to occur, the gene promoter should be readily accessible to 
transcription factors and other regulatory elements (e.g. enhancers). Generally, when CpG 
islands in gene promoter regions are methylated, transcription is repressed and the 
expression of the gene is silenced (Moore et al., 2013). In contrast, when promoter region CpG 
islands are unmethylated, transcription is initiated and gene expression is activated (Deaton 
and Bird, 2011). DNA methylation alters gene expression levels primarily through regulating 
methylation dependent interactions with transcriptional activators or repressors, and 
chromatin remodeling enzymes (Moore et al., 2013). Several classes of methyl-DNA binding 
proteins bind to methylated DNA and repress transcription, either by directly disrupting the 
formation of the RNA polymerase complex and associated factors at the transcriptional start 
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site, or by recruiting other chromatin modifiers that result in impaired transcription (Tate and 
Bird, 1993). These modifiers may induce changes in post-translational histone modification 
states leading to the formation of inactive chromatin and the prevention in the formation of 
the RNA polymerase complex (Conerly and Grady, 2010).  
 
Gene expression is a heritable trait and its variation is one of the main driving mechanisms 
underlying complex disease susceptibility (Cookson et al., 2009). The sequencing of the human 
genome has allowed for the detection of disease-causing mutations in many Mendelian 
disorders as well as the identification of significant associations between polymorphisms and 
complex disease (Costa et al., 2013). However, identifying causative variations for 
multifactorial diseases, such as diabetes, remains a complex task (Twine et al., 2011). Gene 
expression analysis provides a valuable understanding of the normal biological and disease 
processes: alterations in gene expression patterns are often responsible for the differences 
observed between disease and healthy states (Shaat and Groop, 2007). Although the genome 
gives a static view of the genetic and regulatory information defining an organisms phenotype, 
knowledge of an organism’s transcriptome (the entirety of transcribed genes) is essential 
(Kratz and Carninci, 2014). Whole-transcriptome analysis represents a powerful tool for 
providing not only insight into the functional elements that contribute to the current genetic 
knowledge of diseases (Costa et al., 2013), but also information that is necessary for the 
complete understanding on how the same genome can produce different cell types in an 
organism and how these genes are regulated in health and disease (Kratz and Carninci, 2014).  
There are two main approaches used to study gene expression, namely a genome-wide or a 
targeted approach. The method chosen depends on the information one has available. When 
the key genes of interest are not known, genome-wide approaches such as the older 
sequence-based microarray technology or the more modern high-throughput sequencing-
based RNA-Seq technology are used (Mortazavi et al., 2008). These methods revolutionized 
expression profiling by enabling the measurement of thousands of genes simultaneously. For 
many years, hybridisation-based microarrays were the dominant platform for high throughput 
analysis of gene expression (Zhao et al., 2014) but they have several limitations. These include 
the need for a priori knowledge of sequences to analyse, an inability to detect splice site 
27 
 
 
 
isoforms and novel genes/exons (Costa et al., 2013), background noise due to cross-
hybridization, and poor detection and quantification of low expressing transcripts (Kratz and 
Carninci, 2014). The use of RNA-seq is fast becoming a more affordable and sensitive 
competitor for differential expression analysis (Frazee et al., 2014). 
1.4.4 Limitations to epigenetic studies 
DNA methylation patterns are cell type and tissue specific (Barouki et al., 2012, Lehnen et al., 
2013). For this reason, it is important to assess epigenetic modification in tissues that 
contribute to the disease being studied. However, in epidemiological studies conducted in 
humans, obtaining relevant tissue is often invasive and/or impossible (Jaffe and Irizarry, 2014, 
Petronis, 2010). For this reason, surrogate tissues, most commonly whole blood, are used 
(Paul and Beck, 2014). The cell types present in the surrogate tissue will reflect epigenetic 
modifications found in the target tissue, or at least yield biomarkers that, although not directly 
causative of the disease, can still be used for predictive and/or diagnostic purposes as well as 
provide new pathophysiological insights into the disease (Lowe and Rakyan, 2014, Rakyan et 
al., 2011). The cause-and-effect relationship between disease and epigenetic modifications is 
complex. The link between epigenetic modification variation observed between affected and 
unaffected individuals and disease  (or predisposition to developing the disease) is difficult to 
determine as these epigenetic changes may simply reflect the differences in cellular 
composition between the disease and non-disease state (Lowe and Rakyan, 2014, Petronis, 
2010, Verma, 2012). The disease itself could induce epigenetic changes so it is important to 
distinguish between causal and non-causal associations (Petronis, 2010).  It is important to  
account for cellular heterogeneity in whole blood. This can be done by using a post hoc 
bioinformatics solution for confounding cell-type bias in EWASs (Jaffe and Irizarry, 2014, Zou 
et al., 2014). Another challenge facing EWAS studies is determining the optimal sample size. 
It is assumed that if the anticipated effects are small, thousands of participants should be 
included to avoid type one errors (Paul and Beck, 2014). It is important to perform a power 
analysis, which is used to determine the minimum sample size for a study to give statistically 
significant results (Petronis, 2010). Careful phenotyping can improve statistical power 
especially in studies with small to moderate sample sizes (Sham and Purcell, 2014).   
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Another important limitation to consider when designing epigenetic and gene expression 
experiments is the effect of confounding factors. For example, a possible confounding factor 
is that environmental stress can alter the relative abundance of different cell types in the 
blood which could lead to altered levels of measured DNA methylation for specific genes (Feil 
and Fraga, 2012). DNA methylation is associated with cell fate determination in 
haematopoiesis, and its perturbation could affect the cell populations that constitute 
peripheral blood (Borgel et al., 2010). To avoid such confounding effects, and if experimental 
design allows, specific cell lineages and/or tissues should be studied (Feil and Fraga, 2012). 
There are a number of methods that have been proposed to minimize the effects of 
confounding. In studies of the association of biomarkers with disease, the technique of 
Mendelian randomization (Davey Smith and Ebrahim, 2004) has received much attention as a 
way of overcoming reverse causation and uncontrolled confounding. They use a gene as an 
instrumental variable to assess the causal effect of the biomarker on disease risk. Relton and 
Davey Smith (2012) have proposed a novel two-step extension of this idea for methylation 
studies, using two genes as instrumental variables, one to estimate the exposure–methylation 
association, the other to estimate the methylation–disease association (Relton and Davey 
Smith, 2012).  
 
1.5 RNA-sequencing (RNA-seq): a revolutionary tool for transcriptomics  
 
RNA-Seq is a widely used and powerful next generation sequencing technique to 
comprehensively study the entire transcriptome (Sultan et al., 2012) and allow one to 
investigate the expression levels and structure of transcripts without prior knowledge of the 
transcriptome content (Costa et al., 2010).  This enables the discovery of novel transcripts and 
also provides the potential to reveal novel molecular biomarkers for human diseases, through 
comparison of the transcriptome from normal and diseased samples (Kratz and Carninci, 
2014).  
 
RNA-seq has emerged as a powerful tool in the study of complex human diseases. A number 
of genes have been identified and implicated in the development of T2D by transcriptome 
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analyses in human or animal models (Ghosh et al., 2010), however, in comparison to T1D and 
T2D, GDM has been subject to fewer transcriptome analyses (Evangelista et al., 2014). 
Nonetheless, many genes related to obesity and oxidative stress have been shown to be 
associated with both T2D and GDM (Watanabe et al., 2011). Transcriptome signatures 
obtained from placenta and whole blood cells have identified genes involved with lipid 
metabolism that are differentially expressed between T2D and GDM (Zhao et al., 2011; 
Radaelli et al., 2009). Recently in a meta -analysis of the transcription profiles of T1D, T2D and 
GDM patients, Evangelista et al. (2014) found that the gene expression profiles of GDM 
patients were more closely related to T1D patients than T2D patients. However, the analysis 
of these gene expression signatures was impaired by the presence of multiple variables 
associated with each type of diabetes (Evangelsita et al., 2014). A GDM transcriptome analysis 
performed in 2014 by Donadi et al. (2014) demonstrated an increased expression of a number 
of genes related to the major histocompatibility complex, namely HLA-DRB6, DQB1, DQB2, 
DOA and DQA2 (Donadi et al., 2014). The modulation of these transcripts in GDM patients 
reinforces the hypothesis of a deregulation of HLA class II genes in GDM patients. Twine et al. 
(2011) provided an extensive transcriptome analysis of post-mortem frontal and temporal 
lobes of patients with Alzheimer’s disease, highlighting a differential expression of known 
causative genes and also of previously unannotated expressed regions (Costa et al., 2013, 
Twine et al., 2011). The introduction of RNA-seq into cancer research has had a large and 
positive impact on this area of research. Using this method to investigate cancer 
transcriptomes may provide answers to the multitude of questions about carcinogenesis in 
humans (Costa et al., 2013).  Many RNA-seq studies have implicated alternative splicing and 
detrimental fusion transcripts in the carcinogenesis of different tissues and organs (Edgren et 
al., 2011, Hong et al., 2016, Nacu et al., 2011). RNA-seq was used to identify genes 
differentially expressed between individuals with heart failure (N=6) and those with non-
failing hearts (N=6). Using the genes identified from this small dataset, they were able to 
accurately classify heart failure status in a larger cohort (N=313). Their results indicate that, 
using a small training dataset, it is possible to use RNA-seq to classify disease status for 
complex diseases (Liu et al., 2015).  
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1.5.1 Challenges for RNA sequencing 
Although RNA-seq has brought a significant qualitative and quantitative improvement to 
transcriptome analysis (Labaj et al., 2011, Shendure, 2008, Shendure and Ji, 2008), there are 
limitations from sample preparation to data analysis. Many procedures are involved in the 
preparation of samples for RNA-seq, namely extraction, fragmentation, reverse transcription 
and amplification, all of which are susceptible to experimental bias (Costa et al., 2013). Unlike 
small RNAs, which can be sequenced directly after adapter ligation, large RNA molecules must 
be fragmented into smaller pieces to be compatible with deep-sequencing technologies 
(Wang et al., 2008). Fragmentation is the process that involves the breakdown of large RNA 
molecules into smaller fragments and the advantage of this process is that it reduces the 
formation of secondary structures (which reduce the ability of RNA to be fragmented), 
allowing higher sequence coverage across the length of the transcript (Costa et al., 2013). The 
presence of ‘susceptibility fragmentation sites’ can alter the representation of that sequence 
within the library (Sendler et al., 2011). The probability of random fragmentation can be 
altered by the GC content of the transcripts. This affects the counting efficiency and will 
present a severe bias in gene expression measurements (Costa et al., 2013). The GC content 
has also been shown to affect the cDNA amplification process because GC rich fragments tend 
to form double stranded or highly paired secondary structures which affect the action of 
reverse transcription (Aird et al., 2011). During the process of reverse transcription, the cDNA 
strand that is being synthesized could dissociate from the template RNA and re-anneal to an 
alternate piece of RNA of similar sequence. This process of ‘template shifting’ generates 
artificial chimeric cDNAs (Ozsolak and Milos, 2011) and can inhibit the identification of exon-
intron boundaries and true chimeric transcripts (Cocquet et al., 2006, Roy and Irimia, 2008). 
Issues also arise with the reverse transcriptase enzymes, as they tend to have a low fidelity 
and variable RNA to cDNA conversion efficiency when compared to other polymerases  
(Ozsolak and Milos, 2011). Another important issue to consider is the coverage versus cost, 
Greater coverage (percentage of transcripts measured) requires more sequencing depth, 
which comes at a larger cost, Considerable sequencing depth is required to detect rare 
transcripts (Wang et al., 2009). Not only does RNA-seq face many experimental challenges, 
but like many high throughput sequencing technologies, this method also faces bioinformatics 
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challenges. These include the development of methods that can efficiently store, retrieve and 
process large amounts of data, remove low quality reads and be able to reduce errors in image 
analysis (Wang et al., 2009).   
 
Motivated by the advantages of RNA-Seq technology for gene expression profiling, and given 
the clinical and public health significance of GDM, we sequenced the transcriptomes of six 
women who developed the disease and 6 healthy controls in order to potentially identify 
genes that are associated with the development of gestational diabetes. We also sequenced 
the transcriptomes of placental tissue that was exposed to an adverse in utero environment 
(presence of GDM) and unexposed placental tissue, to see if exposure had an effect on 
placental gene expression. To date, no genome-wide gene expression RNA-seq studies for 
GDM have been done in black South Africans. 
 
1.6 Specific Aim and Objectives 
The main aim of this research study was to determine whether genes involved in metabolic 
processes had differential expression due to promoter region methylation and whether this 
alteration occurred as an adaptive response to exposure to an adverse in utero environment 
inflicted by the presence of GDM.  
Objectives (Figure 1.5) 
1. To assess differential genome-wide gene expression in blood samples from women with 
GDM and controls to identify genes that display statistically (qvalue<0.05) significant 
differential expression (≥2 fold). 
2. To assess differential genome-wide gene expression in placental tissue from female 
neonates born to women with GDM (exposed) and those born to controls (not exposed; 
absence of GDM) to identify genes that display statistically (qvalue<0.05) significant 
differential expression (≥2 fold). 
3. To identify genes that are significantly (qvalue<0.05) differentially expressed (≥2 fold) in 
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both blood and placental tissue and to determine whether their expression pattern is due to 
aberrant promoter region DNA methylation. 
                                        
Figure 1.5: The different comparisons that will be made in this research study 
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CHAPTER TWO 
2. MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1 Study Participants  
Enrolment: pregnant black South African women from Soweto area  
 
 
Routine Oral Glucose Tolerance Test (OGTT) done at 24 to 28 weeks on all women  
Recruited pregnant women with GDM (n=12) cases 
(GDM diagnosed using IADPSG criteria (Table 2.1)) 
Recruited pregnant women with NGT (n=11) controls 
Participated Pregnant women with GDM (n=6) 
Whole maternal blood collected between 29-33 weeks gestation 
Collect placental biopsy at delivery 
Participated Pregnant women without GDM (n=6) 
Whole maternal blood collected between 29-33 weeks gestation 
Collect placental biopsy at delivery 
 
 
Excluded (n=6) 
 Missed delivery (N=1) 
 HIV positive (N=1) 
 Declined to participate (N=1) 
 Male offspring (N=2) 
 Caesarean (N=1) 
Excluded (n=5) 
 Missed delivery (N=1) 
 HIV positive (N=1) 
 Declined to participate (N=1) 
 Male offspring (N=1) 
 Caesarean (N=1) 
 
 
 Globin removal from blood RNA 
 Prepare cDNA libraries (TruSeq Illumina kit)  for RNAseq 
Confirmatory qRT-PCR (TaqMan Probes) 
                Reduce N 
Significance Qvalue<0.05 
Fold change in expression >2; <-2 
Molecular/Biological Function; Pathways 
Select candidate genes (N=10 from blood; N=10 from placenta)  
Analyse gene-specific methylation in candidate genes  
(N=5) using EpiTech PCR assays (WhiteSci) 
 Extract RNA and DNA  
 QC Nucleic Acid (Gels, Nanodrop™, Bioanalyser) 
  
(B) DNA 
Gene-specific methylation analysis 
(A) RNA 
Genome-wide gene expression analysis 
RNA sequencing using HiSeq 2000 (CRG Core facility) 
(4 samples/lane; 75bp paired end) 
Bioinformatics Data analysis (Tuxedo Suite; R) 
DAVID/PANTHER(cluster genes into pathways/functions); STRING 
Whole blood and Placental tissue 
 Generate a working list of genes (N<100) with 
significantly (p<0.05) differential gene expression 
Bioinformatics Data analysis 
Candidate genes that were successfully validated (N=5)–> DNA methylation  (B) 
Identify genes which are significantly differentially 
expressed in gestational diabetes due to altered promoter 
methylation patterns 
Figure 2.1: An overview of the materials and methods used in the study  
Inclusion criteria 
 Over 18 years of age and during 1st trimester pregnancy 
 HIV negative 
 Naturally conceived pregnancies 
 Singleton pregnancies 
 Natural birth to female neonates 
34 
 
 
 
2.1 Study Participants 
Participant recruitment and sample collection was done in collaboration with the 
Developmental Pathways and Health Research Unit (DPHRU) at Wits, under the umbrella of 
the Foetal/Soweto baby growth study. The Foetal/Soweto baby growth study aims to recruit 
over 3000 participants. It is from this larger cohort that participants for this study were 
recruited. The target population is black South African women in their first trimester of 
pregnancy who present at clinics around the Soweto, Johannesburg area. All women recruited 
were followed from 1st trimester of pregnancy (<14 weeks) to delivery, with five to six visits 
depending on gestational age at entry into the study (visit 1: <14 weeks; visit 2: 14-18 weeks, 
visit 3: 19-23 weeks; visit 4: 24–28 weeks; visit 5: 29–33 weeks; visit 6: 34–38 weeks). At each 
visit, anthropometric variables such as blood pressure and weight were measured using 
standardized procedures. Glucose tolerance was assessed using a 75 g Oral Glucose Tolerance 
Test (OGTT) performed at approximately 24 to 28 weeks gestation. The new International 
Association of the Diabetes and Pregnancy Study Groups criteria (IADPSG) were used to 
diagnose GDM (Table 2.1).  
Table 2.1: IADPSG diagnostic criteria for GDM (Duran et al., 2014)  
  Venous plasma glucose threshold  
    (mmol/L)   
      
 Fasting  ≥ 5.1   
 75 g OGTT: 1 hour  ≥ 10.0   
 75 g OGTT: 2 hours  ≥ 8.5   
            
One or more values equal or exceeding diagnostic threshold is indicative of 
gestational diabetes mellitus 
 
Women with one or more OGTT values equal to or exceeding the above mentioned diagnostic 
thresholds were selected as cases for the study. Women with OGTT results lower than the 
specified diagnostic threshold at each time point were selected as controls. These selected 
women were asked to provide informed consent (Appendix Ai) and were given an information 
sheet (Appendix Aii) that they were asked to sign if they understood the information and 
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agreed to participate before their inclusion in the study. The University of the Witwatersrand 
Human Research Ethics Committee (Medical) approved the project (Ethics clearance No: 
M130420)(Appendix Bi and Bii).  
Initially 23 women were recruited to participate in the study, however, following the strict 
exclusion criteria, 11 women were excluded from the study (Figure 2.1). At the time of 
delivery, seven women were excluded from the study. Three gave birth to male offspring, two 
gave birth at a different hospital and it was not possible to obtain the placental sample and 
there were two missed deliveries (the women failed to contact the nurses prior to delivery). 
The total number of participants for which both blood and placental tissue was obtained was 
12 (6 cases and 6 controls). Studies have shown that there are sex-specific differences in 
placental global gene expression (Osei-Kumah et al., 2011). For this reason, same sex offspring 
(only females) will be used in this study. Venous whole blood was obtained from the women 
at their 5th visit once the OGTT test results were available. Placental samples were taken within 
an hour of birth. Control individuals had normal glucose tolerance (NGT) during pregnancy 
and were as closely matched as possible by age and BMI to case subjects (women with GDM). 
2.2 Sample collection 
2.2.1 Whole Blood Samples 
Two whole blood samples were taken from each of the women at their 5th visit (29-33 weeks 
gestation).  A 6 ml blood sample was collected in a purple top EDTA tube (for DNA extraction). 
These tubes were stored at 4°C until needed.  The second blood sample (3 ml) was collected 
in a blue top Tempus™ tube (for RNA extraction). Two separate blood collection tubes were 
necessary because of the different stabilization and storage conditions for RNA and DNA. The 
Tempus™ tubes contain a RNA Stabilizing Agent that, once mixed with whole blood, 
immediately begins to lyse the cells.  The stabilizing reagent then inactivates cellular RNases 
and selectively precipitates RNA. After the blood was drawn into the Tempus tubes, they were 
vortexed vigorously for 10 seconds to ensure proper mixing of the blood with the stabilizing 
reagent.  These tubes were stored at -80°C until needed.   
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2.2.2 Placental Tissue Samples 
At the time of delivery, the placenta was obtained and two 8 mm vertical placental punch 
biopsies were taken within an hour of birth. These biopsies were taken from the placental 
disc, avoiding the umbilical cord insertion site and approximately 3 cm from the edge of the 
placenta (Figure 2.2). The direction of the punch biopsy was from maternal to foetal side. One 
biopsy (used for RNA extraction) was stored in 4 ml of RNALater solution and stored at  -80°C. 
The second biopsy (used for DNA extraction) was flash frozen by placing the bottom of the 
uncapped tube (containing the placental tissue) in liquid nitrogen and also stored at -80°C until 
needed.  
                            
Figure 2.2: Schematic of placenta tissue sampling. Two placental biopsies were taken, the direction of the 
placental punches was from the maternal side through to the foetal side. 
 
2.3 Nucleic acid (RNA and DNA) extraction  
RNA (transcribed into cDNA) was used for the gene expression analysis and DNA for 
methylation analysis. RNA extraction and expression validation by qRT-PCR, as well as 
methylation studies were performed at Wits. The mRNA library construction and RNA-seq 
were performed at the Centre for Genomic Regulation (CRG), Barcelona, Spain. Data analysis 
was started in Spain and concluded at Wits.               
2.3.1 From whole blood 
Total RNA was extracted from whole blood following the Tempus™ Spin RNA Isolation Kit 
Protocol (Applied Biosystems). The reagents and consumables included in this kit allow the 
isolation of 6 to 25 μg of high quality RNA from 3 ml of whole blood)(Table 2.2). Before 
37 
 
 
 
extraction, the frozen stabilized blood was thawed to room temperature and transferred to a 
50 ml tube containing 1X calcium- and magnesium-free phosphate-buffered saline (PBS). After 
a centrifugation step, the RNA-containing pellet was resuspended and transferred onto a 
purification filter. The purified RNA was eluted following a micro-centrifugation step (For a full 
description of the extraction protocol, refer to Appendix Ci).  
DNA was extracted from whole blood samples using the salting out method (Miller et al., 
1988). This two-day method of extraction yields a high quantity of DNA (ranging from 200 – 
1000 ng/µl)(Table 2.2). Nuclear lysis buffer was added to the blood to break down the red 
blood cells. The cell lysates were digested overnight with a SDS and Proteinase K solution. 
Saturated NaCl was added to the mixture and centrifuged. This step precipitates the protein 
which was then removed. Ethanol was added and the tubes inverted until the DNA precipitate 
formed. The DNA was removed with a pipette tip and transferred to a microcentrifuge tube 
containing 200 µl of TE buffer. The resuspended DNA was stored at 4°C until needed (Full 
protocol in Appendix Cii).  
 
2.3.2 From placental tissue 
Total RNA was extracted from the placental tissue using the RNeasy Mini Kit (Qiagen). This kit 
provides fast purification of high-quality RNA from tissues using silica-membrane RNeasy spin 
columns with a binding capacity of 100 μg RNA. The maximum weight of tissue that can be 
processed for each sample with this kit is 30 mg (Table 2.2). After thawing the placental 
biopsies at room temperature, a 30 mg sample was excised (from just behind the membrane, 
ensuring that the placental sample was largely foetal) from each of the 8 mm placental 
biopsies and placed in a tube containing mercaptoethanol and efficiently disrupted using a 
TissueRuptor system (Qiagen). After the samples had been lysed and homogenized, ethanol 
was added to the lysate. The lysate was loaded onto the RNeasy silica membrane. Up to 100 
µg of RNA binds to the membrane and the contaminants are efficiently washed away. Pure 
RNA is eluted in 50 µl of nuclease free water (For a full description of the extraction protocol, 
refer to Appendix Ciii). 
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DNA was extracted from placental tissue using the DNeasy Blood and Tissue kit (Qiagen). Less 
than 25 mg of placental tissue (Table 2.2) was cut into small pieces and placed into a 
microcentrifuge tube containing Buffer ATL and Proteinase K solution. The mixture was 
incubated overnight at 56°C until the tissue was completely lysed. This mixture, together with 
Buffer AL and ethanol was placed into a DNeasy Mini spin column and centrifuged. The lysate 
was then washed in two separate steps using washing buffer. The DNA was eluted from the 
microcentrifuge tube using an elution buffer (For a full description of the extraction protocol, 
refer to Appendix Civ). 
 
Table 2.2:  Extraction kits used to obtain RNA and DNA from whole blood and placental tissue    
     
                          RNA Extraction    
Tissue Collected per woman Kit Input 
Output 
Whole Blood 1x Tempus Tube Tempus Spin RNA Isolation Kit 3 ml Blood 6-25 µg RNA 
Placenta 1x 8 mm biopsy RNALater RNeasy Mini kit 30 mg tissue 30 µg RNA 
  DNA Extraction   
Whole Blood 1x EDTA purple top tube Salting Out 6 ml Blood +/- 200 µg DNA 
Placenta 1x flash frozen 8 mm biopsy DNeasy Blood and Tissue Kit 25 mg tissue 15-30 µg DNA 
     
  
2.3.3 Nucleic acid Quality and Quantity control 
The total RNA and DNA extracted from whole blood and placental tissue was run on a 0.8 % 
agarose gel to check quality. 1 µl of each nucleic acid sample was run on the Nanodrop 
Spectrophotometer in order to determine quantity (ng/µl). The purity of the nucleic acids was 
assessed through the ratio of absorbance at 260 nm and 280 nm. Generally, a ratio of ~1.8 is 
accepted as “pure” for DNA and  ~2.0  for “pure” RNA. If the ratio is appreciably lower in either 
case, it may indicate the presence of protein, phenol or other contaminants that absorb 
strongly at or near 280 nm. The DNA was stored at -20°C until needed later in study for the 
methylation analysis. 
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For RNA, the Bioanalyser (Agilent Technologies) was used as a second method to measure 
quality. The Bioanalyser measures the RNA Integrity number (RIN) as well as the rRNA ratio 
(28S/18S). The RIN score is generated for each sample on a scale from 1-10 (where 10 indicates 
high quality RNA). The RIN should generally be above 7 and any samples with RIN <5 should 
not be considered for RNA sequencing. The RIN value is not the only index of RNA integrity. 
Some papers indicate that the most accurate factor to evaluate the integrity of the RNA is the 
28S/18S ratio which must generally be above 1.0 (Miller et al., 2004). An aliquot of the RNA 
samples was normalized to 400 ng/µl using nuclease free water and 1 µl of this normalised 
sample was loaded onto the BioAnalyser chip. 
 
2.3.4 Globin mRNA removal from whole blood 
Molecular profiles of circulating blood can be associated with physiological and pathological 
events occurring in other tissues and organs of the bodies (Shin et al., 2014). Peripheral whole 
blood is therefore a highly desirable tissue due to its accessibility and its relatively non-invasive 
mode of collection.  Gene expression profile studies of human blood samples are, however, 
confronted by numerous challenges. Accounting for approximately 80 - 90 % of transcript 
species, globin dominates the peripheral whole blood transcriptome, potentially affecting the 
ability to detect other transcripts, particularly those with lower expression. The process of 
removing globin transcripts from RNA prior to accessing mRNA expression, is not uncommon. 
Shin et al. (2014) showed that globin depletion results in a statistically significant increase in 
the number of detectable transcripts, particularly lower expressing transcripts. Although this 
process significantly lowers the quality and quantity of total RNA (Shin et al., 2014; Liu et al., 
2006), it does not negatively affect the relative abundance of other transcripts when 
proceeding to cDNA library preparation. They showed that there was no statistically significant 
difference in the total number of reads, total number of mapped reads or percentage of reads 
filtered out when comparing globin depleted RNA to non-globin depleted RNA. Overall, globin 
depletion appears to meaningfully improve the quality of peripheral whole blood RNA-seq 
data, increasing the number of detectable transcripts. A key concern with this process is the 
reduction in the quantity of extracted RNA especially in the cases where biological samples 
are rare and difficult to replace (Shin et al., 2014).   
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Before the preparation of the cDNA libraries, globin mRNA was removed from the total RNA 
extracted from the whole blood samples. This was done using the GLOBINclear Kit (human), 
for globin mRNA depletion (ThermoFischer Scientific). Briefly, this kit removes globin mRNA 
from total RNA via hybridization with biotinylated DNA oligos that specifically capture globin 
mRNA followed by binding with streptavidin magnetic beads. This removal method uses novel, 
non-enzymatic technology that rapidly depletes >95 % of the alpha and beta globin mRNA 
from total RNA preparations derived from whole blood. According to the manufacturers, this 
allows detection of up to 50 % more, previously undetected, genes (For the full mRNA removal 
procedure, see Appendix D). 
 
2.4. A standard RNA sequencing workflow 
The RNA-seq workflow, from sample preparation through to data analysis, enables rapid 
profiling and deep investigation of the transcriptome. RNA-seq is the simultaneous execution 
of millions of sequencing reactions of relatively short read length (30 – 500 bp) in parallel, 
generating massive amounts of sequence data per run (Shendure and Ji, 2008). The term RNA-
seq denotes an ever expanding menagerie of protocols, nevertheless, they all have similar 
concepts: extracting cellular RNA, removing rRNAs, isolating the poly-A mRNA transcripts and 
converting this population of mRNA to a library of cDNA fragments, which are then sequenced 
(Kratz and Carninci, 2014). RNA-seq experiments must be analysed with robust, efficient and 
statistically principled algorithms (Trapnell et al., 2013, Trapnell et al., 2012). The direct 
product of an RNA-seq experiment is a large electronic file that contains millions of sequencing 
reads from each sample. The first step is to align the sequencing reads to the reference 
genome in order to know where they have originated from. Because of the massive amount 
of reads produced, specialized algorithms need to be used to do the alignment. These 
algorithms significantly increase the alignment speed by indexing the reference sequence in a 
way which makes it possible to quickly match the reads against the reference (Langmead and 
Salzberg, 2012). Following RNA-seq reads mapping, the data needs to be converted into a 
quantitative measure of gene expression. Because the number of reads produced from an 
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RNA transcript is the function of that transcripts abundance, read density can be used to 
measure transcript and gene expression (Cloonan and Grimmond, 2008). There are many 
different RNA-seq analysis packages that can be used for RNA-seq data analysis however, the 
Tophat and Cufflinks protocol was used in this study.  
 
2.4.1 cDNA library preparation 
The cDNA libraries were prepared using the TruSeq Stranded mRNA preparation kit (Low-
Throughput protocol; Illumina) according to manufacturer’s instructions. Briefly, 2 µg of total 
RNA sample from globin mRNA-depleted whole blood and placental tissue was used for polyA 
mRNA selection using polyT oligo attached magnetic beads and two rounds of purification. 
During the second elution of the polyA RNA, the RNA is fragmented and primed for cDNA 
synthesis. cDNA was synthesized from the enriched and fragmented RNA using reverse 
transcriptase, SuperScript II and random primers. The cDNA was converted into double 
stranded DNA (dsDNA) which was used for library preparation. The overhangs on the dsDNA 
resulting from fragmentation are then converted into blunt ends. A single ‘A’ nucleotide is 
added to the 3’ ends of the blunt fragments to prevent them from ligating to one another 
during the adapter ligation reaction. A corresponding single ‘T’ nucleotide on the 3’ end of the 
adapter provides a complementary extension for ligating the adapter to the fragment. A 
multiple indexing adapter is then ligated to the ends of the dsDNA, preparing them for 
hybridization onto a flow cell in the HiSeq 2000 (Illumina). PCR is then used to selectively 
enrich the DNA fragments that have adapter molecules on both ends and to amplify the 
amount of DNA in the library (For the full protocol description, see Appendix E).   
 
2.4.1.1 cDNA library QC  
The quality and quantity of the sample libraries were assessed before the sequencing 
procedure. To achieve the highest quality data on Illumina sequencing platforms, it is 
important to create optimum cluster densities across every lane of the flow cell. Optimizing 
cluster densities requires accurate quantitation of cDNA library templates. The concentrations 
of the libraries were quantified using the Nanodrop and the size and purity (quality) were 
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measured using the Agilent Bioanalyzer. 1 µl of the cDNA library was loaded on the Bioanalyzer 
using a DNA-specific chip, the Agilent DNA 1000.  
 
2.4.1.2 Normalization and Pooling of cDNA Libraries 
RNA-seq protocols use a RNA fragmentation approach prior to sequencing to gain sequence 
coverage of the whole transcript. This means that long transcripts will have more reads 
mapping to them when compared with short transcripts of similar expression level. For this 
reason, read counts need to be properly normalized to extract meaningful expression 
estimates (Mortazavi et al., 2008). Moreover, each sequencing run has a given variability 
which will influence the number of fragments mapped across samples. Hence, it is also 
necessary to normalize for each sequencing run in order to avoid the possibility that genes 
will appear to be differentially expressed only as a result of the presence of more sequences 
in one condition when compared to another. One of the ways in which sequencing data is 
normalized is to use the reads per kilobase of transcript per million mapped (RPKM) metric, 
which normalizes a transcript’s read by both its length and the total number of reads mapped 
in the sample. In a similar way, fragments per kilobase of transcript per million mapped (FPKM) 
metric normalizes paired-end data (Oshlack et al., 2010). 
 
10 μl of the indexed cDNA libraries were normalized to 10 nM in the DCT (Diluted Cluster 
Template) plate using Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20, and then pooled in equal 
volumes in the PDP (Pooled DCT Plate). Each normalized sample library to be pooled together 
was transferred from the DCT plate to one well of the PDP plate. The 24 indexed cDNA libraries 
were pooled together in equal concentrations into 6 pools (4 samples per pool as follows: 
placenta_case; placenta_control; blood_case; blood_control) (Table 2.3).  
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Table 2.3: Sample arrangement in the flow cell for sequencing.  Each pool indicates the samples run in a single 
lane in the HiSeq2000 sequencer. The indexes used in each pool are listed as this is how the samples are 
recognized. Indexes used in each lane need to be compatible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2 Sequencing the cDNA libraries 
Each of the six pools (containing 4 samples each) was sequenced (75 bp, paired-end) in a 
separate lane on the HiSeq 2000 platform in the same sequencing run for side-by-side 
comparison. This sequencing depth should generate ~ 50,000,000 reads per sample. Before 
Sample ID Tissue Case/Control Index  Index Sequence 
          
Pool 1          
1048b Blood Case 2 C G A T G T 
1107b Blood Control 7 C A G A T C 
1087p Placenta Control 14 A G T T C C 
1054p Placenta Case 4 T G A C C A 
Pool 2          
1067p Placenta Control 5 A C A G T G 
1054b Blood Case 18 G T C C G C 
1094b Blood Control 15 A T G T C A 
1060p Placenta Case 16 C C G T C C 
Pool 3          
1048p Placenta Case 5 A C A G T G 
1094p Placenta Control 15 A T G T C A 
1086b Blood Case 12 C T T G T A 
1067b Blood Control 19 G T G A A A 
Pool 4          
10225b Blood Case 2 C G A T G T 
1090b Blood Control 4 T G A C C A 
1090p Placenta Control 7 C A G A T C 
1086p Placenta Case 16 C C G T C C 
Pool 5          
1107p  Placenta Control 12 C T T G T A 
1060b Blood Case 6 G C C A A T 
1087b Blood Control 13 A G T C A A 
10276p  Placenta Case 14 A G T T C C 
Pool 6          
1061p Placenta Control 6 G C C A A T 
10276b Blood Case 13 A G T C A A 
10225p  Placenta Case 18 G T C C G C 
1061b Blood Control 19 G T G A A A 
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analysing the sequences generated and extracting biological conclusions from them, it is 
critical to evaluate the quality of the sequences as well as the overall sequencing performance. 
Therefore, before aligning the sequencing reads to a reference genome, the low-quality bases 
must be removed. Quality Control (QC) of the sequences takes into account duplication rate, 
rRNA abundance, strand specificity, coverage continuity at all annotated transcripts and 
performance at 5’ and 3’ ends. The resulting Phred score is used to evaluate the quality of the 
sequencing; the content of bases; the amount of N (specific nucleotide not called) bases and 
the sequenced read lengths. Based on this type of analysis, the bases with low sequencing 
quality should be trimmed ensuring the high quality of the sequencing data.  In this study, the 
program FASTQC was used to check the quality of high throughput sequence. FASTQC 
produces several quality control plots which are important when evaluating the condition of 
the millions of generated raw sequence files before doing any further analysis. If the quality is 
not optimal, trimming and filtering of sequence reads must be done, otherwise the 
downstream analysis will not provide statistically relevant results (Niiranen, 2015). The 
FASTQC files for each sample were analysed in order to determine the quality of the millions 
of generated sequences.  
 
2.5. Differential gene expression analysis of RNA-seq data using tophat and cufflinks 
The downstream analysis of the sequencing reads generated for each sample was done 
following the pipeline shown in Figure 2.3, using programs called tophat, cufflinks (cuffmerge, 
cuffdiff) and cummeRbund (Trapnell et al., 2012). Tophat and cufflinks are free open source 
software tools used for gene discovery and expression analysis of high throughput RNA-seq 
data. Together they allow for the identification of novel genes and splice variants as well as 
for the comparison of gene expression between disease and healthy states (Trapnell et al., 
2012). 
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Figure 2.3: An overview of the tophat/cufflinks RNA-seq analysis protocol. 
 
The RNA-seq data was aligned to the Human Reference Genome (hg19) with tophat 0.5.9-r16 
(http://tophat.cbcb.umd.edu) with default options. Tophat is a fast splice site junction mapper 
for RNA-seq reads. The script written for tophat  to align the generated reads to the genome 
using the ultra-high throughput short read aligner, ”Bowtie”, and then analyse the mapping 
results to identify splice sites between exons, is shown in Figure 2.4. Tophat generates an 
output file named “accepted_hits.bam” file. This contains all the aligned reads and was used 
as the input file for cufflinks. After running tophat, the resulting alignment files were provided 
to cufflinks (http://cufflinks.cbcb.umd.edu) which assembled the individual transcripts from 
the aligned RNA-seq reads, estimates their abundances, and tested for differential expression. 
Cufflinks produces an assembled transcriptome fragment for each sample using the 
“accepted_hits.bam” file as the input. The script written to run cufflinks is shown in Figure 2.5.  
The resulting transcriptome fragments of each sample are then merged together with the 
reference transcriptome annotation into one file for further analysis. This was done using 
cuffmerge. The script written to merge the cufflinks files is shown in Figure 2.6. 
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Tophat.26.sh 
#!/bin/bash 
 # OGE parameters 
 #$ -q xe-el6 
#$ -N RNAseqANGELA 
#$ -e /no_backup/xe/ahobbs/alignment/0026/e26logs 
#$ -o /no_backup/xe/ahobbs/alignment/0026/o26logs 
 #$ -m abe 
#$ -M angela.hobbs@crg.eu 
 #$ -pe smp 4 
#$ -l h_rt=20:00:00 
#$ -l virtual_free=20G 
  
# paths 
PATH=/users/GD/tools/bowtie/bowtie2-2,1,0:$PATH 
export PATH 
  
/software/bi/el6,3/current/tophat/tophat2 --output-dir /no_backup/xe/ahobbs/alignment/0026 --num-threads 4 --rg-id 0026 --rg-library 0026 --rg-
sample 0026 --rg-platform illumina --transcriptome-index /no_backup/xe/ahobbs/alignment/index 
/db/igenomes/Homo_sapiens/Ensembl/GRCh37/Sequence/Bowtie2Index/genome /no_backup/xe/ahobbs/samples/26_9966_GTCCGC_read1.fastq.gz 
/no_backup/xe/ahobbs/samples/26_9966_GTCCGC_read2.fastq.gz 
Figure 2.4: The script written to align the generated sequences to the reference human genome using Tophat. 
#!/bin/bash 
 # OGE parameters 
 #$ -q xe-el6 
#$ -N RNAseqANGELA 
#$ -e /no_backup/xe/ahobbs/alignment/0009/e,cl9,logs 
#$ -o /no_backup/xe/ahobbs/alignment/0009/o,cl9,logs 
#$ -V 
 #$ -m abe 
#$ -M angela,hobbs@crg,eu 
 #$ -t 1 
  
#$ -pe smp 8 
#$ -l h_rt=20:00:00 
#$ -l virtual_free=40G 
  
/users/GD/tools/cufflinks/cufflinks-2,2,1,Linux_x86_64/cufflinks --output-dir /no_backup/xe/ahobbs/alignment/0009 --num-threads 8 --max-bundle-
frags 100000000 --GTF /db/igenomes/Homo_sapiens/Ensembl/GRCh37/Annotation/Genes/genes,gtf --GTF-guide 
/db/igenomes/Homo_sapiens/Ensembl/GRCh37/Annotation/Genes/genes,gtf /no_backup/xe/ahobbs/alignment/0009/accepted_hits,bam 
Figure 2.5: The script written to assemble a transcriptome for each sample using Cufflinks. 
 
 
 
47 
 
 
 
Cuffmerge_blood.sh 
  #!/bin/bash 
 # OGE parameters 
 #$ -q xe-el6 
#$ -N CuffMerge_Blood 
#$ -e /no_backup/xe/ahobbs/DE/e,cm,logs 
#$ -o /no_backup/xe/ahobbs/DE/o,cm,logs 
#$ -V 
 #$ -m abe 
#$ -M angela,hobbs@crg,eu 
 #$ -t 1 
 #$ -pe smp 8 
#$ -l h_rt=30:00:00 
#$ -l virtual_free=40G 
  
source /users/xe/ahobbs/,bash_profile 
source /users/xe/ahobbs/,bashrc 
  
/users/GD/tools/cufflinks/cufflinks-2,2,1,Linux_x86_64/cuffmerge -o /no_backup/xe/ahobbs/DE --num-threads 8 -g 
/db/igenomes/Homo_sapiens/Ensembl/GRCh37/Annotation/Genes/genes,gtf -s 
/db/igenomes/Homo_sapiens/Ensembl/GRCh37/Sequence/Bowtie2Index/genome,fa /no_backup/xe/ahobbs/samples/assemblies_blood,txt 
Figure 2.6: The Cuffmerge script written to merge all the resulting transcriptome fragments of each sample 
together with the reference transcriptome annotation. 
 
The merged file was then quantified by cuffdiff which is a separate program that is included 
in the cufflinks package. Cuffdiff calculated differential gene expression i.e. the expression 
between our case and control groups and also tested the statistical significance of each 
observed change in the expression between them. The results were given in a set of tabular 
files. Differential expression was considered significant depending on whether the p-value is 
greater than the FDR after Benjamini-Hochberg correction for multiple-testing (Mutryn et al., 
2015). The output file generated by cuffdiff was saved in an excel format for analysis. 
 
Cuffdiff.placenta.final.sh 
 #!/bin/bash 
 # OGE parameters 
 #$ -q xe-el6 
#$ -N cuffdiff_placenta 
#$ -e /no_backup/xe/ahobbs/cuffdiffplacentafinal/e,CDplacentafinal,logs 
#$ -o /no_backup/xe/ahobbs/cuffdiffplacentafinal/o,CDplacentafinal,logs 
#$ -V 
 #$ -m abe 
#$ -M angela,hobbs@crg,eu 
 #$ -t 1 
 #$ -pe smp 8 
#$ -l h_rt=72:00:00 
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#$ -l virtual_free=60G 
  
  
aligndir=/no_backup/xe/ahobbs/alignment 
  
/users/GD/tools/cufflinks/cufflinks-2,2,1,Linux_x86_64/cuffdiff -o /no_backup/xe/ahobbs/cuffdiffplacentafinal -p 8 -L Controls,Cases --library-type fr-
firststrand /db/igenomes/Homo_sapiens/Ensembl/GRCh37/Annotation/Genes/genes,gtf 
$aligndir/0002/accepted_hits,bam,$aligndir/1090/accepted_hits,bam,$aligndir/0017/accepted_hits,bam,$aligndir/0018/accepted_hits,bam,$aligndir/
0002/accepted_hits,bam,$aligndir/1090/accepted_hits,bam 
$aligndir/0006/accepted_hits,bam,$aligndir/0007/accepted_hits,bam,$aligndir/0013/accepted_hits,bam,$aligndir/0006/accepted_hits,bam,$aligndir/
0007/accepted_hits,bam,$aligndir/0013/accepted_hits,bam 
Figure 2.7: The Cuffdiff script. This script was written to extract differential gene expression sequences from the 
blood and placenta dataset. 
 
The number of RNA-seq reads generated from a transcript is directly proportional to the 
relative abundance of that transcript in the sample and because cDNA fragments are generally 
size-selected as part of library construction, longer transcripts produce more sequencing 
fragments than shorter transcripts. In order to determine the correct expression level of each 
transcript, cufflinks must count the reads that map to each transcript and then normalize this 
count by each transcript's length. The commonly used fragments per kilobase of transcript per 
million mapped fragments (or FPKM, also known as RPKM in single ended sequencing 
experiments) is used to normalization expression levels for different genes and transcripts 
(Trapnell et al., 2012). Figure 2.7 shows the script written to run the cuffdiff command to 
extract differential expression gene sequences.  
CummeRbund (http://compbio.mit.edu/cummeRbund) is a powerful plotting tool which was 
used to create commonly used expression plots such as volcano, scatter and box plots, 
cummeRbund transforms cufflinks output files into R objects suitable for analysis with a wide 
variety of other packages available within the R environment. The cuffdiff output file was used 
as an input for cummeRbund.  
 
2.6 Candidate gene selection  
Pairwise comparisons between GDM cases and controls were carried out to identify genes 
that displayed significant (p<0.05) differential expression (log2 fold change> or <2) in the 
blood and placenta dataset. Corrections for multiple testing were performed using the  
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Benjamini-Hochberg correction method. Cuffdiff produced a list of thousands of genes which 
display differential expression between the case and control groups in both tissues.  A filtering 
process was required to identify genes whose differential expression was statsitically 
significant (qvalue<0.05). This helped to reduce this list to a smaller workable number of 
potential candidate genes which may play a role in the development of gestational diabetes.  
2.6.1 Functional annotation of genes  
For an interpretation of the biological functions and molecular processes of the genes that 
show a statistically significant level of differential expression between patient and control 
groups, Gene Ontology (GO) analysis using the PANTHER-v8.1 (Protein Analysis Through 
Evolutionary Relationships) Classification System (http://pantherdb.org/) and DAVID 
(Database for Annotation, Visualisation and Integrated Discovery) (https://david.ncifcrf.gov/) 
were used. PANTHER uses the binomial statistics tool to compare the input gene list to a 
reference list (NCBI: Homo sapiens genes) to determine the statistically significant over-
representation of functional groups of genes. Pathway level analysis of gene expression data 
was performed by Gene Set Enrichment Analysis (GSEA). The large gene lists were manually 
analysed to identify genes which displayed consistent significant differential expression in 
each of the individual GDM cases but not in any of the controls.  The filtering process enabled 
the identification of genes which are likely to be strong functional and biological candidates. 
A comprehensive literature search was done using OMIM, Google scholar and PubMed on 
each of the selected genes to identify a possible role in the development of GDM. Search terms 
used included, diabetes, diabetes susceptibility gene, gestational diabetes, insulin resistance, 
glycaemic control, biomarker and glucose metabolism. Using all of the above information, 
potential candidate genes were selected for validation.  
 
2.7 Validation of RNA sequencing data using TaqMan probe assays 
2.7.1 cDNA Synthesis 
Reverse transcription was performed on an input of 250 ng of total RNA per sample using the 
High Capacity RNA-to-cDNA kit (Thermo-Fisher Scientific). The reactions for each RNA sample 
as well as control reactions (do not contain reverse transcriptase (NRT)) were set up according 
to the manufacturer’s instructions. The cDNA was quantified using the Nanodrop, normalised 
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and stored at -20°C until needed (The protocol for reverse transcription is available in 
Appendix F).  
 
2.7.2 Preparing the TaqMan Gene Expression Assays 
Equal concentrations of each of the samples (100 ng of total cDNA) was used to accurately 
measure gene expression using the TaqMan assay method. Each assay (specific for each target 
gene) was pre-designed and readily available from Thermo-Fisher Scientific (The Assay 
number for each gene assay is listed in Appendix F). The expression of each of the target genes 
was normalised to the expression of three housekeeping genes namely, ACTB, HPRT1 and 
RPLP0. For each assay, every sample, including a calibrator, was run in triplicate, a no-reverse 
transcriptase and a no-amplification control was included. The TaqMan gene expression 
assays were run in a 384-well plate format in the ABI-7900HT Real-Time PCR machine. (The 
protocol for the TaqMan qPCR is available in Appendix F). 
 
2.7.3 qRT-PCR data analysis 
The data generated were analysed using the RQ (relative quantification) software on the ABI 
7900HT Real-Time PCR machine. Prior to analysis, specific parameters for the analysis of the 
data were configured following the instruction manual for this purpose. This included the 
selection of endogenous control samples, adjusting the baseline and threshold values as well 
as viewing the amplification and expression plots. The data were then exported for further 
analysis using the R/Bioconductor packages ReadqPCR and NormqPCR (Perkins et al., 2012).  
 
2.8 Promoter region methylation analysis of candidate genes  
The methylation status of selected CpG islands in the promoter regions of the G6PD (CpG Island 
115375), TKT (CpG Island 110332), IGFBP-1 (CpG Island 113146); IGFBP-2 (CpG Island 108855) and IGFBP-
6 (CpG Island 103158) genes were examined by methylation-specific PCR. This was carried out in 
the whole blood samples and placental tissue using the EpiTect Methyl II PCR assay (Qiagen) 
procedure. This method is based on the quantitative detection of remaining input DNA within 
a sample population after treatment with a methylation-sensitive (MSRE) and a methylation-
dependent (MDRE) restriction enzyme. Primers were designed by an optimized computer 
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algorithm to ensure that the amplicon contains cutting sites for both methyl-sensitive and 
methyl-dependent enzymes and are specifically designed for analyzing the DNA methylation 
status of CpG islands using restriction enzyme digestion (SABiosciences-Qiagen). 
Briefly, 2 µg input genomic DNA was aliquoted into four equal portions and subjected to mock 
(no enzyme), methylation-sensitive (MSRE), methylation-dependent (MDRE), and double 
(MSRE and MDRE) restriction endonuclease digestion. The product of the mock (no enzyme) 
digestion represents the total amount of input DNA for real-time PCR detection. In the 
methylation-sensitive digestion (Ms) reaction, the MSRE will digest unmethylated and 
partially methylated DNA. Consequently, the amount of DNA remaining in this reaction 
represents the fraction of fully methylated DNA within the sample population. The remaining 
hypermethylated DNA, DNA in which all CpG sites are methylated, will be detected by real-
time PCR. In contrast, the fraction of unmethylated DNA is determined by the methylation-
dependent digestion (Md) reaction as the MDRE will digest methylated DNA. The remaining 
unmethylated DNA was detected by real-time PCR. The amount of remaining input DNA in 
each digest is then normalized to the total amount of input DNA, which is determined by the 
mock-treated DNA fraction. Both enzymes are present in the double digestion (Msd) reaction 
so methylated and unmethylated DNA will be digested. This reaction measures the 
background and the fraction of input DNA vulnerable to enzyme digestion. To ensure 
restriction enzyme efficiency, two controls were added for each assay, Sensitive Enzyme 
Control (SEC) and Dependent-Enzyme Control (DEC).  
After digestion, the enzyme reactions were mixed directly with qPCR master mix and pre-
designed gene-specific primer mixes. Real-time PCR was carried out using specified cycling 
conditions (Full protocol can be found in Appendix G). Finally, the raw ∆CT values were pasted 
into the data analysis spreadsheet (provided by Qiagen) which automatically calculates the 
relative amount of methylated and unmethylated DNA fractions. Unmethylated represents 
the fraction of input genomic DNA containing no methylated CpG sites in the amplified region 
of a gene. Methylated represents fraction of input genomic DNA containing two or more 
methylated CpG sites in the targeted region of a gene.  Comparisons of gene promoter levels 
between 2 groups (cases blood vs controls blood, cases placenta vs controls placenta; cases 
blood vs cases placenta; controls blood vs controls placenta) were determined using two tailed 
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t-tests. A paired test was used when comparing the blood values with the placental values ie 
data derived from the same individual. When comparing the cases with the controls a non-
paired Student’s t test was used. The p-values of less than 0.05 were considered statistically 
significant. 
2.9 Inferring correlation networks using Spearman’s Rank correlation (SRC) 
In this study it is important to determine whether there is a correlation between the mRNA 
expression levels of a gene in either the blood or placental samples and other measured 
variables such as maternal glucose levels, maternal BMI and foetal birth weight. These 
correlations were determined using the SRC. Spearman’s correlation is a non-parametric 
statistical evaluation that is used to study the strength of a relationship between two variables 
(X and Y). The Spearman’s coefficient is denoted by Rs (or ρ) and the value of Rs ranges from 
-1 to 1. A perfect Spearman correlation (Rs = 1 or Rs = -1) indicates a monotonic relationship 
between the two ranked variables. The sign marks the direction of the correlation: ρ > 0 
(positive correlation) if Y tends to increase when X increases and ρ < 0 (negative correlation) 
if Y tends to decrease when X increased. A p-value for the association is also reported (a p ≤ 
0.05 is considered to indicate statistical significance). Spearman’s Rank correlation analysis 
was performed using Intellectus Statistics (http://www.intellectusstatistics.com) and the 
results were validated in Excel.  
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CHAPTER THREE 
3. RESULTS 
3.1 The identification and selection of study participants 
All GDM cases were diagnosed based on a fasting blood glucose level of ≥ 5.1 mmol/L; a 1-
hour blood glucose level of ≥ 10.0 mmol/L and/or a 2-hour blood glucose level of ≥ 8.5 mmol/L.  
If only one or more values were equal to or exceeded the diagnostic thresholds recommended 
by the IADPSG criteria GDM was diagnosed. Women who had normal blood glucose levels at 
each measured time frame (fasting ≤ 5.0 mmol/L; 1-hour ≤ 8.0 mmol/L and/or 2-hour ≤ 8.0 
mmol/L), were selected as controls. Table 3.1 lists the clinical and biochemical characteristics 
of the maternal group. The OGTT was performed at between 29 to 33 weeks gestation. Each 
measurement indicative of GDM is bolded in red. The difference in blood glucose levels at 
fasting and 1-hr is significantly different (p=0.003 and p=1.93 x 10-5, respectively) between the 
cases and controls. The blood glucose levels at 2-hr post OGTT was not found to be 
significantly different between the two biological groups (p=0.08). However, it was believed 
that the samples making up the two biological groups were diverse enough for the objectives 
of this study (Figure 3.1). Figure 3.1 illustrates that there is a clear separation between the 
blood glucose levels at each measured time point between the case and control samples used 
in this study. The OGTT values in the GDM group (cases) were higher at each measured point 
when compared to the values of the control group.   
 
Figure 3.1: The Oral Glucose Tolerance Test (OGTT) results for each case and control sample. The red and 
orange lines indicate GDM cases and the blue and purple lines represent controls.  
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The Body Mass Index (BMI) of the cases did not differ significantly (p=0.06) to that of the 
controls. The case group had a slightly higher overall BMI (37.9 kg/m2) in comparison to the  
control group (30.8 kg/m2). Women with gestational diabetes tend to have an abnormally high 
weight gain during pregnancy. To determine whether this was seen in the study participants, 
each women’s weight was recorded at each prenatal visit (at <14 weeks, 14-18 weeks, 19-23 
weeks, 24-28 weeks, 29-33 weeks and 34-38 weeks). The overall average weight gain in the 
case group was 11.4 kg which was slightly higher than the average weight gain in the control 
group which was 8.1 kg. This weight gain was not significantly different (p=0.052) between the 
GDM and control groups (Figure 3.2 and Table 3.1). It was not possible to match the cases and 
controls for age and BMI, but we attempted to align the two groups as closely as possible. The 
women with GDM had an average age of 31.3 years compared to 26.7 years for the NGT group. 
Half the GDM group were over 35 years of age, whereas only one control was. This is not 
surprising given that age is a risk factor for GDM, but for reasons not yet known. All women in 
the study were HIV negative, had no history of other diseases, were non-smokers and were 
not receiving any medication (with specific reference to insulin) at the time blood samples 
were taken. Therefore, the relevant differentiating variable between the biological groups is 
the presence or absence of gestational diabetes.  
 
Figure 3.2: A graphical illustration of the women’s weight gain during pregnancy. The red lines indicate case 
subjects and blue lines indicate control subjects.
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Table 3.1: The clinical and biochemical characteristics of the maternal study group. The values bolded in red are those equal to or exceeding the diagnostic threshold that 
is indicative of GDM. 
 Glucose levels   
Lab code 
Fasting  
(>5.1mmol/l) 
1 hr OGTT* 
(>10mmol/l)  
2 hr OGTT* 
(>8.5mmol/l) 
BMI (kg/m2) 
Visit 1 (<14 
weeks) 
Weight (kg) 
Visit 2 (14 - 
18 weeks) 
Weight (kg) 
Visit 3 (19 - 
23 weeks) 
Weight (kg) 
Visit 4 (24 - 
28 weeks) 
Weight (kg) 
Visit 5 (29 - 
33 weeks) 
Weight (kg) 
Visit 6 (34 - 
38 weeks) 
Weight 
gain (kg) 
Age 
(years) 
HIV Status 
Previous  
pregnancies 
GDM       (<                   
Case0_1054 5.56 9.65 6.95 35.4 98.4 101.8 102.1 101.1 108.5 10.1 39 Neg 1 
Case1_1048 5.9 9.19 9.03 36.5 80.6 83.1 85.4 86.5 89.7 9.1 23 Neg 0 
Case2_1060 5.28 9.38 4.17 36.1 93.2 97.5 100.3 99.9 104.5 11.3 25 Neg 0 
Case3_1086 4.52 9.64 8.91 36.2 89.2 90.1 90.9 92.3 98.6 9.4 35 Neg 1 
Case4_10225 4.64 10.75 6.71 48.5 116.2 122.4 122.5 122.6 125.3 17.9 31 Neg 1 
Case5_10276 5.16 8.14 9.15 35.0 96.3 99.5 102.3 105.7 106.8 10.5 35 Neg 1 
Group average 5.2 9.5 7.5 37.9 87.0 89.9 92.2 93.6 98.3 11.4 31.3 N/A 0.7 
NGT                           
Control0_1061 3.9 7.22 6.77 24.0 64.0 67.2 72.4 76.2 81.9 9.3 25 Neg 0 
Control1_1067 4.06 4.76 5.54 23.4 55.5 56.6 58.8 61.5 64.3 8.8 22 Neg 2 
Control2_1090 4.23 5.52 5.48 35.3 98.1 98.4 101.6 103.2 105.6 7.6 27 Neg 0 
Control3_1094 3.71 4.77 5.14 29.7 89.3 91.5 95.8 96.4 99.6 10.3 34 Neg 1 
Control4_1107 4.88 5.89 7.33 38.6 104.6 105.6 108.2 109.5 110.2 5.6 22 Neg 1 
control5_1087 3.82 4.77 3.64 34.0 86.9 90.5 89.4 92.8 93.6 6.7 30 Neg 0 
Group average 4.1 5.5 5.7 30.8 86.7 89.2 91.0 92.7 94.8 8.1 26.7 N/A 0.7 
Significance P = 0.003 P=0.00009 P=0.08 P=0.06      P=0.052    
Abbreviations: BMI: Body Mass Index; GDM: Gestational Diabetes Mellitus; NGT: Normal Glucose Tolerance; OGTT: Oral Glucose Tolerance Test; Neg: Negative     
*OGTT done at approximately 24 to 28 weeks gestation       
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With regards to the newborns (Table 3.2), there was no significant difference between  
gestational age at birth (38.5 vs 38.7 weeks, p=0.41) and birth weight (3.40 vs 3.38 kg; 
p=0.85) between exposed and unexposed placenta respectively.  
 
Table 3.2: Clinical characteristics of the foetal (newborn) study group 
Lab code Sex Birth Weight (kg) Length (cm) 
Gestational Age 
(weeks) 
GDM (mother)         
Case0_1054 FEMALE 3.68 44.0 39 
Case1_1048 FEMALE 3.12 46.2 39 
Case2_1060 FEMALE 3.43 44.6 38 
Case3_1086 FEMALE 3.28 48.1 37 
Case4_10225 FEMALE 3.22 42.1 38 
Case5_10276 FEMALE 3.68 45.2 40 
Group average N/A 3.40 45.0 38.5 
NGT (mother)         
Control0_1061 FEMALE 3.86 54.0 37 
Control1_1067 FEMALE 3.16 53.0 39 
Control2_1090 FEMALE 3.50 48.8 39 
Control3_1094 FEMALE 2.90 50.4 38 
Control4_1107 FEMALE 3.87 46.3 39 
Control5_1087 FEMALE 2.89 44.5 40 
Group average N/A 3.36 49.5 38.7 
Significance  P=0.85 P=0.41  
Abbreviations: GDM: Gestational Diabetes Mellitus; NGT: Normal Glucose Tolerance 
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3.2 Nucleic acid extraction from blood and placental tissue 
3.2.1 Deoxyribonucleic acid (DNA) 
The Nanodrop 1000 Spectrophotometer was used to measure the quantity (ng/µl) and 
quality (260/280 and 260/230 measurements) of the DNA extracted from whole blood and 
placental tissue. Table 3.3 and Table 3.4 lists these measurements for blood and placenta 
tissue respectively. Across both blood (b) and placental (p) samples, the DNA quality and 
quantity did not differ significantly. The concentration ranged from 302 ng/µl – 855.9 ng/µl 
for the blood samples and from 31 ng/µl – 162.3 ng/µl for the placental samples. The 
difference in the concentration range between the blood and placenta samples is 
noticeable and may be due to the different extraction kits/methods that were used for the 
different tissues (salting out versus a Qiagen kit). For the blood samples, the ratio of 
absorbance at 260/280 ranged from 1.79– 1.88 and the 260/230 values ranged from 2.25 
– 2.53.  For the placenta samples, the 260/280 values ranged from 1.82 – 2.03 and the 
260/230 values ranged from 2.05 – 2.63. Overall, the DNA extracted from whole blood and 
placental tissue was of good quality and efficient quantity for further downstream analysis.  
 
Table 3.3: The quality and quantity of the DNA extracted from the blood samples 
DNA from Blood (b) 
Concentration (ng/µl) 
Quantity 
(µg)* 
UV 260/280  UV 260/230 
Lab Code  
1b 10276 765.9 153.2 1.87 2.25 
2b 1107 164.0 32.8 1.79 2.38 
3b 1086 660.5 132.1 1.87 2.50 
4b 1067 617.1 123.4 1.90 2.29 
5b 1060 403.8 80.76 1.79 2.45 
6b 1061 265.4 53.08 1.80 2.53 
7b 10225 167.3 33.46 1.78 2.37 
8b 1094 690.4 138.1 1.87 2.45 
9b 1090 904.5 180.9 1.85 2.33 
10b 1048 242.7 48.54 1.80 2.53 
11b 1054 184.9 36.98 1.88 2.47 
12b 1087 215.7 43.14 1.79 2.60 
* Total volume eluted was 200 µl. Quantity (µg) calculated as concentration (ng/µl) * 200 µl/1000 
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Table 3.4: The quality and quantity of the DNA extracted from placental tissue 
DNA from Placenta (p) Concentration 
(ng/µl) 
Quantity (µg)* UV 260/280  UV 260/230 
Lab Code  
1b 10276 86.8 17.4 1.95 2.44 
2b 1107 119.5 23.9 2.02 2.63 
3b 1086 83.0 16.6 1.96 2.46 
4b 1067 110.7 22.1 1.98 2.14 
5b 1060 141.6 28.3 1.85 2.21 
6b 1061 81.4 16.3 1.82 2.05 
7b 10225 59.6 11.9 1.99 2.11 
8b 1094 159.9 31.9 1.90 2.45 
9b 1090 162.2 32.4 1.92 2.37 
10b 1048 113.4 22.7 1.82 2.11 
11b 1054 184.9 36.9 1.88 2.47 
12b 1087 108.5 21.7 2.03 2.46 
* Total volume eluted was 200 µl. Quantity (µg) calculated as concentration (ng/µl) * 200 µl/1000 
 
3.2.2 Ribonucleic Acid (RNA) 
The Agilent 2100 BioAnalyzer was used to measure the quality (RNA integrity number (RIN) 
and rRNA ratio measurements) and quantity (concentration ng/µl) of the RNA extracted 
from whole blood and placental tissue. The Nanodrop 1000 Spectrophotometer was used 
to obtain the 260/280 and 260/230 measurements which are also indicative of RNA purity. 
Tables 3.5 and 3.6 list the quality and quantity measurements of the RNA extracted from 
whole blood and placental samples respectively. The concentration of total RNA extracted 
from whole blood tissue ranged from 90.9 ng/µl – 455.8 ng/µl and from 84.2 ng/µl – 665.4 
ng/µl for the RNA extracted from the placental tissue. The differences in the concentration 
range between the different tissues is relatively small and may be due to the different 
extraction methods/kits used. The RIN and rRNA ratios indicate sample quality, RIN values 
>7 and rRNA ratios >1.7 indicate good quality RNA. The RIN values and rRNA ratio for the 
blood samples ranged from 7.3 – 8.5 and 1.7 – 2.2 respectively. The RIN values and rRNA 
ratio for the placenta samples ranged from 7 – 8.3 and 1.7 – 2.4 respectively (Table 3.5 and 
Table 3.6). The 260/280 ratio of absorbance values for the blood samples ranged from 2.02 
– 2.08 and the 260/230 values ranged from 2.05 – 2.47. For the placenta samples the 
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260/280 values ranged from 2.02 – 2.11 with the 260/230 values ranging from 2.05 – 2.57. 
Overall, the extracted RNA was of good quality and efficient quantity for further 
downstream analysis.  
 
Table 3.5: The quality and quantity of the total RNA extracted from blood  
RNA from Blood (B) 
Lab Code  
Concentration 
(ng/µl) 
Quantity 
(µg)* 
UV 
260/280 
 UV 
260/230 
RIN 
rRNA ratio 
(28s/18s) 
1b 10276 153.9 13.08 2.08 2.11 8.1 1.7 
2b 1107 90.9 7.73 2.02 2.05 8.0 1.7 
3b 1086 200.5 17.04 2.05 2.05 7.7 1.7 
4b 1067 278.3 23.66 2.05 2.33 8.0 1.7 
5b 1060 455.8 38.74 2.04 2.48 8.2 1.7 
6b 1061 300.7 25.56 2.05 2.46 8.2 1.8 
7b 10225 379.1 32.22 2.04 2.13 7.6 1.8 
8b 1094 262.4 22.3 2.05 2.47 8.2 1.8 
9b 1090 280.3 23.83 2.03 2.47 8.5 1.7 
10b 1048 300.3 25.53 2.05 2.29 7.4 1.9 
11b 1054 220.3 18.73 2.02 2.35 7.3 2.0 
12b 1087 101.8 8.65 2.07 2.38 7.3 2.2 
                        * Total volume eluted was 85 µl. Quantity (µg) calculated as concentration (ng/µl) * 85 µl/1000 
 
Table 3.6: The quality and quantity of the total RNA extracted from placental tissue 
RNA from Placenta (p) Lab Code 
Concentration 
(ng/µl) 
Quantity 
(µg)** 
UV 
260/280 
UV 
260/230 
RIN 
rRNA ratio 
(28s/18s) 
1p 10276 86.3 4.75 2.11 2.11 7.1 1.7 
2p 1107 84.2 4.63 1.98 2.05 7.0 1.7 
3p 1086 330.2 55.17 2.11 2.32 8.0 1.7 
4p 1067 665.4 29.06 2.05 1.94 7.6 1.8 
5p 1060 545.1 46.43 2.1 2.25 7.7 1.7 
6p 1061 527.4 31.48 2.03 2.33 7.5 1.9 
7p 10225 379.1 16.73 2.04 2.13 7.6 1.9 
8p 1094 262.1 10.64 2.05 2.57 8.2 2.4 
9p 1090 493.7 37.77 2.14 2.16 7.6 2.0 
10p 1048 400.0 36.05 2.14 2.18 7.0 2.2 
11p 1054 509.0 43.5 2.02 2.35 7.3 1.8 
12p 1087 471.7 31.61 2.08 2.25 8.3 1.7 
                  ** Total volume eluted was 55 µl. Quantity (µg) calculated as concentration (ng/µl) * 55 µl/1000 
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3.2.3 Globin mRNA removal from whole blood RNA 
Due to the large amounts of globin mRNA in whole blood samples which could potentially 
affect the outcome of sequencing results, the RNA extracted from whole blood was 
subjected to a globin removal step (this process is not necessary for the RNA samples 
extracted from placental tissue). This removal step may slightly decrease the quality and 
quantity of the RNA but may increase the identification of low expressing transcripts. It is 
necessary to re-measure the quality of the RNA once the mRNA globin has been removed.   
The quality and quantity measurements of the RNA after globin mRNA removal are listed 
in Table 3.7. Only a portion (3 µg) of the total extracted RNA samples was used as the input 
for this globin removal step. The ‘output’ indicates what percentage of RNA was lost in the 
removal step and this varied substantially across the samples (0.87 – 2.92 µg). An 
output/input ratio of 1 indicates that no RNA was lost during the removal process where a 
ratio of 0 indicates that the entire RNA sample was lost.  The output/input ratio ranged 
from 0.29 – 0.97. Although some samples lost >50 % of input RNA (sample 1b and 2b), the 
quantity and quality of all these samples was sufficient to continue with mRNA library 
preparation.  
According to the literature, the RIN and rRNA ratio of RNA should decrease after a globin 
removal step (Krjutskov et al., 2016, Liu et al., 2006). Figure 3.3 illustrates an overall 
decrease (in approximately 1 unit for each sample) in the rRNA ratio for the RNA samples 
but an unexpected increase (in approximately 1 unit for each sample) in the RIN. The RIN 
measurement was repeated on two different BioAnalyzer machines but had the same 
result each time. The rRNA ratios after globin removal ranged from 1-1.8 (still acceptable 
for sequencing according to Illumina) and the RIN ranged from 7.2 – 9.1. 
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Table 3.7: The quality and quantity of the RNA AFTER the globin mRNA removal step 
Blood RNA 
Samples  
Concentration 
(ng/µl) 
Input 
Quantity (µg) 
Total RNA 
Output 
Quantity 
(µg) 
Ratio 
(Output µg/ 
Input µg) 
UV 
260/280 
 UV 
260/230 
RIN 
rRNA ratio 
(28S/18S) 
1b 34.9 3 0.87 0.29 1.87 0.30 9.1 1.6 
2b 46.3 3 1.16 0.39 1.96 0.49 9.0 1.7 
3b 77.9 3 1.95 0.65 2.04 0.85 8.7 1.2 
4b 93.6 3 2.34 0.78 2.03 0.81 8.9 1.5 
5b 103.9 3 2.6 0.87 2.01 0.63 8.7 1.6 
6b 86.8 3 2.17 0.72 1.99 0.89 8.4 1.0 
7b 91.0 3 2.28 0.76 2.02 0.79 8.6 1.6 
8b 64.0 3 1.6 0.53 2.01 0.61 8.8 1.7 
9b 100.4 3 2.51 0.84 1.97 0.80 9.0 1.7 
10b 116.7 3 2.92 0.97 1.99 1.05 7.2 1.0 
11b 90.4 3 2.25 0.75 2.02 0.95 8.4 1.8 
12b 85.3 3 2.13 0.71 2.01 0.72 8.0 2.0 
 
A)      B) 
       
Figure 3.3: The average change in RNA integrity by A) RIN measurement and B) rRNA ratio after the globin 
mRNA step.  
 
3.3 cDNA library preparation using the Illumina TruSeq Stranded mRNA preparation kit  
The quality and quantity of the RNA extracted from whole blood and placental tissue met 
the Illumina quality control guidelines (Conesa et al., 2016, Trapnell et al., 2013, Trapnell et 
al., 2012). All samples were therefore used for cDNA/mRNA library preparation for RNA 
sequencing.  
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3.3.1 Library Validation 
The concentrations of the libraries varied significantly (1.51 – 28.23 ng/µl), however, even 
the library with the smallest concentration (1.51 ng/µl) was sufficient for sequencing. 
According to the Illumina protocol, the size of the libraries should be >260 bp; these ranged 
from 296 – 361 bp. No samples failed library preparation and each library was used for 
sequencing. 
Table 3.8: The quantity and size of the resulting mRNA libraries 
mRNA library 
results               
BLOOD RNA 
Concentration 
(ng/µl) 
Size (bp) 
Molarity 
(nmol/l) 
mRNA library 
results PLACENTAL 
RNA 
Concentration 
(ng/µl) 
Size 
(bp) 
Molarity 
(nmol/l) 
1b 10276 1.5 337 7.2 1p 10276 24.1 336 115.0 
2b 1107 30.0 337 146.6 2p 1107 20.4 320 101.4 
3b 1086 7.5 296 38.5 3p 1086 19.0 322 94.2 
4b 1067 21.4 296 109.8 4p 1067 28.2 333 136.3 
5b 1060 7.1 312 35.9 5p 1060 6.1 337 32.7 
6b 1061 11.4 337 54.5 6p 1061 8.3 316 39.9 
7b 10225 26.7 324 132.4 7p 10225 20.7 335 99.5 
8b 1094 12.3 337 58.7 8p 1094 19.7 327 96.1 
9b 1090 16.0 361 72.2 9p 1090 9.3 337 50.0 
10b 1048 5.0 296 28.2 10p 1048 0.6 337 3.4 
11b 1054 13.9 359 63.1 11p 1054 15.8 326 73.8 
12b 1087 18.8 322 92.8 12p 1087 21.9 315 110.8 
                                     
3.3.2 Whole genome-sequencing using the Illumina HiSeq 2000 Sequencing System   
Sequencing in the HiSeq was set up to ensure excellent coverage of each sample: 4 samples 
per lane; 75 bp paired end (sequencing from the left and right). This criteria should produce 
more than 50,000,000 reads per sample. These millions of reads were mapped against a 
reference human genome (UCSC: GRCh38). Table 3.9 gives the sequencing statistics for 
each sample. The statistics include the following: Input: this is the total number of raw 
sequences generated through sequencing; Mapped Left Reads: this is the number of 
forward sequence reads mapped to the genome; Mapped Right Reads: this is the number 
of reverse sequence reads mapped to the genome and the Alignment Score: this is the 
percentage reflecting how well the total input raw reads aligned/mapped to the reference 
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genome, Illumina recommends an overall alignment score of >80 % and a Phred score of 
>30 (which indicates that base calling was done with 99.9 % accuracy and only 1:1000 bases 
were called with inaccuracy). The overall alignment/read mapping rate of the samples in 
this study ranged from 89.3 – 97.4 % and more than 96 % of the sequences were called 
with 99.99 % accuracy. For each sample, with the exception of 1048 placenta, more than 
90 % of the produced reads mapped successfully to the genome. For sample 1048 placenta, 
only 80 % of the produced sequences mapped to the genome. This is still acceptable by 
Illumina guidelines.  
Table 3.9: Sequencing statistics 
 
 
Input (No of 
reads) 
Mapped Left 
Reads 
% of 
input 
Mapped 
Right Reads 
% of input 
Alignment (% 
overall read 
mapping rate) 
Phred 
quality 
score (Q 
score>30) 
1048placenta 52026636 41869010 90.5 40679970 88.2 89.3 96.0 
1061placenta 58358710 53917568 92.4 52954040 90.7 91.6 96.1 
1048blood 55158114 51531303 93.4 51174684 92.8 93.1 96.6 
1054placenta 62219053 60113365 96.6 59576938 95.8 96.2 96.4 
1060placenta 53042983 49708403 93.7 49277347 92.9 93.3 96.5 
1090Placenta 72058148 70076414 97.2 69514836 96.5 96.9 96.7 
1086blood 70811795 67064391 94.7 66704621 94.2 94.5 96.3 
1067blood 69716379 67577952 96.9 66556776 95.5 96.2 96.0 
10276blood 88050506 84099631 95.5 82784494 94.0 94.8 96.4 
1094blood 85513343 83033919 97.1 82120902 96.0 96.6 96.1 
1086placenta 93613852 91290170 97.5 89748267 95.9 96.7 95.9 
1087placenta 85648415 83597848 97.6 82739970 96.6 97.1 97.0 
1061blood 80754619 78394763 97.1 77565393 96.1 96.6 96.7 
10225blood 86701746 84773781 97.8 83829540 96.7 97.2 96.8 
1094placenta 106504113 103139807 96.8 102629475 96.4 96.6 96.4 
1067placenta 99974533 96665446 96.7 95934572 96.0 96.3 95.6 
1090blood 72043915 69224839 96.1 68632978 95.3 95.7 95.5 
1107blood 82069631 79334105 96.7 78347937 95.5 96.1 96.4 
10276placenta 88442275 85757815 97.0 85097904 96.2 96.6 96.2 
1107placenta 61240854 59534955 97.2 58938622 96.2 96.7 96.4 
1054blood 72312560 69857753 96.6 69455306 96.0 96.3 95.7 
1060blood 79262465 76974845 97.1 76531105 96.6 96.8 96.0 
1087blood 79620469 76964845 97.2 76963734 97.2 97.4 96.5 
10225placenta 70396381 61189834 96.9 60458960 95.6 96.3 96.5 
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Figure 3.4 illustrates the number of sequences produced per sample and the number of 
these sequences that successfully mapped to the reference genome. Each of the samples 
produced over 50,000,000 reads, with the range being 52,026,636 to 106,504,113. The 
mapped left reads for each sample did not differ significantly to the mapped right reads 
indicating good sequencing coverage for each sample.  
 
 
Figure 3.4: The total number of sequencing reads generated per sample.  The number of reads which 
successfully mapped to the reference human genome (Genome Reference Consortium GRCh38 (hg38)) are 
also given. 
  
3.3.2.1 FASTQC Quality Control of sequencing fragments 
The quality of all of the sequences produced for each sample was evaluated using a 
program called FASTQC. FASTQC gives an indication of the following: per base sequence 
quality which is an overview of the range of quality values across all bases at each position; 
per sequence quality score which indicates if a subset of the sequences have universally 
low quality values; per base sequence content which plots out the proportion of each base 
position for which each of the four normal DNA bases has been called; per base GC content 
which plots out the GC content of each base position; per sequence GC content which 
measures the GC content across the whole length of each sequence and compares it to a 
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modelled normal distribution of GC content; per base N content which plots out the 
percentage of base calls at each position for which an N was called; sequence length 
distribution which generates a graph showing the distribution of fragment sizes in the file 
which was analysed and an indication of duplicate sequences and overrepresented 
sequences.  A FASTQC file was generated for each sample. All sequences for each sample 
passed the QC evaluation and trimming of unreliable sequences was not necessary.  All  of 
the sequences produced for each sample were used for downstream differential 
expression analysis.  
 
3.4. Analysing data generated from BLOOD (GDM vs NGT) comparisons 
Once the aligned sequences passed the quality check, they were analysed using cufflinks 
and cuffdiff.  
3.4.1 Cuffdiff output analysis 
Table 3.10 lists the output generated by cuffdiff once it has been exported into an excel 
format. The test_id and gene_id are the Ensembl gene IDs and are unique identifiers 
describing the transcript, gene, primary transcript, or CDS being tested. The gene is 
identifed through its gene name. The genomic coordinate (locus) of the gene is also given. 
Sample_1 represents the control group and Sample_2 represents the case group. The test 
status is either given as OK (test successful), NOTEST (not enough alignments for testing), 
LOWDATA (too complex or shallowly sequenced), HIDATA (too many fragments in locus), 
or FAIL, when an ill-conditioned covariance matrix or other numerical exception prevents 
testing. Value_1 and value_2 represent the FPKM (Fragments Per Kilobase of transcript per 
Million mapped reads) values of Sample_1 (controls) and Sample_2 (cases) respectively. 
The log2 fold change value is the (base 2) log of the fold change Sample_2(cases)/Sample_1 
(controls). Therefore a positive log2 fold change represents an up-regulation of gene 
expression in the case group and a negative log2 fold change represents a down-regulation 
of the gene in the case group. The test_stat is the value of the test statistic used to compute 
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significance of the observed change in FPKM. The p-value is the uncorrected p-value of the 
test statistic and the q-value is the FDR-adjusted p-value of the test statistic. The significant 
column can be either “yes” or “no”, depending on whether the p-value is greater than the 
FDR after Benjamini-Hochberg correction for multiple-testing.  
 
Table 3.10: The output data obtained from running Cuffdiff on the blood dataset. The same information is 
given for the placenta dataset.  
test_id 
ENSG000000 
gene_id 
ENSG000000 
gene locus sample_1 sample_2 status 
75213 75213 SEMA3A 7:83587658-84122040 Controls Cases OK 
81985 81985 IL12RB2 1:67773046-67862583 Controls Cases OK 
156113 156113 KCNMA1 10:78637354-79398353 Controls Cases OK 
175445 156113 LPL 8:19759227-19824769 Controls Cases OK 
       
value_1 value_2 log2(fold_change) test_stat p_value q_value significant 
0.069 0.302 2.114 0.771 3.5E-04 2.1E-02 yes 
0.808 2.438 1.592 1.490 4.5E-04 2.5E-02 yes 
0.062 0.365 2.560 0.486 1.2E-03 4.8E-02 yes 
0.547 1.408 1.362 1.473 5.0E-05 5.1E-03 yes 
 
3.4.2 The filtering process used to reduce the number of potential candidate 
genes 
A simple filtering process was used to identify genes which displayed significant differential 
expression (qvalue<0.05; log2 fold change of >2 or <-2) between cases (women who 
develop gestational diabetes) and controls (women with normal glucose tolerance during 
pregancy).  The data were first sorted to only include genes with an “OK” status (N=17980). 
Only a few genes had the LOWDATA (N=32) and HIDATA (N=4) outcome and were 
subsequently excluded. The second filtering step removed all the genes that did not display 
significant differential expression (qvalue>0.05) between the cases and controls. This 
filtering step reduced the number of potential candidates. The level of statistical 
significance was increased to qvalue<0.05 and only genes with this level of significant 
differential expression were included. The total number of genes displaying highly 
significant (qvalue<0.05) differential expression beween the two groups was 440. The third 
filtering step focused on genes with highly significant (qvalue<0.05) differential expression 
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greater than 1 fold between the two biological groups. This gene list was further reduced 
by focussing on genes which had a differential expression greater than 2 fold between the 
two biological groups. These genes were targeted as potential candidates as they displayed 
the largest difference in expression between GDM cases and controls. This reduced the 
number of genes of interest to 60 (Figure 3.5).        
                            
 
 
 
 
 
 
 
 
 
 
Figure 3.5: A flow diagram depicting how the genes of interest from the blood dataset were selected for 
further analysis. 
 
3.4.2.1 The identification of genes displaying significant differential 
expression between case and control blood samples 
The volcano plot (Figure 3.6) plots the relationship between the p-values of a statistical test 
and the magnitude of the difference in expression of 17980 genes.  The -log10 p-values are 
plotted on the y-axis and the log2 fold change values are plotted on the x-axis. The red 
circles indicate the genes of interest that display both large-magnitude fold-change (x-axis) 
Total number of genes identified in the blood dataset  
with OK status N=17980  
Include only genes with statistically 
significant (p-value<0.05) differential 
expression Filter: Increase level of 
statistical significance to qvalue<0.05 
N = 440 
 
 N=440 
Filter: log2 fold change > 1 
or <1; qvalue<0.05 N=369 
Filter: log2 fold 
change >2 or 
<2; qvalue<0.05 
N=60 
Gene classification 
using OMIM 
Gene Ontology and 
enrichment analysis using 
PANTHER and DAVID 
Inspection of gene 
expression in each 
individual’s sample 
Literature research to 
identify genes linked 
to diabetes/glucose 
metabolism 
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as well as high statistical significance (-log10 of p-value, y-axis). The dashed red-line shows 
where qvalue = 0.05 with points above the line having qvalue < 0.05 and points below the 
line having qvalue > 0.05. This plot is colored such that the green points represent the genes 
with significant (qvalue>0.05) fold change of more than 1 (log2 < 1). The red dots represent 
genes with significant (qvalue>0.05) fold change of more than 2.   
         
Figure 3.6:  The volcano plot illustrating significant fold change differential expression for the blood data 
set comparing cases to controls. Volcano plot for the 17980 genes from the blood data set (log2 fold 
change >1; qvalue<0.05: green; log2 fold change >2; qvalue<0.05: red).  
 
The scatter plot (Figure 3.7) illustrates the relationship between the corrected p-value (q-
value) and the log2 fold change value of the genes which display the largest difference in 
expression and highest statistical significance (red dots in the volcano plot). The majority 
of the genes had a lower (-)(down regulated) gene expression in cases when compared to 
controls. Only 3 genes (KCNMA1; SEMA3A and GSK3A) had a higher (up regulated) 
expression in cases.  
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Figure 3.7:  The Scatter Plot illustrating the genes which display significant fold change differential 
expression for blood dataset when comparing cases to controls. The scatter plot shows only the genes 
which have a log2 fold change >2 and <-2; qvalue<0.05 (corrected for multiple testing). 
 
The 60 genes showing the most significant and largest differential expression in the case 
group (as highlighted in Figure 3.7) were used for further analysis. Table 3.11 lists these 
gene names, their location within the genome, the log2 fold change values and the 
corresponding p-value (showing level of significance) as well as the q-value. The q-values 
are the Benjamini-Hochberg corrected p-value measure (corrected for multiple testing). 
 
Table 3.11: The top genes (N=60) displaying significant (qvalue<0.05) differential expression between 
cases and controls in the blood data set  
Gene_id 
ENSG00000 
Gene Symbol Gene Name Locus 
log2(fold_ch
ange) 
p_value q_value 
2726 ABP1 amiloride binding protein 1  7:150521714-150558592 -2.14 8.00E-04 0.0389 
105221 AKT2 RAC-beta serine/threonine-protein kinase 19:40736223-40791443 -2.28 5.00E-05 0.0052 
149925 ALDOA Fructose-bisphosphate aldolase A 16:30064410-30081778 -2.26 1.00E-04 0.0089 
99624 ATP5D ATP synthase subunit delta. mitochondrial 19:1241748-1244824 -2.05 4.50E-04 0.0257 
175756 AURKAIP1 Aurora kinase A-interacting protein 1:1309109-1310875 -2.05 5.00E-05 0.0052 
177191 B3GNT8 
BetaGal beta-1.3.N 
acetylglucosaminyltransferase8 
19:41931263-41934635 -2.26 6.00E-04 0.0319 
168062 BATF2 
Basic leucine zipper transcriptional factor 
ATF-like 2 
11:64755414-64764517 -2.23 5.00E-05 0.0052 
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185347 C14orf80 Uncharacterized protein C14orf80 
14:105952653-
105965912 
-2.13 
 1.00E-
04 
0.0089 
173369 C1QB Complement C1q subcomponent subunit B 1:22979254-22988031 -2.10 5.00E-05 0.0052 
7080 CCDC124 Coiled-coil domain-containing protein 124 19:18043824-18054800 -2.16 3.50E-05 0.0219 
229119 CTB-63M22.1 Not Annotated 5:165809309-165809604 -3.49 7.55E-04 0.0372 
169738 DCXR Xylulose reductase 17:79993011-79995608 -2.18 5.50E-04 0.0299 
164741 DLC1 Rho GTPase-activating protein 7 8:12940869-13373167 -2.34 5.00E-05 0.0052 
147647 DPYS Dihydropyrimidinase 8:105342551-105479281 -2.61 8.00E-04 0.0402 
228502 EEF1A1P11 Not Annotated 1:96912485-96913874 -3.83 5.00E-05 0.0052 
225663 FAM195B Protein FAM195B 17:79780286-79791178 -2.51 5.00E-05 0.0052 
160211 G6PD Gluscose-6-phosphate dehydrogenase X:153759605-153796782 -3.09 5.00E-05 0.0052 
171298 GAA Lysosomal alpha glucosidease 17:78075354-78093678 -2.88 5.00E-05 0.0052 
169704 GP9 Platelet glycoprotein IX 3:128779609-128781249 -2.87 5.00E-05 0.0052 
250510 GPR162 Not Annotated 12:6930710-6949018 -3.44 5.00E-05 0.0052 
105723 GSK3A Glycogen synthase kinase-3 alpha 19:42734337-42759309 3.20 5.00E-05 0.0052 
188536 HBA2 Hemoglobin. alpha 2; hemoglobin. alpha 1 16:222845-223709 -3.17 5.00E-05 0.0052 
86506 HBQ1 Hemoglobin subunit theta-1 16:230451-231180 -2.56 5.00E-05 0.0052 
196331 HIST1H2BO Histone H2B type 1-O 6:27861202-27861669 -2.13 1.00E-04 0.047 
203813 HIST1H3H Not Annotated 6:27777841-27778314 -2.86 1.00E-04 0.0089 
146678 IGFBP-1 Insulin growth factor binding protein 1 7: 45888357 - 45893668 -2.22 5.00E-05 0.0052 
211895 IGHA1 Ig alpha-1 chain C region 
14:106173456-
106175002 
-2.19 5.00E-05 0.0052 
211890 IGHA2 Ig alpha-2 chain C region 
14:106053225-
106054732 
-2.10 5.00E-05 0.0052 
211677 IGLC2 Ig lambda-2 chain C regions 22:23243155-23243617 -3.43 5.00E-05 0.0052 
211662 IGLV3-21 Immunoglobulin lambda variable  22:23054173-23055688 -2.49 5.00E-05 0.0052 
185507 IRF7 Interferon regulatory factor 7 11:612552-615999 -2.62 5.00E-05 0.0052 
187608 ISG15 Ubiquitin-like protein ISG15 1:948802-949920 -3.39 5.00E-05 0.0052 
156113 KCNMA1 
Calcium-activated potassium channel subunit 
alpha-1 
10:78637354-79398353 2.56 1.15E-03 0.048 
53918 KCNQ1 
Potassium voltage-gated channel subfam KQT 
member 
11:2465913-2882798 -2.02 1.00E-04 0.0089 
110811 LEPREL2 Prolyl 3-hydroxylase 3 12:6930710-6949018 -2.74 5.00E-05 0.0052 
112139 MDGA1 
MAM domain glycosylphosphatidylinositol 
anchor 1  
6:37598454-37667082 -4.75 5.00E-05 0.0052 
162576 MXRA8 Matrix-remodeling-associated protein 8 1:1288068-1297157 -2.16 5.00E-05 0.0052 
147813 NAPRT1 Nicotinate phosphoribosyltransferases 8:144655659-144660819 -2.16 5.00E-05 0.0052 
165178 NCF1C Putative neutrophil cytosol factor 1C 7:74572444-74587848 -2.89 5.00E-05 0.0052 
174886 NDUFA11 
NADH dehydrogenase 1 alpha subcomplex. 
11 
19:5865836-5904017 -2.19 4.00E-03 0.0239 
107281 NPDC1 
Neural proliferation differentiation control 
protein 1 
9:139933921-139940655 -2.07 5.00E-05 0.0052 
79156 OSBPL6 Oxysterol binding protein-like 6 2:179059207-179264160 -2.09 5.00E-05 0.0052 
172367 PDZD3 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF4 
11:119056165-
119067479 
-2.04 0.00065 0.0337 
130313 PGLS 6-phosphogluconolactonase 19:17579577-17632097 -2.52 2.00E-03 0.0198 
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257704 PRR24 Not Annotated 19:47778141-47778979 -2.28 5.00E-03 0.028 
107317 PTGDS Prostaglandin-H2 D-isomerase 9:139871955-139880862 -2.82 1.00E-04 0.0089 
183010 PYCR1 
Pyrroline-5-carboxylate reductase 1. 
mitochondrial 
17:79890259-79905477 -2.34 2.00E-03 0.0492 
265150 RN7SL2 Not Annotated 14:50329270-50329567 -3.06 5.00E-05 0.0052 
236552 RPL13AP5 Ribosomal protein L13a pseudogene 5 10:98510044-98510675 -2.09 5.00E-05 0.0052 
215030 RPL13P12 Not Annotated 17:17286690-17287326 -2.39 5.00E-05 0.0052 
125910 S1PR4 Sphingosine 1-phosphate receptor 4 19:3172343-3180329 -2.07 5.00E-05 0.0052 
139410 SDSL Serine dehydratase-like 
12:113830249-
113876081 
-2.76 1.50E-03 0.012 
75213 SEMA3A Semaphorin-3A 7:83587658-84122040 2.11 0.00035 0.0219 
74803 SLC12A1 Solute carrier family 12 member 1 15:48481233-48596275 -3.29 5.00E-05 0.0052 
177542 SLC25A22 Mitochondrial glutamate carrier 1 11:790474-798316 -2.23 5.00E-05 0.0052 
183751 TBL3 Transducin beta-like protein 3 16:2022037-2034193 -2.10 1.00E-04 0.0355 
163931 TKT Transketolase 3:53258722-53290068 -2.94 5.00E-05 0.0052 
184281 TSSC4 Protein TSSC4 11:2421717-2425106 -2.29 1.50E-03 0.012 
263563 UBBP4 Protein UBBP4 17:21729600-21731762 -2.05 5.00E-05 0.0052 
160446 ZDHHC12 Probable palmitoyltransferase ZDHHC12 9:131464801-131486406 -2.37 5.00E-05 0.0052 
 
After the filtering process, only the genes which displayed the largest change in expression 
(log2 fold change >2 and <-2) at a high significance (q<0.05) were chosen for further analysis 
(N=60). The genes are organised alphabetically. 
3.4.2.2 Gene ontology  
The list of significantly differentially regulated genes (N=60; Table 3.11) was sorted into 
gene ontology (GO) term categories for molecular function and biological processes using 
the programs DAVID (https://david.ncifcrf.gov/ ) and PANTHER (http://pantherdb.org/).  
The molecular function GO terms associated with the differentially regulated genes include 
a large percentage annotated as “binding activity” (39.7%) and “catalytic activity” (34.5%) 
(Figure 3.8). Other differentially regulated gene molecular function GO terms included 
those for “receptor activity” (5.2%); “structural molecule activity” (6.9%); “transporter 
activity” (12.1%) and “transcription factor activity” (1.7%). The biological process of 
differentially regulated genes GO terms included “metabolic process” (26.9%), “cellular 
process” (25.8%), “developmental process” (9.0%); “immune system process” (9.0%); 
“localization” (6.7%); “biological regulation” (5.6%); “biogenesis” (4.5%); “biological 
adhesion” (3.4%) and “apoptotic process” (1.2%) (Figure 3.8).  
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Figure 3.8: Functional categories based on the molecular process and biological function for the top 60 
genes using DAVID and PANTHER.  
 
Table 3.12 lists these top 60 genes with their molecular function and biological process. 
The genes which function in metabolic processes are shown in bold in red. From these gene 
ontology analyses, metabolic processes were among the most significant processes 
represented by the gene set. Diabetes is a metabolic disorder, and for this reason, these 
genes are strong functional candidates. These genes include; AKT2 (RAC-beta 
serine/threonine-protein kinase); ALDOA (Fructose-bisphosphate aldolase A) ; ATP5D (ATP 
synthase subunit delta, mitochondrial); B3GNT8 (BetaGalbeta-1,3,N 
acetylglucosaminyltransferase8); DCXR (Xylulose reductase); G6PD (Glucose-6-phosphate 
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dehydrogenase); GAA (Lysosomal alpha glucosidase); GSK3A (Glycogen synthase kinase-3 
alpha); HIST1H2BO (Histone H2B type 1-O); ISG15 (Ubiquitin-like protein ISG15); NAPRT1 
(nicotinate phosphoribosyltransferases); NCF1C (Putative neutrophil cytosol factor 1C); 
PDZD3 (Na(+)/H(+) exchange regulatory cofactor NHE-RF4); PGLS (6-
phosphogluconolactonase); PTGDS (Prostaglandin-H2 D-isomerase); PYCR1 (Pyrroline-5-
carboxylate reductase 1, mitochondrial), TKT (Transketolase) and UBBP4 (Protein UBBP4). 
 
Table 3.12: Gene ontology results using DAVID and PANTHER for the top 60 genes found to be 
differentially expressed in the blood data set         
 
Gene_id 
ENSG000000 
Gene Molecular Function  Biological Process  
002726 ABP1 Binding Cellular 
105221 AKT2 
Binding; Catalytic  
Apoptotic; Biological regulation; Biogenesis; 
Cellular; Developmental; Metabolic 
149925 ALDOA Binding; Catalytic  Metabolic 
099624 ATP5D Catalytic; Transporter Cellular; localization; Metabolic 
175756 AURKAIP1 No hit Developmental 
177191 B3GNT8 
Catalytic  
Cellular; Developmental; Metabolic; Multicellular 
organismal; Reproductive 
168062 BATF2 Binding; Transcription Factor   Cellular; biological regulation 
185347 C14orf80 No hit No hit 
173369 C1QB Binding; Catalytic  Immune system response 
007080 CCDC124 No hit No hit 
229119 CTB-
63M22,1 
Not annotated No hit 
169738 DCXR Catalytic  Metabolic 
164741 DLC1 Catalytic  Developmental 
147647 DPYS Catalytic  Metabolic 
228502 EEF1A1P11 Not annotated No hit 
225663 FAM195B 
Catalytic; Receptor  
Apoptotic; Biological regulation; Cellular; 
Developmental 
160211 G6PD Catalytic  Metabolic 
171298 GAA Catalytic  Metabolic 
169704 GP9 No hit Biological adhesion; Cellular 
250510 GPR162 Not annotated No hit 
105723 GSK3A 
Catalytic  
Cellular; Developmental; Metabolic; multicellular 
organismal 
188536 HBA2 Binding; Transporter  Cellular 
086506 HBQ1 Binding; Transporter  Localization; Multicellular organismal  
196331 HIST1H2BO Binding Biogenesis; Cellular;  
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203813 HIST1H3H Not annotated No hit 
146678 IGFBP-1 Binding 
Biological Regulation, Cellular; Response to stimuli; 
Metabolic 
211895 IGHA1 Binding Immune system response 
211890 IGHA2 Binding Immune system response 
211677 IGLC2 Binding Immune system response 
211662 IGLV3-21 Binding Immune system response 
185507 IRF7 No hit Immune system process; response to stimulus 
187608 ISG15 Binding; Structural  Metabolic 
156113 KCNMA1 Transporter  Biological regulation; Cellular; localization 
053918 KCNQ1 Transporter  Biological regulation; Cellular; Localization 
110811 LEPREL2 Binding; Catalytic  Biological adhesion; Cellular 
112139 MDGA1 No hit Developmental 
162576 MXRA8 No hit No hit 
147813 NAPRT1 Catalytic  Metabolic 
165178 NCF1C Binding; Catalytic  Cellular 
174886 NDUFA11 No hit Cellular 
107281 NPDC1 No hit No hit 
079156 OSBPL6 No hit Cellular; Localization 
172367 PDZD3 Catalytic  Metabolic; Cellular 
130313 PGLS Catalytic  Metabolic 
257704 PRR24 Not annotated No hit 
107317 PTGDS Binding; Catalytic  Cellular;; localization 
183010 PYCR1 Catalytic  Metabolic; Cellular 
265150 RN7SL2 Not annotated No hit 
236552 RPL13AP5 Structural Cellular 
215030 RPL13P12 Not annotated No hit 
125910 S1PR4 Receptor  Cellular 
139410 SDSL Binding Biological adhesion 
075213 SEMA3A 
Binding 
Cellular; Developmental; Immune system; 
Multicellular organismal 
074803 SLC12A1 Transporter  Cellular 
177542 SLC25A22 Binding; Structural; Transporter  Localization; Metabolic 
183751 TBL3 Binding Biogenesis; Cellular; Metabolic 
163931 TKT Catalytic  Metabolic 
184281 TSSC4 No hit No hit 
263563 UBBP4 Binding; Structural   Metabolic 
160446 ZDHHC12 Binding No hit 
 No hit: No known recorded biological process or molecular function in PANTHER and/or DAVID database 
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Genes that have not yet been annotated (CTB63M22,1; EEF1A1P11; GPR162; HIST1H3H; 
PRR44; RN7SL2 and RPL13P12) were excluded from further analysis. In order to identify 
what pathways these genes may play a role in, the PANTHER and KEGG 
(http://www.kegg.jp/kegg/pathway.html) gene list classification systems were used. Table 
3.13 lists the known pathways that these genes are associated with. Only 11 genes out of 
the 60 genes of interest had known links to annotated pathways in the KEGG database.  
Pathways of interest include the fructose galactose metabolism pathway (P02744); 
glycolysis (P00024); insulin/IGF pathway (P00033) and the pentose phosphate pathway 
(P02762) as they all have a function in the metabolism of sugars (in bold in red in Table 
3.13). The genes associated with these pathways are ALDOA; AKT2; GSK3A; TKT; DCXR; 
PGLS; and G6PD.  
 
Table 3.13: Pathway analysis using PANTHER and KEGG 
 
 Pathways in bold in red indicate pathways of interest as they  all function to some extent in the metabolism of sugars 
 FGF: Fibroblast Growth Factor; IGF: Insulin Growth Factor; PDGF: Platelet derived growth factor; RIG: retinoic acid-inducible 
gene 1 
 
PANTHER/KEGG pathway Gene 
Axon guidance (P000007) SEMA3A, AKT2 
Angiogenesis (P00005) AKT2 
Apoptosis Signalling pathway (P00006) AKT2 
Blood coagulation (P00011) GP9 
Endothelin signalling pathway (P00019) AKT2 
FGF signalling pathway (P00021) AKT2 
Fructose galactose metabolism (P02744) ALDOA 
Glycolysis (P00024) ALDOA 
Heterotrimeric G-protein signalling pathway (P00026) GSK3A 
Huntington disease (P00029) AKT2 
Hypoxia response via HIF activation (P00030) AKT2 
Inflammation mediated by chemokine and cytokine signalling pathway (P00031) AKT2 
Insulin/IGF pathway (P00033) GSK3A, AKT2 
Interleukin signalling pathway (P00036) AKT2 
Oxidative phosphorylation (66043) ATP5D 
PDGF signalling pathway (P00047) GSK3A; AKT2 
PI5 kinase pathway (P00048) AKT2 
Pentose phosphate pathway (P02762) ALDOA, TKT, DCXR, G6PD, PGLS 
Proline biosynthesis (P02768) PYCR1 
Ras pathway (P04393) GSK3A 
RIG-I-like receptor signalling pathway ISG15 
T cell activation (P00053) AKT2 
p53 pathway (P00059) AKT2 
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3.4.2.3 Visual inspection of gene expression within biological groups 
To further reduce and prioritize the list of potential candidate genes, the gene expression 
pattern was examined in each individual sample (as opposed to gene expression within a 
biological group). A gene with a similar expression profile among cases and controls or that 
showed considerable variation within a biological group was excluded from further 
analysis. Genes with an expression pattern observed to be similar in all six of the GDM 
women and similar in all six controls, but showing significant differences between cases 
when compared to controls were selected for further analysis. MDGA1 was initially one of 
the top candidates because it had a statistically significant (qvalue<0.05) lower level of 
expression (-4.75 fold) (under-expression) in the case group (Figure 3.9 A). However, when 
analysing the expression levels of this gene in each individual case and control (Figure 3.9 
B); it became clear that control individuals 0, 1, 3 and 5 have similar levels of MDGA1 
expression seen in all the case individuals. For this reason, the lower expression of MDGA1 
is unlikely to play a role in the aetiology of gestational diabetes as low expression is 
common in control individuals. This gene was excluded from further analysis.  
Figure 3.9 C shows that there is a substantially lower expression of G6PD in women with 
GDM when compared to women with normal glucose tolerance during pregnancy. When 
investigating the expression of this gene in each individual, it becomes clear that in each 
case, there is less gene expression when compared to controls, who have evidently higher 
expression of G6PD (Figure 3.9 D). For this reason, G6PD was included for further 
evaluation as a potential candidate in the development of gestational diabetes. Student t-
tests were performed to confirm the results of the visual inspection to ensure that only 
genes that display significant differential expression (log2 fold change) between cases and 
controls, are included in further analysis.   
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Figure 3.9: Visual inspection of the normalised average gene expression of each gene in in each group 
(case and control) (A and C). B and D shows the normalised expression of the gene in each individual 
sample. 
 
Fifteen of the 60 genes displayed significant differential expression unique to cases when 
compared to controls and were included for further analysis. Gene enrichment analysis was 
done using these 15 genes as an input. These genes include AKT2 (V-akt murine thymoma 
viral oncogene homolog 2); ALDOA (Aldolase A, Fructose Biphosphate); C14orf80; DCXR 
(Dicarbonyl/L-Xylulose reductase); G6PD (Glucose-6-phosphate dehydrogenase); GSK3A 
(Glycogen Synthase Kinase 3-Alpha); KCNQ1 (potassium channel, voltage gated KQT-like 
subfamily Q, member 1); PGLS (6-phosphogluconolactonase); SLC25A22 (Solute carrier 
Family 25/Mitochondrial carrier, glutamate member 22); TKT (Transketolase); UBBP4 
(ubiquitin B pseudogene 4); SEMA3A (Semaphorin 3A); GAA (acid alpha glucosidase); 
PDZD3 (PDZ domain containing 3) and ISG15 (Ubiquitin-like protein ISG15).  
3.4.2.4 Gene Enrichment 
Gene enrichment (functional enrichment analysis) is a method to identify classes of genes 
or proteins that are over-represented in a large set of genes or proteins. The method uses 
statistical approaches to identify significantly enriched or depleted groups of genes. Table 
3.14 shows the outcome of the gene enrichment for the above mentioned 15 genes. The 
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gene enrichment output highlighted a group of genes (N=5) that were significantly enriched 
for a particular GO term. These five genes (G6PD, TKT, ALDOA, PGLS and DCXR) are 
significantly associated together with the GO terms “pentose metabolic process”; “NADP 
metabolic process” and “pyridine nucleotide metabolic process”. Upon further 
investigation, it was observed that these 5 genes encode enzymes that function in the 
pentose phosphate pathway (Figure 3.10).  
After doing an extensive literature search using each of the 15 genes as subjects and taking 
into consideration the gene enrichment and gene ontology output, the list of potential 
candidates was reduced to ten strong functional and biological candidates. Table 3.15 lists 
these ten genes and provides further rationale for their selection.   
 
Table 3.14: Gene enrichment using PANTHER  
      
  
GO Biological Process 
# genes from ref list 
(Homo Sapiens) 
#  genes from 
Input list 
Fold 
Enrichment 
p Value 
A Pentose Metabolic process (GO: 0005996) 12 3 >5 2.1E-02 
B NADP Metabolic Process (GO: 0006734) 14 4 >5 4.8E-03 
C Pyridine Nucleotide Metabolic Process (GO: 0019362) 92 5 >5 7.8E-04 
      
      
  Gene Gene Name log2 fold change q-Value   
1 DCXR Xylulose reductase -2.18 0.030  
2 G6PD 
Gluscose-6-phosphate 
dehydrogenase 
-3.09 0.005  
3 PGLS  
6-
Phosphogluconolactonase 
-2.52 0.020  
4 ALDOA 
Fructose-bisphosphate 
aldolase A 
-2.26 0.009  
5 TKT Transketolase -2.93 0.005   
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Figure 3.10: The pentose phosphate pathway illustrating the genes found to be differentially expressed between GDM cases and controls.  
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Table 3.15: The top ten genes chosen as candidates for validation for differential gene expression in the 
blood data set (p-values were calculated using a Students t-test)  
Gene Gene Name Reason for validation 
AKT2 (log2 fold change -2.28; p=5.1E-04) 
 
RAC-beta 
serine/threonine-
protein kinase 
AKT2 has been implicated in T2D                                                                                                                                                                                                                                                                                                                                       
* A Family with Severe Insulin Resistance and Diabetes Mellitus due to a 
Missense Mutation in AKT2                                                                                                                                                                                                                       
*  Contribution of the AKT2 gene to type 2 diabetes in the Chinese Han 
population: The AKT2 protein kinase is thought to be a key mediator of 
the insulin signal transduction process, AKT2 is suggested to play a role 
in glucose metabolism and the development or maintenance of proper 
adipose tissue and islet mass * Insulin resistance and a diabetes 
mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB 
beta):  show that mice deficient in Akt2 are impaired in the ability of 
insulin to lower blood glucose because of defects in the action of the 
hormone on liver and skeletal muscle, These data establish AKT2 as an 
essential gene in the maintenance of normal glucose homeostasis (Cho 
et al., 2001, George et al., 2004, Sun et al., 2011). 
ALDOA (log2 fold change -2.26; p=7.1E-6) 
 
Fructose-
bisphosphate 
aldolase A 
Key enzyme in the Pentose Phosphate Pathway and catalyses the 
transformation between dihydroxyacetone phosphate, glyceraldehyde-
3- phosphate and fructose 1, 6 - biphosphate in the glycolytic pathway, 
* ALDOA was found to be down regulated in brown adipose tissue, 
which might indicate impaired glucose utilization (Medrikova et al., 
2015, Meugnier et al., 2007). 
 
 
 
 
 
 
 
C14orf80 (log2 fold change -2.13; p=5.0E-5) 
 
 
 
Uncharacterized 
protein C14orf80 
Possible marker for uncontrolled gestational diabetes  
DCXR (log2 fold change -2.18; p=2.9E-4) 
 
Xylulose reductase The protein encoded by this gene acts as a homotetramer to catalyze 
diacetyl reductase and L-xylulose reductase reactions, The encoded 
protein may play a role in the uronate cycle of glucose metabolism and 
in the cellular osmoregulation in the proximal renal tubules, Mutations 
in this gene are a cause of pentosuria ((Lee et al., 2013). 
G6PD (log2 fold change -3.09; p=5.6E-5) 
 
Gluscose-6-
phosphate 
dehydrogenase 
G6PD is the rate-limiting enzyme of the pentose phosphate pathway * 
Time-resolved metabolomics analysis of β-cells implicates the pentose 
phosphate pathway in the control of insulin release pathway, 
Pathophysiologic roles for G6PD have also been identified in such 
disease processes as diabetes, aldosterone-induced endothelial 
dysfunction,  cancer, and others, * Effects of laparoscopic Roux-en-Y 
gastric bypass on glucose-6 phosphate dehydrogenase activity in obese 
type 2 diabetics: G6PD overexpression has been implicated in insulin 
resistance, hyperlipidaemia, and increased oxidative stress in animals 
(Schneider et al., 2012, Spegel et al., 2013) 
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GSK3A (log2 fold change 3.20; p=5.4E-4) 
 
Glycogen synthase 
kinase-3 alpha 
GSK3A is a key target for the development of novel treatments for 
T2D,   GSK-3 has recently been the subject of much research because it 
has been implicated in a number of diseases, including Type II diabetes 
(Diabetes mellitus type 2)  * Analysis of hepatic gene transcription in 
mice expressing insulin-insensitive * GSK3 regulation is proposed to 
play a key role in the hormonal control of many cellular processes, 
Inhibition of GSK3 in animal models of diabetes leads to normalization 
of blood glucose levels, while high GSK3 activity has been reported in 
Type II diabetes (Gokhale and Tilak, 2013; Lipina et al,, 2015) 
KCNQ1 (log2 fold change -2.02; p=4.0E-4) 
 
Potassium 
voltage-gated 
channel subfam 
KQT member 
KCNQ1 has been identified as a  susceptibility gene for T2D * Genome-
wide association studies in Japanese and Dutch  populations recently 
identified common variants in the KCNQ1 gene to be associated with 
type 2 diabetes (Been et al., 2011, Kasuga, 2011) 
PGLS (log2 fold change -2.52; p=3.0E-4) 
 
6-
phosphogluconola
ctonase 
Gene found in the Pentose Phosphate Pathway 
No other information in the literature linking this gee with glucose 
metabolism. 
SLC25A22 (log2 fold change -2.23; p=7.0E-4) 
 
Mitochondrial 
glutamate carrier 
1 
MiR-184 regulates insulin secretion through repression of SLC25A22:  
report that miR-184 inhibits insulin secretion in the MIN6 pancreatic 
cell line through the repression of its target Slc25a22, a mitochondrial 
glutamate carrier, The study provides new insight into the regulation of 
insulin secretion by glutamate transport in mitochondria ((Morita et al., 
2013). 
TKT (log2 fold change -2.94; p=2.11E-6) 
 
Transketolase Gene found in pentose phosphate pathway * Effect of high dose 
thiamine therapy on activity and molecular aspects of transketolase in 
Type 2 diabetic patients: All enrolled Type 2 diabetics had > 40% lower 
mononuclear transketolase activity as compared to healthy individuals, 
* Genetic variability in enzymes of metabolic pathways conferring 
protection against non-enzymatic glycation versus diabetes-related 
morbidity and mortality; hypothesized that genetic variability in genes 
encoding enzymes metabolizing glycolytic intermediates produced in 
excess under hyperglycemic conditions [i,e,, transketolase (TKT), 
transaldolase, TKT-like protein 1, fructosamine 3-kinase (FN3K), 
glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence 
progression of diabetic nephropathy (DN) and diabetes-related 
morbidity and mortality (Halim et al., 2013, Tanhauserova et al., 2014). 
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3.5 Analysing data generated from PLACENTA (exposed vs unexposed) comparisons 
3.5.1 A simple filtering process to reduce the number of possible candidate genes 
The data were first sorted to only include genes with an “OK” status (N=19880). Only a few 
genes had the LOWDATA (N=26) and HIDATA (N=6) outcome and were subsequently excluded. 
The second filtering step removed all the genes that did not display significant differential 
expression (qvalue>0.05) between the cases and controls. This filtering step reduced the 
number of potential candidates substancially. The total number of genes displaying highly 
significant (qvalue<0.05) differential expression beween the two groups was 1088. The third 
filtering step focused on genes with significant (qvalue<0.05) differential expression greater 
than 1 fold between the two biological groups. This gene list was further reduced by focussing 
on a genes which had a differential expression greater than 2 fold between the two biological 
groups. These genes were targeted as potential candidates as they displayed the largest 
difference in expression between GDM cases and controls. This reduced the number of genes 
of interest to 52 (Figure 3.11).        
           
 
 
 
 
 
 
 
 
 
Figure 3.11: Flow diagram depicting how potential candidate genes from the placenta data set were selected 
for validation.  
Total number of genes identified in the placenta 
dataset N=19880 
Include all genes with statistically 
significant differential expression Filter: 
Increase level of statistical significance to 
qvalue<0.05 N=1088 
Filter: Log2 Fold Change >1 
or <1; qvalue<0.05 N=489 
Filter: Log2 Fold 
Change >2 or <2; 
qvalue<0.05 N=52 
Gene classification 
using OMIM 
Gene Ontology and 
enrichment analysis using 
PANTHER and DAVID 
Literature research to identify 
genes linked to 
diabetes/glucose metabolism 
Inspection of gene expression 
in each individual’s sample 
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3.5.1.1 The identification of genes displaying significant differential expression 
between cases and controls  
The volcano plot (Figure 3.12) plots the relationship between the p-values of a statistical test 
and the magnitude of the difference in expression of 19880 genes.  The -log10 p-values are 
plotted on the y-axis and the log2 fold change values are plotted on the x-axis. The red circles 
indicate the genes of interest that display both large-magnitude fold-changes (x-axis) as well 
as high statistical significance (-log10 of p-value, y-axis). The dashed red-line shows where q = 
0.05 with points above the line having qvalue < 0.05 and points below the line having qvalue 
> 0.05. This plot is colored such that the green points represent the genes with significant 
(qvalue>0.05) fold-change of more than 1 (log2 < 1); the blue dots represent genes with a 
significant log2 fold change of >2 or <-2. The red dots represent genes with the largest 
significant (qvalue<0.05) differential expression (log2 fold change >3 or <-3) (log2 >2).   
 
Figure 3.12:  The Volcano Plot illustrating significant fold change differential expression for placenta data set 
comparing cases to controls. Volcano plot for the 19880 genes from the placenta  data set (log2 fold change 
>1; qvalue<0.05: green; log2 fold change >2; qvalue<0.05: blue; log2 fold change >3; qvalue<0.05: red). 
 
The scatter plot (Figure 3.13) illustrates the relationship between the corrected p-value (q-
value) and the log2 fold change value of the genes showing the largest change in expression 
and largest significance (red dots from the volcano plot).  
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Figure 3.13:  Scatter Plot illustrating significant fold change differential expression for placenta data set 
comparing cases to controls. The scatter plot shows only the genes which have a log2 fold change >2 and <-2; 
qvalue<0.05 (corrected for multiple testing). 
 
These 52 genes (shown in the scatter plot) were used for further analysis. Table 3.16 lists the 
gene names, their location within the genome, the log2 fold change values of each gene, the 
corresponding p-value (showing level of significance) as well as the qvalue. The qvalues are 
the Benjamini-Hochberg corrected p-values for multiple-testing.  
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Table 3.16: List of genes displaying significant differential expression between cases and controls from 
placental tissue (log2 fold change >2 and >-2; qvalue < 0.05)  
gene_id 
ENSG00000 
gene Name locus Log2 fold change p_value q_value 
173467 AGR3 Anterior gradient protein 3 homolog 
7:16899028-
16921611 
3.31 1.00E-04 0.0349 
162551 ALPL 
Alkaline phosphatase. tissue-
nonspecific isozyme 
1:21835857-
21904905 
-2.49 5.00E-05 0.0195 
179913 B3GNT3 
UDP-GlcNAc:betaGal beta-1.3-N-
acetylglucosaminyltransferase 3 
19:17905636-
17923891 
2.08 5.00E-05 0.0195 
266405 CBX3P2 Not annotated 
18:2652168-
2655394 
4.07 5.00E-05 0.0195 
149970 CNKSR2 
Connector enhancer of kinase 
suppressor of ras 2 
X:21392535-
21672813 
2.66 5.00E-05 0.0195 
250182 
CTD-
2165H16.1 
Not annotated 
5:14652046-
14653438 
-3.84 2.00E-04 0.0195 
163464 CXCR1 C-X-C chemokine receptor type 1 
2:219027567-
219031718 
-3.37 5.00E-05 0.0195 
180871 CXCR2 C-X-C chemokine receptor type 2 
2:218990011-
219001976 
-2.35 1.00E-04 0.0349 
169738 DCXR L-xylulose reductase 
17:79993011-
79995608 
-2.40 5.00E-05 0.0195 
134757 DSG3 Desmoglein-3 
18:29027757-
29058665 
3.16 5.00E-05 0.0195 
83782 EPYC Epiphycan 
12:91357455-
91398803 
-2.72 4.60E-03 0.0195 
163377 FAM19A4 
family with sequence similarity 19 
(chemokine (C-C motif)-like). member 
A4 
3:68780916-
68981761 
-3.42 5.00E-05 0.0195 
186431 FCAR Immunoglobulin alpha Fc receptor 
19:55385548-
55401838 
-3.12 5.00E-05 0.0195 
160211 G6PD Glucose-6-phosphate dehydrogenase 
X:153759605-
153796782 
-2.68 5.00E-05 0.0195 
197421 GGT3P 
Putative gamma-
glutamyltranspeptidase 3 
22:18761177-
18830912 
8.01 1.00E-04 0.0349 
151948 GLT1D1 
Glycosyltransferase 1 domain-
containing protein 1 
12:129337971-
129469509 
-2.87 1.00E-04 0.0349 
146678 IGFBP-1 
Insulin-like growth factor-binding 
protein 1 
7: 45888357-
45893668 
-4.74 3.00E-05 0.0195 
115457 IGFBP-2 
Insulin-like growth factor-binding 
protein 2 
2: 216632828 - 
216664436 
-2.65 4.00E-05 0.0195 
211896 IGFBP-6 
Insulin-like growth factor-binding 
protein 6 
7:45927955-
45933267 
-2.92 5.00E-05 0.0195 
211892 IGHG4 
immunoglobulin heavy constant 
gamma 4 (G4m marker)  
14:106090686-
106092403 
-4.91 5.00E-05 0.0195 
211949 IGHV3-23 immunoglobulin heavy variable 3-23  
14:106725200-
106725733 
-4.5 4.00E-05 0.0195 
132465 IGJ Immunoglobulin J chain 
4:71494460-
71552533 
-3.11 5.00E-05 0.0195 
211592 IGKC 
similar to hCG26659; immunoglobulin 
kappa constant  
2:89109983-
89165653 
-4.65 3.00E-05 0.0195 
243466 IGKV1-5 
Ig kappa chain V-I region HK102 
(Fragment) 
2:89246818-
89247475 
-6.72 5.00E-05 0.0195 
241351 IGKV3-11 Not annotated 
2:89326667-
89327228 
-3.81 5.00E-05 0.0195 
211598 IGKV4-1 Ig kappa chain V-IV region (Fragment) 
2:89184912-
89185669 
-4.64 5.00E-05 0.0195 
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167916 KRT24 Keratin. type I cytoskeletal 24 
17:38854242-
38860002 
2.41 1.00E-05 0.0349 
186081 KRT5 Keratin. type II cytoskeletal 5 
12:52908358-
52914471 
3.63 5.00E-05 0.0195 
197683 KRTAP26-1 Keratin-associated protein 26-1 
21:31691451-
31692607 
-2.05 5.00E-05 0.0195 
110347 MMP12 Macrophage metalloelastase 
11:102733466-
102745764 
2.03 5.00E-05 0.0195 
118946 PCDH17 Protocadherin-17 
13:58205943-
58303445 
2.12 5.00E-05 0.0195 
197991 PCDH20 Protocadherin-20 
13:61983990-
62002220 
-3.93 5.00E-05 0.0195 
172179 PRL Prolactin 
6:22260652-
22318027 
-2.75 3.00E-05 0.0195 
199916 RMRP 
RNA component of mitochondrial RNA 
processing endoribonuclease  
9:35657750-
35658014 
5.31 5.00E-05 0.0195 
202198 RN7SK Not annotated 
6:52860417-
52860748 
4.04 5.00E-05 0.0195 
265150 RN7SL2 Not annotated 
14:50329270-
50329567 
4.17 5.00E-05 0.0195 
251705 RNA5-8SP6 Not annotated 
Y:10037763-
10037915 
5.28 5.00E-05 0.0195 
200795 RNU4-1 Not annotated 
12:120730899-
120731040 
5.61 5.00E-05 0.0195 
202538 RNU4-2 Not annotated 
12:120729565-
120729706 
5.85 5.00E-05 0.0195 
201098 RNY1 Not annotated 
7:148684227-
148684340 
5.86 5.00E-05 0.0195 
262902 
RP11-
750B16.1 
Not annotated 
17:51183094-
51183719 
2.32 0.0001 0.0349 
234338 
RP11-
797H7.1 
Not annotated 
7:64295657-
64297260 
2.93 5.00E-05 0.0195 
163221 S100A12 Protein S100-A12 
1:153346183-
153348125 
-2.21 5.00E-05 0.0195 
143546 S100A8 Protein S100-A8 
1:153362507-
153363664 
-2.01 5.00E-05 0.0195 
197641 SERPINB13 Serpin B13 
18:61254222-
61271873 
3.82 0.0001 0.0349 
206075 SERPINB5 Serpin B5 
18:61143993-
61172318 
2.94 5.00E-05 0.0195 
166396 SERPINB7 Serpin B7 
18:61420168-
61472604 
3.21 5.00E-05 0.0195 
167037 SGSM1 Small G protein signalling modulator 1 
22:25202235-
25323545 
-3.06 5.00E-05 0.0195 
18280 SLC11A1 
Natural resistance-associated 
macrophage protein 1 
2:219246751-
219261617 
-2.04 5.00E-05 0.0195 
20236 SNORD3A Not annotated 
17:19091328-
19092027 
4.63 5.00E-05 0.0195 
163931 TKT Transketolase 
3: 53224707 - 
53256114 
-2.56 0.0001 0.0349 
After the filtering process, only the genes which displayed the largest change in expression (log2 fold change >2 and >-2) at the highest 
statistical significance (qvalue<0.05) were chosen for further analysis (N=52).  
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3.5.1.2 Gene ontology  
The list of significantly differentially regulated genes (N=52) was sorted into gene ontology 
(GO) term categories for molecular function and biological processes using the programs 
DAVID (https://david.ncifcrf.gov/) and PANTHER (http://pantherdb.org/). The molecular 
function GO terms associated with the differentially regulated genes include a large 
percentage of “binding activity” (39.1%) and “catalytic activity” (26.1%). Other differentially 
regulated gene molecular function GO terms included those for “receptor activity” (13%); 
“enzyme regulator activity” (10.9%); “structural molecule activity” (6.4%); “transporter 
activity” (4.3%) (Figure 3.14). Biological process of differentially regulated genes GO terms 
included “immune system process” (20.8%); “metabolic process” (16.7%); “cellular process” 
(12.5%); “developmental process” (12.5%); “biological adhesion” (4.2%); “biological 
regulation” (9.4%); “developmental process” (11.5%) and “localization” (12.5%) (Figure 3.14). 
          
Figure 3.14: The molecular function and biological process of the significantly differentially expressed genes 
identified from the placenta data set. 
18 (39.1%)
12 (26.1%)
5 (10.9%)
6 (13%)
3 (6.4%)
2 (4.3%)
GO 
Molecular Function Placental Genes
Total # genes: 41; Total # function hits: 46
log2 fold change >2; p<0.005
Binding (GO: 0005488)
Catalytic activity (GO:
0003824)
Enzyme regulator activity (GO:
0030234)
Receptor activity (GO:
0004872)
structural molecule activity
(GO: 0005198)
Transporter Activity (GO:
0005215)
1 (1%)
4(4.2%)
9 (9.4%)
3(3.1%)
20 20.8%)
12 
(12.5%)
12 
(12.5%)2(2.1%)
16 (16.7%)
5 (5.2%)
1 (1%)
11 
(11.5%)
GO 
Biological Process 
Placental Genes
Total # genes: 43; Total # function hits: 96
log2 fold change>2; p<0.005
Biological Adhesion (GO:
0022610)
Biological Regulation
(GO: 0065007)
Cellular Component
organization or
biogenesis (GO:
0071840)
Cellular Process (GO:
0009987)
Developmental process
(GO:0032502)
Immune System Process
(GO: 0002376)
Localization (GO:
0051179)
Metabolic Process (GO:
0008152)
Multicellular organismal
process (GO: 0032501)
Reproduction (GO:
00000003)
* No biological process 
/not annotated N=11 
* No known molecular function  
/not annotated N=11 
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Table 3.17 lists these top 52 genes with their molecular functions and biological processes. 
The genes which play a role in metabolic processes are shown in bold in red. From this gene 
ontology analysis, metabolic and immune system processes were among the most significant 
processes represented by the gene set. Diabetes is a metabolic disorder, and for this reason, 
these genes are strong functional candidates. These genes include; CNKSR2 (Connector 
enhancer of kinase suppressor of ras 2); CXCR1 (C-X-C chemokine receptor type 1); CXCR2 (C-
X-C chemokine receptor type 2) EPYC (Epiphycan); G6PD (Glucose-6-phosphate 
dehydrogenase); GLT1D1 (Glycosyltransferase 1 domain-containing protein 1); GGT3P 
(Putative gamma-glutamyltranspeptidase 3); IGFBP-1 (Insulin growth factor binding 1), IGFBP-
2 (Insulin growth factor binding 2); IGFBP-6 (Insulin growth factor binding 6); MMP12 
(Macrophage metalloelastase); S100A12 (Protein S100-A12); S100A8 (Protein S100-A8); 
SerpinB5; SerpinB7; SerpinB13; SGSM1 (Small G protein signalling modulator 1) and TKT 
(Transketolase). Only 4 of these genes are associated with known pathways (Table 3.18).  
 
Table 3.17: Gene ontology using DAVID and PANTHER for genes found to be differentially expressed in 
placenta samples from cases when compared to controls (log2 fold change>2; qvalue<0.05) 
Gene_id 
(ENSG00000) 
Gene Molecular function Biological Process 
162551 ALPL Binding Developmental 
266405 CBX3P2 No hit No hit 
149970 CNKSR2 
Binding; Catalytic; Enzyme 
Regulator 
Biological Regulation; Metabolic 
250182 CTD-2165H16,1 No hit No hit 
163464 CXCR1 Catalytic; Receptor Cellular; Immune System; Metabolic; Response to stimulus 
180871 CXCR2 Catalytic; Receptor Cellular; Immune System; Metabolic; Response to stimulus 
134757 DSG3 Binding Cellular Process 
83782 EPYC Receptor Biological Adhesion; Cellular; Immune System; Metabolic 
163377 FAM19A4 No hit No hit 
186431 FCAR Binding; Receptor Cellular; Immune System; Response to stimulus 
171557 FGG Binding Biological Adhesion; Cellular; Response to stimulus 
197421 G6PD Catalytic Metabolic 
197421 GGT3P Catalytic Metabolic 
151948 GLT1D1 Catalytic Metabolic 
188536 HBA2 Binding Cellular  
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146678 IGFBP-1 Binding 
Biological Regulation; Cellular; Response to stimulus; 
metabolic 
211896 IGFBP-2 Binding 
Biological Regulation; Cellular; Response to stimulus; 
metabolic 
211892 IGFBP-6 Binding 
Biological Regulation; Cellular; Response to stimulus; 
metabolic 
211949 IGHV3-23 Binding Immune System 
132465 IGJ Binding Immune System; Response to stimulus 
211592 IGKC Binding Immune System 
243466 IGKV1-5 Binding Developmental; Immune System; Response to stimulus 
241351 IGKV3-11 Binding Immune System 
211598 IGKV4-1 Binding Developmental; Immune System; Response to stimulus 
167916 KRT24 Structural Molecule Biogenesis; Cellular Process; Developmental 
186081 KRT5 Structural Molecule Biogenesis; Cellular; Developmental 
197683 KRTAP26-1 Structural Molecule Cellular Process 
110347 MMP12 Binding; Catalytic Cellular Process, Metabolic 
118946 PCDH17 Binding Biological Adhesion; Cellular; Developmental 
197991 PCDH20 Binding Cellular Process 
172179 PRL Binding Cellular; Developmental 
199916 RMRP No hit No hit 
202198 RN7SK No hit No hit 
265150 RN7SL2 No hit No hit 
251705 RNA5-8SP6 No hit No hit 
200795 RNU4-1 No hit No hit 
202538 RNU4-2 No hit No hit 
201098 RNY1 No hit No hit 
262902 RP11-750B16,1 No hit No hit 
234338 RP11-797H7,1 No hit No hit 
163221 S100A12 Binding Cellular; Immune System; Metabolic; Response to stimulus 
143546 S100A8 Binding Cellular; Metabolic 
197641 SERPINB13 Catalytic; Enzyme Regulator Biological Regulation; Metabolic 
206075 SERPINB5 Catalytic; Enzyme Regulator Biological Regulation; Metabolic 
166396 SERPINB7 Catalytic; Enzyme Regulator Biological Regulation; Metabolic 
167037 SGSM1 
Binding; Catalytic; Enzyme 
Regulator 
Biological Regulation,;  Cellular; Developmental; 
Localization; Metabolic 
18280 SLC11A1 Transporter Localization; Response to stimulus 
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202,364,263,934 SNORD3A No hit No hit 
149256 TKT Catalytic Metabolic  
 
 
Table 3.18: Pathway analysis using PANTHER and KEGG 
 
PANTHER/KEGG pathway Gene 
Inflammation mediated by chemokin and cytokine signalling pathway 
(P00031) 
CXCR1; CXCR2 
Pentose phosphate pathway (P02762) TKT, G6PD 
p53 pathway (P00059) SerpinB5 
PI3 Kinase Pathway (P00048) IGFBP-1 
 
3.5.1.3 Visual inspection of gene expression 
To further reduce the list of potential candidate genes, the expression pattern of each gene 
was analysed in each individual sample (as opposed to an overall expression in a group). Genes 
which displayed similar levels of varied expression within cases and within controls where the 
differences were not consistent between cases compared to controls were excluded from 
further analysis. Genes with an expression pattern unique to cases were included for further 
analysis. CBX3P2 was also one of the top potential candidates because it had statistically 
significant (P=5.0E-05) differential expression (log2 fold change) of 4.07. However, when 
analysing this gene in the case versus controls as a group (Figure 3.15 A) it is evident that the 
expression of CBX3P2 is substantially higher in the case group than in the controls. However, 
when looking at the expression of this gene in each individual (Figure 3.15 B); it becomes clear 
that case 2 and case 4 have similar expression levels of CBX3P2 to control individuals. For this 
reason, it is unlikely that the over-expression of CBX3P2 contributes to the aetiology of 
gestational diabetes and is therefore excluded from further analysis.  
Figure 3.15 C illustrates the substantially lower expression of IGFBP-1 in women with GDM 
when compared to women with normal glucose tolerance during pregnancy. When 
investigating the expression of this gene in each individual, it becomes clear that in each case, 
IGFBP-1 is significantly under-expressed when compared to controls, who have evidently 
higher expression of IFGBP-1 (Figure 3.15 D).  For this reason, IGFBP-1 was included for further 
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evaluation as a potential candidate in the development of gestational diabetes. Student t-tests 
were performed to confirm the results of the visual inspection to ensure that only genes that 
display significant differential expression (log2 fold change) between cases and controls, were 
included in further analysis.   
 
Twenty (N=20) of the 52 genes displayed significant differential expression unique to the cases 
when compared to the controls. These twenty genes are CXCR1 (C-X-C chemokine receptor 
type 1); CXCR2 (C-X-C chemokine receptor type 2); DSG3 (Desmoglein-3); G6PD (Glucose-6-
phosphate dehydrogenase); GGT3P (Putative gamma-glutamyltranspeptidase 3); GLT1D1 
(Glycosyltransferase 1 domain-containing protein 1); IGFBP-1 (Insulin-like growth factor-
binding protein 1); IGFBP-2 (Insulin-like growth factor-binding protein 2); IGFBP-6 (Insulin-like 
growth factor-binding protein 6); IGKV1-5 (Ig kappa chain V-I region HK102 (Fragment); 
PCDH2 (Protocadherin-20); RMRP (RNA component of mitochondrial RNA processing 
endoribonuclease); RN7SK (Not annotated); RN7SL2 (Not annotated); S100A12 (Protein S100-
A12); SNORD3A (Not annotated); TKT (Transketolase); SGSM2 (Small G protein signalling 
modulator 2); SLC11A1 (Natural resistance-associated macrophage protein 1) and TKT 
(Transketolase). These twenty genes were used as the input for a gene enrichment analysis 
using PANTHER.  
        
Figure 3.15: Visual inspection of the normalised gene expression in the case versus control groups (A, C) as 
well as in each individual sample (B, D).  
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3.5.1.4 Gene Enrichment 
The gene enrichment output highlighted two genes, CXCR1 and CXCR2 that were significantly 
enriched for the particular GO terms “interleukin-8-mediated signalling pathway” 
(GO:0038112); “cellular response to interleukin-8” (GO:0098759); and “response to 
interleukin-8” (GO:0098758). There have been studies which associate an increase in 
interleukin-8 with diabetes (Dakovic et al., 2013, Srinivasan et al., 2004, Zozulinska et al., 
1999)(Table 3.19). The process of gene enrichment also highlight TKT and G6PD to be 
significantly associated with the GO term “pentose metabolic process”. These two genes were 
also found to be significantly under expressed in the blood of women with GDM. These genes 
transcribe key enzymes in the PPP.  
Table 3.19: Gene enrichment of placental dataset using PANTHER  
  GO Biological Process 
# genes from ref list 
(Homo Sapiens) 
#  genes from 
Input list 
Fold 
Enrichment 
p-value 
A Interleukin-8-mediated signalling 
pathway (GO:0038112) 
2 2 >5 0.042 
B Cellular response to Interleukin-8 
(GO:0098759) 
2 2 >5 0.045 
C Response to interleukin-8 
(GO:0098758) 
2 2 >5 0.056 
D Pentose metabolic process (GO: 
0005996) 
2 2 >5 0.003 
      
  Gene Gene Name 
log2 fold 
change 
q-Value   
1 CXCR1 
C-X-C chemokine 
receptor type 1 
-3.84 0.019   
2 CXCR2 
C-X-C chemokine 
receptor type 2 
-3.37 0.029  
3 G6PD 
Glucose-6-phosphate 
dehydrogenase 
 
  
4 TKT Transketolase 
 
  
  
After doing an extensive literature search for each of these top 20 genes and taking into 
consideration the gene enrichment and gene ontology output, the list was reduced to ten 
genes believed to be strong functional and biological candidates. Table 3.20 lists these ten 
genes  and provides a rationale for their selection.   
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Table 3.20: The top ten genes chosen as candidates for validation for differential gene expression  
Gene  Gene Name Reason to validate 
CXCR1 (log2 fold change -3.37; p=4.6E-6) 
 
Chemokine 
Receptor 1 
 
* CXCR1/CXCR2 pathway - involvement in diabetes 
pathophysiology                                                                                           
* CXCR1/2 Inhibition blocks and reverts T1D in mice                                                                                                        
* Type 1 Diabetes Prone NOD Mice Have Diminished Cxcr1 
mRNA Expression in Polymorphonuclear Neutrophils and 
CD4+ T Lymphocytes, Although numerous 
chemokine/chemokine receptor pathways have been 
described to be implicated in the pathogenesis of type 1 
diabetes (T1D), the CXCR1/2 axis has recently been proved 
to be crucial for leucocyte recruitment involved in insulitis 
and β cell damage (Citro et al., 2015a, Citro et al., 2015b, 
Haurogne et al., 2015). 
CXCR2 (log2 fold change -2.35; p=5.0E-5) 
 
Chemokine 
Receptor 2 
 
* CXCR1/CXCR2 pathway - involvement in diabetes 
pathophysiology                                                                                     
* CXCR1/2 Inhibition blocks and reverts T1D in mice                                                                                                        
* Type 1 Diabetes Prone NOD Mice Have Diminished Cxcr1 
mRNA Expression in Polymorphonuclear Neutrophils and 
CD4+ T Lymphocytes, Although numerous 
chemokine/chemokine receptor pathways have been 
described to be implicated in the pathogenesis of type 1 
diabetes (T1D), the CXCR1/2 axis has recently been proved 
to be crucial for leucocyte recruitment involved in insulitis 
and β cell damage (Citro et al., 2015a, Citro et al., 2015b, 
Haurogne et al., 2015) 
G6PD (log2 fold change -2.68; p=2.9E-6) 
 
Glucose-6-
phosphate 
dehydrogenase 
 
G6PD is the rate-limiting enzyme of the pentose 
phosphate pathway * Time-resolved metabolomics 
analysis of β-cells implicates the pentose phosphate 
pathway in the control of insulin release pathway, 
Pathophysiologic roles for G6PD have also been identified 
in such disease processes as diabetes, aldosterone-
induced endothelial dysfunction,  cancer, and others, * 
Effects of laparoscopic Roux-en-Y gastric bypass on 
glucose-6 phosphate dehydrogenase activity in obese type 
2 diabetics: G6PD overexpression has been implicated in 
insulin resistance, hyperlipidaemia, and increased 
oxidative stress in animals (Schneider et al., 2012, Spegel 
et al., 2013). 
IGFBP-1 (log2 fold change -4.74; p=8.3E-6) 
 
Insulin like growth 
factor binding 
protein 1 
 
 Increased DNA methylation levels of IGFBP1- are 
associated with T2D in Swedish men                                                                                                                                           
* Low concentrations of IGFBP-1 are associated with 
insulin resistance, diabetes and cardiovascular disease, 
Insulin-like growth factor-binding protein 1 and 7 
concentrations are lower in obese pregnant women, 
women with gestational diabetes and their foetuses 
(Lappas, 2015). Inverse changes in foetal insulin-like 
growth factor (IGF)-1 and IGF binding protein-1 in 
association with higher birth weight in maternal diabetes 
(Lindsay et al., 2007). Insulin-like growth factor axis and 
gestational diabetes: A longitudinal study in a multiracial 
cohort (Zhu et al., 2016). 
IGFBP-2 (log2 fold change -2.65; p=1.1E-7) 
 
Insulin like growth 
factor binding 
protein 2 
 
Insulin-like growth factors (IGFs) and IGF-binding proteins 
(IGFBP-1, -2 and -3) in diabetic pregnancy: relationship to 
macrosomia (Yang et al., 1996). Insulin-like growth factor 
axis and gestational diabetes: A longitudinal study in a 
multiracial cohort (Zhu et al., 2016). 
0
50
100
150
200
250
300
350
 C
o
n
tr
o
l 2
C
o
n
tr
o
l 0
C
o
n
tr
o
l 1
C
o
n
tr
o
l 3
 C
o
n
tr
o
l 4
C
o
n
tr
o
l 5
C
as
e 
0
C
as
e 
1
C
as
e 
2
C
as
e 
3
C
as
e 
4
C
as
e 
5
N
o
rm
al
si
ed
 F
P
K
M
 V
al
u
es
0
0.1
0.2
0.3
0.4
 C
o
n
tr
o
l 2
C
o
n
tr
o
l 0
C
o
n
tr
o
l 1
C
o
n
tr
o
l 3
 C
o
n
tr
o
l 4
C
o
n
tr
o
l 5
C
as
e 
0
C
as
e 
1
C
as
e 
2
C
as
e 
3
C
as
e 
4
C
as
e 
5
N
o
rm
al
is
e
d
 F
P
K
M
 V
la
u
es
0
100
200
300
400
 C
o
n
tr
o
l 2
C
o
n
tr
o
l 0
C
o
n
tr
o
l 1
C
o
n
tr
o
l 3
 C
o
n
tr
o
l 4
C
o
n
tr
o
l 5
C
as
e 
0
C
as
e 
1
C
as
e 
2
C
as
e 
3
C
as
e 
4
C
as
e 
5
N
o
rm
al
si
ed
 F
P
K
M
 V
al
u
es
0
100
200
300
400
500
C
o
n
tr
o
l 0
C
o
n
tr
o
l 1
C
o
n
tr
o
l 2
C
o
n
tr
o
l 3
C
o
n
tr
o
l 4
C
o
n
tr
o
l 5
C
as
e 
0
C
as
e 
1
C
as
e 
2
C
as
e 
3
C
as
e 
4
C
as
e 
5
N
o
rm
al
is
ed
 F
P
K
M
 V
al
u
es
0
50
100
150
200
250
300
C
o
n
tr
o
l 0
C
o
n
tr
o
l 1
C
o
n
tr
o
l 2
C
o
n
tr
o
l 3
C
o
n
tr
o
l 4
C
o
n
tr
o
l 5
C
as
e 
0
C
as
e 
1
C
as
e 
2
C
as
e 
3
C
as
e 
4
C
as
e 
5
N
o
rm
al
is
ed
 F
P
K
M
 V
al
u
es
94 
 
 
 
IGFBP-6 (log2 fold change -3,37; p=7.1E-4) 
 
Insulin like growth 
factor binding 
protein 6 
 
* Expression of IGFBP-6 increased in patients with T1D, 
IGFBP-6 is an O-linked glycoprotein that preferentially 
binds IGF-II, inhibiting IGF-II actions including proliferation, 
survival and differentiation of a wide range of cells, IGFBP-
6 levels were higher in patients with type 1 diabetes and 
its complications, although there was substantial overlap 
with control subjects (Bach, 2015c, Bach, 2015b, Lu et al., 
2012). )Insulin-like growth factor axis and gestational 
diabetes: A longitudinal study in a multiracial cohort (Zhu 
et al., 2016). 
TKT (log2 fold change -2.56; p=5.1E-5) 
 
Transketolase 
 
Gene found in pentose phosphate pathway * Effect of high 
dose thiamine therapy on activity and molecular aspects 
of transketolase in Type 2 diabetic patients: All enrolled 
Type 2 diabetics had > 40% lower mononuclear 
transketolase activity as compared to healthy individuals, 
* Genetic variability in enzymes of metabolic pathways 
conferring protection against non-enzymatic glycation 
versus diabetes-related morbidity and mortality; 
hypothesized that genetic variability in genes encoding 
enzymes metabolizing glycolytic intermediates produced 
in excess under hyperglycemic conditions [i,e,, 
transketolase (TKT), transaldolase, TKT-like protein 1, 
fructosamine 3-kinase (FN3K), glyoxalase 1 and glucose-6-
phosphate dehydrogenase] could influence progression of 
diabetic nephropathy (DN) and diabetes-related morbidity 
and mortality ((Halim et al., 2013, Tanhauserova et al., 
2014).  
MMP12 (log2 fold change 2.03; p=5.0E-3) 
 
MMP12 matrix 
metallopeptidase 
12  
 
* Elevated MMP12 levels are associated with 
atherosclerotic burden and symptomatic cardiovascular 
disease in subjects with T2D, The plasma level of MMP-7 
and -12 were found to be elevated in type 2 diabetes 
mellitus and higher levels were associated with more 
severe atherosclerosis and an increased incidence of 
coronary events (Goncalves et al., 2015).  
GLT1D1 (log2 fold change -2.87; p=1.0E-4) 
 
Glycosyltransferas
e 1 domain 
containing 1 
 
No known association with diabetes but had almost 3 fold  
lower expression cases (log 2 fold change = 2.87)                                                                                                                                   
GGT3P ( log2 fold change 8; p=2.0E-4) 
 
Putative gamma-
glutamyltranspept
idase 3 
 
No known association with diabetes but had a much higher 
expression in cases (log 2 fold change = 8.01)                                                                                                                                   
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3.6 RNA-seq differential expression validation using single gene TaqMan assays 
The validation of the RNA-seq results was limited to the ten most likely candidate genes for 
the blood dataset and ten genes for the placenta dataset (twenty genes were validated in 
total). This subset of genes was chosen using specific criteria including the magnitude of 
differential gene expression (fold change), the significance levels observed (p-value) and also 
their role in pathways linked to glucose metabolism. All of the TaqMan assays were 
successfully optimised and permitted data analysis for the purpose of validation. The TaqMan 
methodology is the gold-standard for validation of RNA-seq experiments. The validation using 
TaqMan showed complete concordance of expression with the RNA-seq results. Before the 
data for the target genes was analysed, the data from the three housekeeping genes was 
analysed to determine that they had stable and consistent gene expression across the 
samples. Figure 3.16 illustrates the CT values of the three housekeeping genes for each blood 
(A) and placenta sample (B) (average of the triplicates). The CT values are relatively consistent 
and show little variation among the samples regardless of disease status. This indicates stable 
expression which is desirable for a housekeeping gene. For this reason, all three housekeeping 
genes were used for normalization of target expression in the samples.   
 
A)                                                                            B) 
 
Figure 3.16: The CT values across all samples (cases and controls) for the three housekeeping genes for A) the 
blood samples and B) the placental samples. These graphs indicate that all three genes have stable and 
consistent gene expression cross the samples and can be used for the normalization.  
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Figures 3.17 and 3.19 illustrate the normalised expression values of each individual sample 
generated via the TaqMan method. The expression observed in the cases was significantly 
altered compared to that observed in the controls and this was similar to the patterns of 
expression observed using RNA-seq. Figures 3.18 and 3.20 show that the RNA-seq data had a 
linear relationship with qRT–PCR (a goodness of fit (R2) of 0.937 for the blood samples and 
0.923 for the placental samples). R2 values of 0.9 - 1 indicate a strong correlation between the 
two techniques.  
 
Table 3.21 qRT-PCR validation of RNA-seq data on a selection of ten potential candidate  genes from the 
blood data set 
  RNA-seq qRT-PCR 
  
Normalised FPKM 
Values 
    Normalised expression Value2   
Fold 
Change  
  
Gene Cases Controls 
Normalis
ed fold 
changes1 
p-value 
△CT Cases 
(SD)  
△CT Controls 
(SD) 
△△CT3 2-∆∆CT4 p-value 
ALDOA 63.50 301.98 -2.26 1.12E-04 -2.67 (0.14) -1.70 (0.27) -0.97 1.95 1.24E-05 
G6PD 20.96 193.25 -3.20 5.01E-05 -5.07 (0.68) -3.36 (0.16) -1.17 2.25 7.27E-06 
DCXR 3.15 28.33 -3.16 5.50E-04 -5.93 (1.47) -5.10 (0.27) -0.83 1.77 2.63E-04 
PGLS 4.21 24.16 -2.52 3.10E-04 -3.04 (0.72) -2.36 (0.17) -0.68 1.60 1.86E-03 
TKT 63.37 642.36 -3.36 5.00E-05 -4.35(0.67) -3.02 (0.15) -1.33 2.5 2.78E-05 
C14ORF80 3.81 16.69 -2.13 1.00E-04 -2.34 (0.48) -2.21. (0.41) -0.13 1.09 2.54E-03 
AKT2 8.46 40.91 -2.27 5.36E-04 -3.25 (0.59) -2.4 (0.33) -0.85 1.80 2.96E-05 
GSK3A 146.97 10.21 3.84 5.00E-05 5.45(1.05)  6.95(0.10) 1.5 0.35 1.48E-03 
KCNQ1 16.93 168.86 -3.32 1.12E-04 -5.09 (1) -3.91 (0.39) -1.18 2.26 4.83E-05 
SLC25A22 15.51 72.96 -2.22 5.00E-05 -3.66 (0.41) -2.30 (0.44) -1.36 2.56 2.92E-07 
1Normalized log2 fold changes: fold changes as log2 (normalized expression value control/normalized expression value case), 
2∆CT cases = (Average CT value Target gene  - Average CT value Housekeeping gene) case sample, ∆CT controls = (Average CT value Target 
gene  - Average CT value Housekeeping gene) control sample 
3 △△CT - ∆CT cases - ∆CT controls, Negative ∆∆CT values indicate a lower expression of the target gene in the case group when compared to 
controls,  
4 2-∆∆CT is the fold change (not indicative of direction of expression only magnitude of expression) 
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A)      B) 
       
Figure 3.17: RT-qPCR validation of RNA-seq results. Ten genes from the blood data set were selected for 
differential expression confirmation in the same RNA samples used for RNA-seq. A: log 2 fold change 
comparison B: Correlation analysis between RNA-seq and RT-qPCR log 2 fold change results from the same RNA 
samples. Spearman correlation coefficient is displayed (Rs). 
 
 
 
 
Figure 3.18. The average CT values for each sample and for each of the ten genes chosen for validation from 
the blood data set. The CT values for the case samples are shown in red and the control samples are shown in 
blue.  Higher CT values are indicative of a lower expression of mRNA.  
 
 
  
-4
-3
-2
-1
0
1
2
3
4
5
N
o
rm
al
is
ed
 F
o
ld
 C
h
an
ge
Genes
RNASeq
qRT-PCR
y = 0.7909x + 0.1862
Rs= 0.9377
-3
-2
-1
0
1
2
3
4
-4 -2 0 2 4 6
D
if
fe
re
n
ti
al
 e
xp
re
ss
io
n
 r
at
io
 
R
N
A
 S
eq
Differential expression ratio qRT-PCR
98 
 
 
 
 
 Table 3.22 qRT-PCR validation of RNA-seq data on a selection of ten potential candidate genes from the 
placental dataset 
 RNA-seq qRT-PCR 
 Normalised FPKM Values   Normalised expression Value2    
Gene Cases Controls 
Normalised 
fold changes1 
p-value 
∆CT Cases 
(SD) 
∆CT Controls 
(SD) 
△△CT3 2-∆∆CT4 p-value 
CXCR1 0.45 4.74 -3.37 5.00E-05 -6.00 (0.85) -5.01 (0.68) -4.0 4.00 3.6E-04 
CXCR2 21.85 29.46 -2.34 5.00E-05 -9.36 (2.07) -8.95 (0.58) -0.41 1.33 1.4E-04 
MMP12 52.87 15.22 1.79 1.00E-04 -8.68 (1.04) -7.87 (1.71) -0.81 1.75 3.2E-02 
GLT1D1 0.14 1.23 -3.05 5.00E-05 -1.78 (0.80) -1.46 (0.80) -0.32 1.24 6.2E-02 
IGFBP-1 55.40 419.66 -3.92 5.00E-05 -9.52 (2.3) -7.50 (0.97) -2.02 4.05 2.8E-02 
IGFBP-2 6.52 30.13 -2.20 5.00E-05 -5.51 (3.3) -4.42 (0.91) -1.09 2.21 8.1E-04 
IGFBP-6 20.65 86.43 -2.68 5.00E-05 -3.62 (3.96) - 1.39 (0.71) -2.23 4.69 7.36E-07 
TKT 4.18 22.17 -2.47 4.23E-04 -6.18 (0.67) -4.45 (0.62) -1.73 3.31 1.6E-06 
G6PD 0.16 1.19 -2.86 1.00E-04 -6.18 (0.67) -4.25 (0.62) -1.93 3.8 8.6E-04 
GGT3P 0.30 0.0011 8.01 1.00E-04 6.55 (1.35) 9.63 (2.31) -3.08 8.45 2.17E-07 
1Normalized log2 fold changes: fold changes as log2 (normalized expression value control/normalized expression value case), 
2∆CT cases = (Average CT value Target gene  - Average CT value Housekeeping gene) case sample, ∆CT controls = (Average CT value Target 
gene  - Average CT value Housekeeping gene) control sample 
3 △△CT - ∆CT cases - ∆CT controls, Negative ∆∆CT values indicate a lower expression of the target gene in the case group when compared to 
controls,  
4 2-∆∆CT is the fold change (not indicative of direction of expression only magnitude of expression) 
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Figure 3.19: RT-qPCR validation of RNA-seq results. Ten genes from the placenta data set were selected for 
differential expression confirmation in the same RNA samples used for RNA-seq, A: log 2 fold change 
comparison B: Correlation analysis between RNA-seq and RT-qPCR log 2 fold change results from the same RNA 
samples. Spearman correlation coefficient is displayed (Rs). 
 
 
 
Figure 3.20. The average CT values for each sample and for each of the ten genes chosen for validation from 
the placenta data set. The CT values for the exposed samples are shown in red and the unexposed samples are 
shown in blue.  Higher CT values are indicative of a lower expression of mRNA.  
 
From these twenty validated genes, only five could be selected for methylation analysis due 
to cost constraints. G6PD and TKT were selected based on the fact that they both display 
significant differential expression in the blood and placental samples and also encode enzymes 
that determine the rate at which the pentose phosphate pathway will function.  The other 
three genes chosen for promoter region methylation analysis were the three insulin growth 
factor binding proteins (IGFBP-1, IGFBP-2 and IGFBP-6) that were all significantly under 
expressed in placenta exposed to a GDM environment. These were considered important to 
analyse as one of the aims of this study was to determine epigenetic effects that may be 
observed in the placenta (as a proxy for the foetus) that had been exposed to the adverse in 
utero environment, in this case GDM.   
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3.7. Promoter region methylation analysis of selected genes (G6PD, TKT, IGFBP-1, IGFBP-2 
and IGFBP-6) 
Methylation at a gene promoter region is a known epigenetic mechanism correlated with gene 
expression. Hypermethylation usually results in a decrease in gene expression whereas 
hypomethylation is correlated with increased gene expression.  To explain the mechanism of 
altered gene expression of these genes, the methylation status of the promoter region was 
analyzed. Correlation between DNA methylation level and gene expression was investigated 
to assess to what degree gene expression may be influenced by altered DNA methylation in 
women who develop gestational diabetes and to determine whether this aberrant 
methylation was inherited by the foetus. 
The CT values of each of the digests (mock (M), methylation-sensitive (Ms), methylation-
dependant (Md), double (Msd)) for each gene assay were in the range of what was expected 
(recommended)(Ceccarelli et al., 2016, Laska et al., 2013). The mock digests for all genes were 
within the range of 18 to 27 cycles and the CT values of the Ms and Md digests were between 
the values of the mock and double digests. The CT values of the double digests were higher 
than the CT values of the mock digest (All the resulting CT values are listed in Appendix J). The 
difference in CT values between the double digest and mock digest samples represents the 
analytical window of the assay and should be greater than 3 (Laska et al., 2013). This means 
that more than 93.6 % of all DNA molecules in the samples were digested, and that the assay 
results are reliable and meaningful. For each gene assay, this criterion was met.  
For the methylation-sensitive enzyme control (SEC), the difference in CT values between the 
methylation-sensitive and mock digests should be equal to or greater than 4 to pass the quality 
control (Karatzas et al., 2014). Likewise for the methylation-dependent enzyme control (DEC), 
the difference in CT values between the methylation dependent and mock digests should be 
equal to or greater than 4 to pass the quality control. (Agrogiannis et al., 2014, Duron et al., 
2012, Gupta, 2015, Gupta et al., 2015) 
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3.7.1 DNA methylation analysis of candidate genes 
Figure 3.21 shows the percentage (%) of DNA promoter region methylation observed for each 
gene analyzed in both the blood and placental samples and also lists the p-value which 
indicates whether the level of promoter region methylation between cases and controls 
reaches statistical significance. The p-value was calculated using a paired Student’s t-test 
when comparing the blood values with the placental values and when comparing the cases 
with the controls, a non-paired student’s t-test was used. There was no significant alteration 
in promoter region methylation for the IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-6) in the women 
who develop GDM when compared to the controls (blood samples) (p=0.85; p=0.91 and 
p=0.11 respectively; Figure 3.21 A, B and C). However, we do observe significant alterations in 
DNA methylation at the promoter region of these genes in the placenta. Thus, the promoter 
region of IGFBP-1 and IGFBP-2 in exposed placenta is significantly hypermethylated compared 
to the unexposed group (p=2.2x10-8 and p=2.x10-5, respectively) (Figure 3.21 A and B). For 
IGFBP-6, there appears to be a trend towards increased promoter region methylation in the 
placenta of the cases when compared to the controls, however this difference did not quite 
reach statistical significance (p=0.08, Figure 3.21 C).  
The level of G6PD promoter region methylation in blood samples from cases was significantly 
higher (p=1.9x10-5, Figure 3.21 D) than that seen in the controls. Similarly, the level of G6PD 
promoter region methylation in exposed placenta was significantly higher than that seen in 
unexposed placenta (p=1.25x10-11, Figure 3.21D). The level of methylation at the TKT 
promoter region did not appear to be statistically significant between cases and controls in 
both the blood and placenta groups (Figure 3.21 E).  
For the IGFBPs, the methylation levels are higher in the placenta than in the blood for both 
cases and control groups. This is not the case for G6PD, where the methylation levels are 
higher in the blood and placenta cases, and for TKT, where methylation is low across both 
tissues and biological groups.  
  
102 
 
 
 
  
 
 
      
Figure 3.21: Promoter region methylation status of the IGFBP-1(A), IGFBP-2 (B), IGFBP-6 (C), G6PD (D) and TKT 
(E) gene in DNA from maternal case and control blood samples and DNA from exposed and unexposed 
placental samples. Case blood and placenta samples are enclosed in the black blocks. Blue arrows indicate p-
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P=0.85 P=2.2x10-8 
p=6.7x10-12; p=6.7x10-10 
P=0.91 P=2.0x10-5 
P=0.11 P=0.76 P=1.9x10
-5 P=1.25x10
-11 
P=0.93 P=0.34 
p=1.3x10-9; p=5.5x10-5  
p=1.7x10-8;  p=1.2x10-3 
P=0.22; p=0.23  
p=0.41; p=0.36 
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values for comparing cases and controls and the green arrow indicates p-values for comparing methylation 
between blood and placenta.   
 
3.7.2 Understanding the relationship between promoter region methylation and 
mRNA expression of IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT   
 
There is a significant negative association that exists between the level of promoter region 
methylation and the magnitude of gene expression for IGFBP-1 (p=0.012) and IGFBP-2 
(p=0.006) in the placental samples (Figure 3.22 A and B). A higher gene expression is 
associated with lower promoter region methylation. For both genes, this association is absent 
in the blood samples (mothers)(p=0.58 and p=0.56, respectively). There is no significant 
association between gene expression and promoter region methylation levels for IGFBP-6 in 
the blood or placenta samples (p=0.43 and p=0.65, respectively)(Figure 3.22 C). There is a 
significant negative association between G6PD mRNA expression and promoter region 
methylation in both the blood (p=0.002) and placenta (p=0.025) samples. A lower expression 
in the GDM group and exposed placenta is associated with hypermethylation at the promoter 
region while hypomethylation at the promoter region is associated with increased gene 
expression (Figure 3.26D). There is no significant association between mRNA expression and 
promoter region methylation for TKT in both the blood (p=0.74) and placenta (p=0.17) 
samples (Figure 3.22E).  
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Figure 3.22: The association between gene expression (bars) and promoter region DNA methylation (black line) 
in maternal blood and placental samples for IGFBP-1(A), IGFBP-2 (B), IGFBP-6 (C), G6PD (D) and TKT (E). 
Spearman’s correlation rank for each gene IGFBP-1(A), IGFBP-2 (B), IGFBP-6 (C), G6PD (D) and TKT (E) is also 
indicated. Red dots represent case samples and blue dots represent control samples.  
 
 
Figure 3.23: Heat map illustrating the levels of promoter region DNA methylation in selected genes for blood 
(case and control) and placenta (exposed and unexposed) samples.  Maternal case and exposed placenta 
samples are enclosed in blue blocks.  
The heat map (Figure 3.23) illustrates the higher promoter region methylation of IGFBP-1, 
IGFBP-2 and IGFBP-6 in the placenta exposed to GDM in utero environment in comparison to 
the control samples. This figure also highlights the higher level of G6PD promoter region 
methylation in the women who develop GDM in comparison to the control samples.    
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3.8 Performing Spearman’s rank correlation analysis between the mRNA expression values 
obtained for IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT with other variables 
 
3.8.1 Correlation determination between maternal glucose levels and candidate gene 
mRNA expression levels in maternal blood  
Table 3.23: Maternal blood glucose levels (mmol/L) at fasting; 1-hr and 2-hrs post oral glucose (OG) intake 
and the corresponding levels of mRNA expression for IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT in maternal 
blood.  
  Maternal Glucose levels  Normalised FPKM Values  
Sample Fasting   1-hr OG*  2-hr OG* IGFBP-1 IGFBP-2 IGFBP-6 G6PD TKT 
Case0_1054 5.56 9.65 6.95 100 25 58 2 20 
Case1_1048 5.90 9.19 9.03 52 20 55 2 22 
Case2_1060 5.28 9.38 4.17 105 45 59 3 53 
Case3_1086 4.52 9.64 8.91 150 70 68 10 61 
Case4_10225 4.64 10.75 6.71 100 60 34 9 50 
Case5_10276 5.16 8.14 9.15 75 50 28 8 69 
Control0_1061 3.90 7.22 6.77 150 80 32 52 350 
Control1_1067 4.06 4.76 5.54 155 65 64 50 220 
Control2_1090 4.23 5.52 5.48 160 75 53 56 262 
Control3_1094 3.74 4.77 5.14 180 100 42 100 310 
Control4_1107 4.88 5.89 7.33 150 90 28 130 320 
Control5_1087 3.82 4.77 3.64 165 90 58 50 420 
         
* Indicates the maternal glucose levels measured 1-hr and 2-hrs after the ingestion of 75g anhydrous glucose. OG: Oral glucose 
Table 3.23 lists the normalised FPKM values, which represent mRNA expression levels, for 
IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT in maternal blood and the maternal glucose levels 
(at fasting; 1-hr and 2-hr post oral glucose (OG)). These data were used to perform Spearman’s 
rank correlation analysis between the variables. For the IGFBPs, significant negative 
correlations exist between the mRNA expression levels of IGFBP-1 in maternal blood and 
maternal glucose levels at fasting (p=0.0001); at 1-hr (p=0.005); and 2-hrs (p=0.012) post OG 
(Figure 3.24 A); and for IGFBP-2 at fasting (p=0.0001); and 1-hr post OG (p=0.025) (Figure 3.24 
B). No significant correlation was observed between mRNA expression levels and maternal 
glucose levels 2-hr post OG for IGFBP-2. No significant correlation was observed between 
maternal glucose levels and mRNA expression levels for IGFBP-6 (Figure 3.24 C). For both 
G6PD and TKT, significant negative correlations were observed between the level of mRNA 
expression and maternal glucose levels at fasting (p=0.006 and p= 0.016, respectively) and at 
1-hr post OG (p=0.001 and p=0.005, respectively)(Figure 3.24D and E).   
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Figure 3.24: Spearman’s rank correlation between maternal glucose levels (mmol/L) and normalized mRNA 
expression of IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT in maternal blood. The red dots indicate GDM cases 
and the blue dots indicate control samples. 
 
3.8.2 Correlation determination between maternal glucose levels and candidate gene 
mRNA expression levels in the placenta  
 
Table 3.24: Maternal blood glucose levels at fasting, 1-hr and 2-hrs post OG (Oral Glucose)(mmol/L) and the 
corresponding levels of mRNA expression for IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT in the placenta 
  Maternal Glucose levels  Normalised FPKM Values in the placenta 
Sample Fasting   1-hr OG* 2-hr OG*  IGFBP-1 IGFBP-2 IGFBP-6 G6PD TKT 
Case0_1054 5.56 9.65 6.95 95 10 3 40 10 
Case1_1048 5.90 9.19 9.03 66 25 3 30 9 
Case2_1060 5.28 9.38 4.17 98 20 11 90 15 
Case3_1086 4.52 9.64 8.91 165 70 12 100 61 
Case4_10225 4.64 10.75 6.71 150 45 8 50 50 
Case5_10276 5.16 8.14 9.15 100 60 9 70 60 
Control0_1061 3.90 7.22 6.77 364 190 22 260 350 
Control1_1067 4.06 4.76 5.54 360 260 20 170 290 
Control2_1090 4.23 5.52 5.48 372 245 28 280 260 
Control3_1094 3.74 4.77 5.14 420 240 32 250 310 
Control4_1107 4.88 5.89 7.33 260 210 41 240 320 
Control5_1087 3.82 4.77 3.64 95 10 3 290 420 
* Indicates the maternal glucose levels measured 1-hr and 2-hrs after the ingestion of 75g anhydrous glucose. OG: Oral glucose 
 
For the placenta, significant negative correlations exist between the mRNA expression levels 
of  IGFBP-1 and maternal glucose levels at fasting (p=0.0004); at 1-hr (p=0.005); and 2-hrs 
(p=0.05) post OG (Figure 3.25 A); for IGFBP-2 at fasting (p=0.001 and 1-hr post OG (p=0.001) 
(Figure 3.25 B) and for IGFBP-6 at fasting (p=0.008) and at 1-hr (p=0.012) post OG (Figure 3.25 
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C). For G6PD significant negative correlations were observed between the level of mRNA 
expression and maternal glucose levels at fasting (p=0.001); at 1-hr post OG (p=0.007); and at 
2-hr post OG (p=0.04)(Figure 3.25 D). No significant correlation was observed between 
maternal glucose levels and mRNA expression levels for TKT in the placenta (Figure 3.25 E). 
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Figure 3.25: Spearman’s rank correlation between maternal glucose levels (mmol/L) and normalized mRNA 
expression of IGFBP-1, IGFBP-2, IGFBP-6, G6PD and TKT in the placenta. The red dots indicate GDM cases and 
the blue dots indicate control samples.   
 
3.8.3 Correlation determination between mRNA expression of the IGFBPs in maternal 
blood and placental samples with foetal birth weight and maternal BMI 
 
IGFBPs are known to play a role in foetal growth (Agrogiannis et al., 2014, Duron et al., 2012, 
Gupta, 2015, Gupta et al., 2015) and for this reason, we wanted to observe whether there was 
an association between IGFBP-1, IGFBP-2 and/or IGFBP-6 mRNA expression levels and foetal 
birth weight in this study. Table 3.25 lists the BMI (kg/m2) of the mother as well as the birth 
weight of the corresponding foetus. The mRNA expression levels of the IGFBP genes in the 
blood and placenta are listed in Table 3.23 and Table 3.24 respectively. These data were used 
to perform Spearman’s rank correlation analysis between the variables. 
Table 3.25: Maternal BMI and the birth weight (kg) of her neonate 
 
   
Sample 
Birth 
weight (kg) 
BMI 
Case0_1054 3.87 35.4 
Case1_1048 3.31 36.5 
Case2_1060 3.20 36.1 
Case3_1086 3.53 36.2 
Case4_10225 3.50 48.5 
Case5_10276 3.68 35.0 
Control0_1061 3.40 24.0 
Control1_1067 3.22 23.4 
Control2_1090 3.12 35.3 
Control3_1094 3.01 29.7 
Control4_1107 3.28 38.6 
Control5_1087 2.89 34.0 
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Figure 3.26: Spearman’s rank correlation (Rs) between foetal birth weight (kg) and normalized IGFBP-1, IGFBP-
2 and IGFBP-6 mRNA expression (measured via RNA-seq) in the placenta (A) and in maternal blood (B). The 
red dots indicate case samples and blue dots indicate control samples.  
 
There was a significant correlation between birth weight and IGFBP-1 (p=0.017); IGFBP-2 
(p=0.02) and IGFBP-6 (p=0.04) mRNA expression levels in the placenta. A lower expression of 
these genes is associated with larger birth weight (Figure 3.26 A). There was also a significant 
negative correlation between IGFBP-1 mRNA expression in maternal blood and foetal birth 
weight (p=0.005). There was no significant correlation observed between IGFBP-2 and IGFBP-
6 in maternal blood and foetal birth weight (Figure 3.26 B). Although there appears to be a 
trend towards a lower expression of IGFBPs in women with higher BMI, this association is not 
significant in our cohort for any of the IGFBPs studied (Figure 3.27).  
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Figure 3.27: Spearman’s rank correlation (Rs) between normalized IGFBP-1, IFGBP-2 and IGFBP-6 mRNA 
expression in maternal blood and Body Mass Index (BMI). The red dots indicate case samples and blue dots 
indicate control samples. 
 
3.8.4 Correlation between maternal glucose levels and DNA methylation in maternal 
blood and placental tissues  
 
There was no significant correlation observed between promoter region methylation of 
IGFBP-1, IGFBP-2 and IGFBP-6 in maternal blood and maternal glucose levels (Figure 3.28 A, 
3.29 A and 3.30 A, respectively). However, in the placenta (Figure 3.28 B), there appears to be 
a significant positive correlation between IGFBP-1 promoter region methylation and maternal 
glucose levels at fasting (p=0.03) and 1-hr post OG (p=0.005) but not at 2-hrs. For IGFBP-2, a 
significant positive correlation was observed between promoter region methylation in the 
placenta and maternal glucose levels at fasting and 1-hr post OG (p=0.01 and p=0.001 
respectively, Figure 3.29 B) but not at 2-hrs. For IGFBP-6, a significant positive correlation was 
observed between promoter region methylation in the placenta and maternal glucose levels 
at fasting (p=0.02) and 1-hr post OG (p=0.05)(Figure 3.30B). For G6PD, a significant positive 
correlation was observed in maternal blood (Figure 3.31 A) and placental tissue (Figure 3.31 
B) at fasting (p=0.001 and p=0.02, respectively) and 1-hr post OG (p=0.001 and p=0.004, 
respectively). This association was not observed at 2-hr post OG in either the blood or placenta 
tissue (Figure 3.31 A and B, respectively). No correlation between promoter region 
methylation and maternal glucose levels were observed for TKT in either maternal blood or 
placenta samples (Figure 3.32 A and B, respectively).  
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Figure 3.28. Spearman’s rank correlation between blood (A) and placental (B) IGFBP-1 gene promoter DNA methylation and maternal glucose levels (fasting; 1-hr 
post OG and 2-hrs post OG). Red dots indicate case samples and blue dots indicate control samples. 
0
2
4
6
8
10
12
3 4 5 6 7
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Fasting glucose levels (mmol/L) in pregnant women
IGFBP-1; blood;  fasting
0
2
4
6
8
10
12
3 5 7 9 11 13
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels (mmol/L) in pregnant women 1hr post 
OG
IGFBP-1; blood; 1hr
0
2
4
6
8
10
12
3 5 7 9 11
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels i(mmol/L) in pregnant women 2hrs post 
OG
IGFBP-1; blood; 2hrs
0
20
40
60
80
100
120
3 4 5 6 7
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Fasting glucose levels (mmol/L) in pregnant women
IGFBP-1; placenta; fasting 
0
20
40
60
80
100
120
3 5 7 9 11 13
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels (mmol/L) in pregnant women 1hr post 
OG
IGFBP-1; placenta; 1hr
0
20
40
60
80
100
120
3 5 7 9 11
IG
FB
P
-1
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels i(mmol/L) in pregnant women 2hrs post 
OG
IGFBP-1; placenta; 2hrs
Rs= -0.15 
P=0.65 
Rs=-0.21 
P=0.71 
Rs= -0.10 
P=0.58 
Rs=0.63 
P=0.027 
Rs= 0.75 
P=0.005 
Rs= -0.19 
P=0.32 
A
  Rs+ -0.15 
B
  Rs+ -0.15 
114 
 
 
 
 
Figure 3.29. Spearman’s rank correlation between maternal blood (A) and placental (B) IGFBP-2 gene promoter DNA methylation and maternal glucose levels 
(fasting; 1-hr post OG and 2-hr post OG). Red dots indicate case samples and blue dots indicate control samples. 
 
0
2
4
6
8
10
12
3 4 5 6 7IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Fasting maternal glucose levels (mmol/L)
IGFBP-2; Blood; fasting 
0
2
4
6
8
10
12
3 5 7 9 11 13
IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels (mmol/L) in pregnant women 1hr post 
OG
IGFBP-2; Blood; 1hr
0
2
4
6
8
10
12
3 5 7 9 11
IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels i(mmol/L) in pregnant women 2hrs post 
OG
IGFBP-2; Blood; 2hr
0
10
20
30
40
50
60
70
80
90
3 4 5 6 7
IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Fasting maternal glucose levels (mmol/L)
IGFBP-2; Placenta; Fasting
0
20
40
60
80
100
3 5 7 9 11 13IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels (mmol/L) in pregnant women 1hr post 
OG
IGFBP-2; Placenta; 1hr 
0
20
40
60
80
100
3 5 7 9 11
IG
FB
P
-2
 p
ro
m
o
te
r 
re
gi
o
n
 m
et
h
yl
at
io
n
 
(%
)
Glucose levels i(mmol/L) in pregnant women 2hrs post 
OG
IGFBP-2; Placenta; 2hr
Rs=-0.17 
P=0.39 
Rs=0.20 
P=0.41 
Rs=-0.38 
P=0.71 
Rs=-0.50 
P=0.78 
Rs=0.87 
P=0.001 
Rs=0.68 
P=0.014 
A 
B 
115 
 
 
 
 
Figure 3.30. Spearman’s rank correlation between maternal blood (A) and placental (B) IGFBP-6 gene promoter DNA methylation and maternal glucose levels 
(fasting; 1-hr post OG and 2-hr post OG). Red dots indicate case samples and blue dots indicate control samples. 
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Figure 3.31 Spearman’s rank correlation between maternal blood (A) and placental (B) G6PD gene promoter DNA methylation and maternal glucose levels (fasting; 
1-hr post OG and 2-hr post OG). Red dots indicate case samples and blue dots indicate control samples. 
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Figure 3.32. Spearman’s rank correlation between maternal blood (A) and placental (B) TKT gene promoter DNA methylation and maternal glucose levels (fasting; 1-
hr post OG and 2-hr post OG). Red dots indicate case samples and blue dots indicate control samples. 
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3.8.5 Correlation between foetal birth weight and IGFBP promoter region 
methylation in the placenta and maternal blood samples   
There is a significant positive correlation between foetal birth weight and the level of IGFBPs 
(1, 2 and 6) promoter region methylation in the placenta. The higher the level of methylation 
at the promoter region, the higher the birth weight (Figure 3.33 A). There was no significant 
correlation observed between IGFBP-1, IGFBP-2 and IGFBP-6 promoter region methylation in 
the mothers blood and birth weight (Figure 3.33 B).   
 
 
 
 
Figure 3.33. Spearman’s rank correlation between methylation levels in the promoter region of IGFBP-1, 2 
and 6 in placental (A) and maternal blood (B) samples and birth weight. Red dots indicate case samples and 
blue dots indicate control samples. 
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CHAPTER 4 
4. DISCUSSION 
Gestational diabetes mellitus, an important health issue that is increasing in prevalence every 
year (Dabalea et al., 2005), creates an adverse in utero environment for the developing foetus 
and increases the risk of developing T2D in the foetus as well as the mother. Therefore, GDM 
is a good model to study the mechanisms involved in foetal metabolic programming and also 
to elucidate new mechanisms to help diagnose, treat and prevent its consequences for the 
offspring (as newborns and later as adults) as well as for successive generations. Currently 
there is little molecular understanding of how foetal programming may occur (Finer et al., 
2015). Epigenetic modification is currently a very promising mechanism to explain foetal 
metabolic programming and many studies are beginning to shed light on the mechanisms for 
the intergenerational transmission of disease risk (Bouchard et al., 2012). Epigenetic control 
of gene expression is a key step in understanding the development of a particular phenotype. 
Biological conditions and disease status are known to be largely characterized by differences 
in gene expression levels. Epigenetic mechanisms provide a component of plasticity that 
allows for adaptation during times of early environmental stresses such as prenatal over-
nutrition and under-nutrition (Joss-Moore and Lane, 2012).  
Gene methylation in placental tissue is generally lower when compared to other somatic 
tissues (Christensen et al., 2009, Nawathe and Lees, 2016, Nawathe et al., 2016). This lower 
level of methylation has been associated with promoting healthy foetal development 
throughout gestation. Placental function and the intrauterine environment play critical roles 
in foetal programming (Nawathe and Lees, 2016). Altered DNA methylation in the placenta 
plays a significant role in optimal placental and foetal growth (Serman et al., 2007). Candidate 
gene studies have demonstrated an association between DNA methylation in placental tissue 
and maternal hyperglycemia (Bouchard et al., 2010, Nawathe and Lees, 2016, Nawathe et al., 
2016). Bouchard et al. (2010) observed an association between maternal hyperglycemia with 
lower DNA methylation in placental tissue at the LEP gene (Bouchard et al., 2010) as well as 
higher levels of methylation at the ADIPOQ gene in foetal placental tissue (Bouchard et al., 
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2012). Associations have also been observed between maternal hyperglycemia and lower DNA 
methylation at the promoter region of other candidate genes involved in metabolism such as 
ABCA1 (in cord blood), LPL (in placenta) and in IGFBP3 (maternal and cord blood) (Houde et 
al., 2013, Houde et al., 2014). 
In pregnancy, many adaptions occur to ensure a healthy metabolic balance between the 
mother and foetus while ensuring proper foetal development. In the context of glucose 
metabolism, these adaptions occur to ensure that sufficient amounts of glucose reach the 
foetus to promote normal development. In GDM, although insulin sensitivity is only slightly 
decreased compared with pregnant women with normal glucose tolerance, insulin secretion 
in women with GDM is significantly decreased (Angueira et al., 2015). This results in the 
accumulation of glucose in the mother’s blood. In normal pregnancies, the ß-cells of the 
pancreas will up-regulate insulin secretion in response to the increasing concentration of 
glucose, but in a certain percentage of women, this up-regulation does not take place. This 
results in GDM. 
In this study I used RNA sequencing to study gene expression as it produces a large dataset 
that is useful both in identifying genes that are differentially expressed between cases and 
controls in the blood of the mother and in the placenta, and provides a good quantitative 
estimate of gene expression. This study is not hypothesis driven as is the case in candidate 
gene studies, but is exploratory, thereby covering the entire range of RNA transcription. 
Twenty genes with large differential expression were selected as good candidates based on 
the gene ontology (GO) and enrichment analysis results as well as an extensive literature 
research. These candidate genes were validated using quantitative real-time PCR and 
exhibited significant differential expression in the quantitative real-time PCR assays (p<0.05), 
confirming the RNA sequencing results. It is noteworthy to mention that the direction of 
change (increase/decrease) in expression was 100 % consistent between RNA sequencing and 
qPCR data for the validated genes. Each case and control participant in the study was matched 
as closely as possible with regard to ethnicity, age and BMI, variables that are known to affect 
DNA methylation (Zaghlool et al., 2015, Zhang et al., 2011). Reducing the number of variables 
between case and control groups ensures that the differential variation in gene expression is 
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most likely due to the presence or absence of gestational diabetes, rather than confounding 
factors. Only cases with female offspring were analyzed as methylation patterns of a large 
number of genes, especially in the placenta, have been shown to be foetal sex-specific (Hall 
et al., 2014, McCarthy et al., 2014).  
We observed that 60 genes were significantly differentially expressed in the mother’s blood 
at the time GDM was diagnosed (24-28 weeks gestation), of which three are well characterized 
genes that have known associations with T2D and therefore also potentially with GDM (AKT2, 
KCNQ1 and GSK3A). Others included an open reading frame of unknown function that has 
been mentioned previously as a possible marker for GDM (C8ORF80); a mitochondrial 
glutamate carrier 1 gene (SLC25A22) as well as five genes that encode enzymes which function 
in the pentose phosphate pathway (G6PD, TKT, ALDOA, DCXR and PGLS). The G6PD and TKT 
genes were also significantly under-expressed in exposed placenta. Placental tissue taken 
from the mothers with GDM contained 52 genes that were significantly differentially 
expressed, three  of which were insulin-like growth factor binding proteins (IGFBP-1, IGFBP-2 
and IGFBP-6). The IGFBP-1 and IGFBP-2 genes were also under-expressed in the blood of 
women who develop GDM, however this differential expression only reached levels of 
significance for IGFBP-1. The five genes chosen for promoter region methylation analysis were 
all significantly down-regulated in either the women who developed GDM (G6PD, TKT and 
IGFBP-1) or in exposed placenta (G6PD, IGFBP-1, IGFBP-2 and IGFBP-6).  
Significant hypermethylation at the promoter region of G6PD was observed in both women 
who developed GDM as well as in exposed placenta. There was no observed variation in the 
methylation of the promoter region of TKT in either group. Significant hypermethylation at 
the promoter region of IGFBP-1 and IGFBP-2 was observed in exposed placenta, but not in 
women with GDM. There appeared to be a trend towards increased promoter region 
methylation of IGFBP-6 in exposed placenta, however this did not reach levels of significance 
when compared to unexposed placenta (Table 4.1). 
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Table 4.1 The five genes chosen for gene specific promoter region methylation 
   
    
      
4.1 Insulin-like growth factor binding proteins (IGFBPs) mRNA expression, gestational 
diabetes and foetal growth 
Normal foetal development is dependent on a balanced interplay between growth 
suppressors and promoters originating from foetal, placental and maternal compartments. 
The IGF axis is a complex system composed of a family of interacting ligands (IGF-1 and IGF-
2), two receptors (IGF-1R and IGF-2R) and insulin-like growth factor binding proteins 
(IGFBPs)(Huang et al., 2015, Lu et al., 2012). This system plays an important role in the 
regulation of somatic growth in an endocrine manner and in the proliferation and 
differentiation of normal and malignant cells in a paracrine-autocrine manner (Lee et al., 
2016). IGF-1 and -2 are predominately produced by adult and foetal liver although the 
placenta also expresses these peptides (Hiden et al., 2009). The majority of IGFs in blood and 
tissues are bound to six of the named IGFBPs that have been identified in humans (Gonzalez-
Parra et al., 2002). These IGFBPs form complexes with both IGF-1 and IGF-2 with a high affinity 
preventing them from binding to their receptors (Allen et al., 2003, Hiden et al., 2009). In this 
way, the bioavailability of IGFs is controlled by IGFBPs. Therefore, as modulators of IGF 
actions, IGFBPs assume an important role in the process of foetal growth (Giudice et al., 1995, 
Lu et al., 2012). 
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The IGFBPs are globally distributed in all tissues and cells, but the majority of circulating levels 
of these proteins in humans are produced by the liver under the regulation of IGFs and insulin 
(Rajpathak et al., 2009). Four of the IGFBPs, (IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-5) have 
been implicated in T1D, obesity and insulin resistance in both animal models and human 
subjects (Lu et al., 2012, Ruan and Lai, 2010). The IGFBPs have also been identified as 
surrogate markers for metabolic syndrome, cardiovascular disease and cancers (Lu et al., 
2012, Pon et al., 2015, Vasylyeva and Ferry, 2007). In terms of glucose metabolism, IGFBPs 
play an important role in insulin signalling, enhancing peripheral glucose uptake, decreasing 
hepatic glucose output and modifying lipid metabolism. A number of studies have 
demonstrated an association between IGFBPs, glucose tolerance and insulin resistance 
(Aguirre et al., 2016, Heald et al., 2001). Nawathe et al. (2016) found elevated mRNA and 
protein levels of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4 and IGFBP-7 in placenta of small for 
gestational age (SGA) neonates and decreased expression of IGFBP-1, IGFBP-2, IGFBP-3 and 
IGFBP-4 in the large for gestational age (LGA) group. These findings suggest that IGFBPs play 
a role in the “net IGF bioavailability” in pregnancies affected with SGA and LGA (Nawathe et 
al., 2016).  
The IGFBPs also contain functional domains which enable IGF-independent actions (Bach, 
2015c, Bach, 2015a, Bach, 2015b, Wheatcroft and Kearney, 2009). This is a result of their 
transport into the nucleus where they may exert IGF-independent activities by transcriptional 
activation of genes. The IGF-independent actions of IGFBPs are not as well understood in 
comparison to their IGF-dependent actions (Forbes et al., 2012).  
4.1.1 IGFBP-1 
IGFBP-1 is the main insulin-like growth factor binding protein of amniotic fluid and a significant 
binding protein in maternal and foetal serum (Hills et al., 2013, Holmes et al., 2000). This 25 
kDa protein is mainly secreted by the liver, however, it is also produced by granulosa cells and 
decidualised endometrium (Juul, 2003, Khosravi et al., 2007). The primary physiological 
function of IGFBP-1 appears to be the regulation of the bioavailability of IGF-1 and IGF-2,  
although it does also have effects that are IGF-independent. IGFBP-1 is the only IGFBP acutely 
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affected by glucoregulatory hormones and may play an active role in glucose modulation. 
According to many studies, insulin is the main regulator of IGFBP-1 under basal (non-stress) 
conditions, exerting a suppressive effect (Gibson et al., 1995, Heald et al., 2001, Loukovaara 
et al., 2005).  Therefore, the production of IGFBP-1 in the liver is dependent on insulin supply 
in the portal circulation and the concentration of this binding protein in circulation varies 
significantly depending on whether the individual is in the non-fed or postprandial state 
(Heald et al., 2006). In a study performed by Bae et al. (2013) they observed that an increase 
in insulin resulted in the suppression of hepatic IGFBP-1 gene expression, and that IGFBP-1 
levels rapidly declined after feeding (Bae et al., 2013).  
The levels of IGFBP-1 are decreased in conditions associated with insulin resistance (Aguirre 
et al., 2016, Sandhu et al., 2002). Kabir et al. (2010) showed that the expression of IGFBP-1 
increases in a fasting state (Kabir, 2014, Lappas, 2015) in an effort to recruit and increase the 
expression and activity of IGFs. In vivo studies have shown that IGFBP-1 injection into rats 
resulted in a significant increase in glucose, which was suggested to be secondary to the 
suppression of the hypoglycaemic effect of endogenous IGF-I. However, the deletion of the 
IGFBP-1 gene in mice did not show significant changes in glucose metabolism (Wheatcroft and 
Kearney, 2009). Studies have also shown that the expression of IGFBP-1 mRNA is affected by 
metabolic disturbances (Beale, 2013, Gu et al., 2014, Heald et al., 2001). Heald et al. (2001) 
observed an association between low circulating levels of IGFBP-1 and the development of 
macrovascular disease and hypertension in T2D patients (Heald et al., 2001). It was recently 
observed that IGFBP-1 had lower concentrations in women with GDM as well as in the cord 
blood of their foetuses (Lappas, 2015). During pregnancy complicated by T1D, maternal 
plasma IGFBP-1 was found to be elevated more than two fold compared with normal 
pregnancy (Lappas, 2015). Another study has shown that cord blood IGFBP-1 levels negatively 
correlate with birth weight and that IGFBP-1 levels are lower in pregnancies complicated by 
T2D and GDM in comparison to those measured in normal pregnancies (Hiden et al., 2009).  
In healthy pregnancies not complicated by diabetes, IGF-1 is the most important growth factor 
in utero and is predominantly bound to IGFBP-1 which is a known regulator of foetal growth 
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and differentiation. Gestational diabetes is associated with increased birth weight and high 
rates of macrosomia (Lindsay et al., 2007). It is generally accepted that maternal 
hyperglycemia and foetal hyperinsulinemia are the main cause of this excessive growth, 
however, the role that IGFs and their binding proteins play in excessive foetal growth are less 
clear. The expression of IGFBP-1 and its relative protein levels have been shown to be 
decreased in individuals with GDM (Lappas, 2015). Decreased placental expression levels of 
IGFBP-1 have been demonstrated in pregnancies with foetal growth restriction (FGR), 
however, whether these alterations are a causative factor of FGR or accompany other 
pathogenic mechanisms requires further investigation (Koutsaki et al., 2011). IGFBP-1 has not 
been extensively studied in the offspring of pregnant women, however studies examining 
IGFBP-1 concentrations in cord blood obtained from neonates exposed to a pregnancy 
complicated by diabetes have been inconsistent, with high and low concentrations found 
(Culler et al., 1996, Lindsay et al., 2007, Yang et al., 1996).   
Several posttranslational changes modulate the affinity of IGFBP-1 for IGFs, particularly to IGF-
I. These include phosphorylation/de-phosphorylation, proteolysis and polymerization and 
methylation (Gupta, 2015) and this is mentioned in a number of studies (Gibson et al., 1995, 
Shen et al., 2015).  
4.1.2 IGFBP-2 
Like IGFBP-1, IGFBP-2 is a modulator of IGF-1 and IGF-2 bioavailability and plays an important 
role in the regulation of several cellular processes (Shen et al., 2015). IGFBP-2 is the most 
abundant IGFBP and is expressed in several tissues (Jones and Clemmons, 1995). Besides 
binding to IGFs in circulation, the IGF-regulatory activities of IGFBP-2 involve interactions with 
components of the extracellular matrix, cell surface proteoglycans and integrin receptors (Yau 
et al., 2015). IGFBP-2 exerts other key functions within the nucleus where it directly or 
indirectly promotes the transcription of other genes. All these activities of IGFBP-2, whether 
dependent or independent on IGFs, contribute to functional roles in growth and development 
(Yau et al., 2015).  
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IGFBP-2 has been previously linked to obesity and diabetes. Studies have shown that the 
administration of IGFBP-2 can be beneficial in improving metabolic responses (Yau et al., 
2015). The association between IGFBP-2 levels and obesity are well established but are not 
yet well understood in terms of diabetes. In 2016, Kammel et al. (2016) observed a significant 
association between decreased IGFBP-2 expression and the development of obesity in 
adolescence. Allen et al. (2003) observed decreased plasma IGFBP-2 levels in obese males and 
females (Allen et al., 2003). It is hypothesized that the reduced circulating levels of IGFBP-2 in 
obese individuals are associated with an increased bioavailability of IGF-1, and hence 
stimulated growth (Kammel et al., 2016).  
In terms of diabetes, the actions of IGFBP-2 have been linked to insulin, although only in cases 
of hyperinsulemia where it appears to play a role in autocrine control in adipocytes (Aguirre 
et al., 2016). Lappas et al. (2015) found that low postnatal levels of IGFBP-2 are a “significant 
risk factor for the development of T2D in women with a previous history of GDM”. This study 
reports IGFBP-2 as a potential biomarker for the prediction of T2D in women who developed 
GDM (Lappas, 2015). They also found that cord plasma levels of IGFBP-2 were significantly and 
negatively correlated to the fasting glucose level in an OGTT when corrected for maternal BMI. 
It is not clear as to whether a decreased expression of IGFBP-2 may contribute to the 
pathophysiology of GDM or whether it is a result of the chronic insulin resistance of these 
patients (Retnakaran, 2016).  
4.1.3 IGFBP-6 
The data relating to the expression of IGFBP-6 and its association with diabetes are 
contradictory. In a study using diabetic rats, reduced levels of IGFBP-6 mRNA were observed 
when compared to healthy rats (Bergman et al., 2005). In 2012, IGFBP-6 serum levels were 
found to be significantly higher in patients with T1D (Bach, 2015c) however no associations 
with T2D or GDM have been reported. In an animal study using sheep, it was observed that 
placental weight increased between days 45 and 90 of gestation and this increase was 
accompanied by a reduction in IGFBP-6 expression. Lappas (2015) found that the maternal 
plasma levels of IGFBP-6 were significantly lower in obese individuals with NGT compared with 
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NGT non-obese and non-obese women with GDM. This finding suggests that reduced levels 
of IGFBP-6 may play a role in the development of obesity.    
4.1.4 The possible implication of maternal IGFBP-1 and IGFBP-2 in abnormal foetal 
growth associated with gestational diabetes 
Throughout pregnancy, the expression, circulating levels and covalent modifications of IGFBPs 
continuously change in the mother and may influence circulating IGF bioavailability (Sferruzzi-
Perri et al., 2011). The maternal IGF system plays a vital role in foetal growth regulation via 
stimulation of extravillous trophoblast migration/invasion and facilitation of nutrient 
exchange through the promotion of growth and development of the placenta (Qiu et al., 
2005). Decreased maternal pregravid insulin resistance coupled with an inadequate insulin 
response are the pathophysiological mechanisms underlying the development of gestational 
diabetes (Catalano et al., 2003). It is well known that IGFBP-1 acts to inhibit IGF function and 
is inversely related to insulin levels. 
In my study, the blood samples taken from the mothers who develop gestational diabetes 
show a significant down regulation of IGFBP-1 mRNA expression when compared to controls. 
IGFBP-2 and IGFBP-6 appear to have lower levels of mRNA expression in GDM cases when 
compared to controls, however, this difference does not reach levels of significance. The levels 
of IGFBP-1 and IGFBP-2 mRNA expression in maternal blood samples are significantly 
associated with maternal glucose levels at fasting and at 1-hr post OG (and at 2-hr post OG for 
IGFBP-1 only). No correlation is observed between maternal glucose levels and IGFBP-6 mRNA 
expression in maternal blood samples. There is a significant negative correlation between the 
levels of IGFBP-1 mRNA expression in maternal blood and foetal growth. There was no 
statistical association observed between maternal IGFBP mRNA expression and BMI. The 
significant under expression of IGFBP-1 mRNA in women with GDM is not associated with 
promoter region methylation and no association was observed between maternal glucose 
levels and IGFBP methylation.  
The changes in maternal carbohydrate metabolism (increased glucose and insulin levels) that 
result from the presence of gestational diabetes may lead to a decrease in maternal IGFBP-1 
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levels. It may be possible that high glucose levels cause a decrease in IGFBP-1 mRNA 
expression (Zhang et al., 2010). Given the role of IGFBP-1 in regulating IGF-1 bioavailability, 
the reduced IGFBP-1 levels in women diagnosed with GDM may be an important contributor 
to the development of insulin resistance through increased IGF-1 bioavailability. Therefore, 
we hypothesize that the significantly lower level of IGFBP-1 mRNA expression observed in 
women with GDM may be due to the inhibitory effect of high glucose levels that are 
characteristic of women with GDM. It is also possible that high insulin levels in women with 
GDM may also cause reduced expression of maternal IGFBPs (Gibson et al., 1996, Heald et al., 
2001, Rajwani et al., 2012) but unfortunately, one of the limitations to this study was that the 
fasting insulin levels of the mothers were not measured and therefore an association between 
the levels of IGFBP-1 mRNA expression and insulin concentration could not be determined.  
Our data have shown that the maternal IGFBP-1 gene expression levels are inversely 
correlated with birth weight, as was also observed in other studies (Verhaeghe et al., 1993, 
Whittaker et al., 1990). This data supports the hypothesis that low levels of maternal IGFBP-1 
may lead to increased levels of bioavailable IGF peptides, thereby increasing IGF-induced 
foetal growth (Giudice et al., 1995). Alterations in circulating IGF and IGFBPs may alter birth 
weight and/or neonatal adiposity (Lappas, 2015). This may lead to a change in the ideal growth 
trajectories, resulting in the development of  metabolic disorders later in life. Data from this 
study suggest that the level of IGFBP-1 mRNA expression in the mother may be regulated by 
her glucose levels. Decreased expression of IGFBP-1, as observed in GDM in this and other 
studies, is likely a consequence of the presence of GDM-associated glycaemia, leading to 
greater bioavailable IGFs which in turn induce the characteristic macrosomia observed in 
neonates in GDM pregnancies. Although this is a possibility, we do not see a significant 
difference in the birthweight between the GDM and the control group.  
The slightly lower (but statistically non-significant) level of IGFBP-2 expression in blood cells 
from GDM compared to non-GDM women and the lack of correlation between levels of IGFBP-
2 mRNA expression and maternal BMI and foetal birth weight may indicate that maternal 
IGFBP-2 does not play a significant role in the outcome of foetal size in gestational diabetes.  
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However, in a study performed by Zhu et al. (2016), they found that the maternal plasma 
levels of IGFBP-2 decreased throughout pregnancies affected by GDM. They also observed a 
significant association between higher IGFBP-2 levels and a lower risk of developing GDM (Zhu 
et al., 2016). This finding together with the data from this study showing a trend towards lower 
IGFBP-2 expression in GDM women, lead us to hypothesise that IGFBP-2 is implicated to some 
extent in the development of GDM. It is possible that we don’t see a significant under 
expression of this gene in our cohort due to small sample size.  
In terms of maternal IGFBP-6, we do not observe any significant difference in the level of 
expression between the case and control groups. There were no significant correlations 
between the mRNA expression of this gene in maternal blood and other variables such as 
maternal glucose levels, maternal BMI and foetal birth weight. In the literature there is an 
established link between low maternal plasma IGFBP-6 levels and obesity (Hair et al., 2015, 
Lappas, 2015) whereas the link between maternal IGFBP-6 and gestational diabetes is not so 
well defined (Ferrero et al., 2012; Lappas et al., 2015). Therefore we can conclude that it is 
unlikely that the high glucose and insulin levels of the mother have any significant effect on 
IGFBP-6 mRNA expression.  
4.1.5 Placental IGFBPs mRNA expression and possible implications for foetal growth 
Gestational diabetes contributes to adverse foetal outcomes such as the development of 
insulin resistance in utero (Catalano et al., 2009) and large-for-gestational age (Ferraro et al., 
2012) neonates. One of the many functions of the placenta is to produce a number of growth 
factors which may regulate the growth and the functions of the placenta in an autocrine or 
paracrine manner. The insulin-like growth factors (IGFs) have been shown to play a vital role 
in foetal growth and development (Baker et al., 1993, Liu et al., 1996). At the feto-maternal 
interface, IGFBP-1 to IGFBP-6 are predominantly expressed by the decidua during human 
pregnancy, with IGFBP-1 being the most abundant (Hill et al., 1993). Additionally, IGFBP-3, 
IGFBP-4 and IGFBP-5 are expressed by the chorionic mesoderm (Han and Carter, 2000). Given 
IGFBP expression at the feto-maternal interface, IGFBPs may play a significant role in 
modulating IGF actions in the placenta, as well as having IGF-independent effects. Although 
the molecular mechanisms controlling normal foetal growth and development remain poorly 
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understood, it is thought that the placenta may play an important role through the secretion 
of placental hormones (Freemark, 2010). These hormones are secreted either into the 
umbilical circulation to directly affect foetal metabolism and growth, or into the maternal 
circulation to alter maternal metabolism and substrate availability for placental transfer 
(Sferuzzi-Perri et al., 2011).  
The data presented in this study reveal that there is a significant down regulation of IGFBP-1, 
IGFBP-2 and IGFBP-6 mRNA expression in the placenta samples taken from infants born to 
women who developed gestational diabetes. The suppression of IGFBP-1 in the placenta 
exposed to gestational diabetes can be logically explained by hyperglycemia and raised 
maternal and foetal insulin levels, as insulin inhibits IGFBP-1 production (Loukovaara et al., 
2005). The levels of IGFBP-1, IGFBP-2 and IGFBP-6 mRNA expression in the placenta were 
significantly negatively associated with maternal glucose levels at fasting and at 1-hr post OG 
(and at 2-hr post OG for IGFBP-1 only). This finding may indicate that the reduced expression 
of these IGFBPs is a result of high maternal glucose and hyperinsulinaemia that is 
characteristic of gestational diabetes. Collectively, these data may suggest that high maternal 
glucose levels during pregnancy influence the bioavailability of IGFs indirectly through 
regulating IGFBPs, ultimately increasing foetal tissue and overall foetal somatic growth, 
resulting in larger than normal weight babies that is characteristic of GDM (Lappas, 2015). An 
alternative explanation is that the placental IGFBP expression might impact placental growth 
(and perhaps indirectly foetal growth). However, in this study we do not see a significant 
difference in the birthweight between the GDM and control groups.  
IGFBP-1, IGFBP-2 and IGFBP-6 mRNA expression levels are negatively correlated with foetal 
birth weight. This finding may implicate these IGFBPs in mechanisms underlying foetal growth. 
Reduced levels of these  binding proteins in the placenta will result in an increase in free, 
unbound IGFs. These IGFs are then free to bind to their respective receptors, thus promoting 
foetal growth. It is possible for the free IGFs to cross the placenta, stimulating this effect in 
the foetal circulation, however, IGFs do not cross the placenta in very large quantities 
(Sferruzzi-Perri et al., 2011).   
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4.1.6 Maternal and placental IGFBPs promoter region methylation and foetal growth 
In this study we did not observe significantly altered promoter region methylation in the blood 
of women with GDM for either IGFBP-1 or IGFBP-2.  It appears that the significant decreased 
expression of IGFBP-1 in the women with GDM is not associated with promoter region 
methylation. This supports our hypothesis that the reduced expression of IGFBP-1 mRNA is 
likely to be a result of inhibition due to high levels of glucose and/or insulin that is 
characteristic of GDM women.  
In the placental tissue, the under expression of IGFBP-1 and IGFBP-2 mRNA is significantly 
correlated with hypermethylation at the promoter region of these genes. We therefore 
conclude that hypermethylation at the promoter region significantly reduces the expression 
of IGFBP-1 and IGFBP-2; which could possibly have an effect on the bioavailability of certain 
growth factors (namely IGF-1) and consequently effect foetal growth. This hypothesis is 
supported by the observation of a significant correlation between foetal birth weight and the 
level of promoter region methylation in placental IGFBP-1 and IGFBP-2. Our data suggests that 
an increase in maternal glucose levels will have an effect on the methylation and expression 
of these binding proteins in the placenta. This results in increased foetal growth and larger 
birth weight babies, as observed with GDM. The data suggest that DNA methylation may 
reduce expression of these binding proteins in the placenta but not in the mother. It may be 
essential that the placenta requires the ability to respond to prevailing nutrient levels and an 
epigenetic process would allow that, whilst in the adult linking growth to nutrients would be 
less essential than in the placenta and/or foetus. We conclude that the hypermethylation 
observed at the promoter region of these binding proteins in the placenta, may be a result of 
the presence of GDM and not an adaptive response by the foetus.  The absence of IGFBP-1 
promoter methylation in the blood from women with GDM may suggest that any effect that 
GDM has on IGFBP-1 should be reversible in the mothers after birth (as GDM is a transient 
form of the disease). Conversely, the presence of IGFBP-1 promoter methylation in placental 
tissue obtained from GDM exposed foetuses suggests that the effect of GDM on IGFBP-1 may 
potentially be manifested long term in the infants after birth. 
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4.2 The Pentose Phosphate Pathway (PPP) 
Gestational diabetes mellitus is characterised by hyperglycemia that results from an insulin 
supply that is inadequate to overcome the rise of insulin resistance that occurs during 
pregnancy (Buchanan and Xiang, 2005). Glucose can have different metabolic fates once taken 
up into a cell. Glycolysis, the first step of which is the production of glucose-6-phosphate, is 
the main pathway of glucose metabolism, generating ATP and pyruvate. Alternative pathways 
for glucose-6-phosphate are into the PPP or to glycogen synthesis. The PPP (also referred to 
as the hexose monophosphate shunt) is a metabolic pathway parallel to glycolysis. It 
generates precursors for the synthesis of coenzymes, nucleotides, RNA and DNA (ribose-5-
phosphate) and nicotinamide adenosine dinucleotide phosphate (NADPH). The shift of 
glucose to this pathway tends to occur in organs with intense growth or with high biosynthesis 
demands (Michalek et al., 2011). The activity of the PPP is regulated according to the 
immediate metabolic situation and the needs of the organism; if not needed, the products of 
PPP are readily converted to glycolytic intermediates and oxidized. Shunting of accumulated 
cytosolic glycolytic intermediates into the PPP supposedly unburdens glycolysis and 
quantitatively limits processing of glycolytic intermediates into harmful metabolic products. 
In this way, the PPP represents a potentially ‘protective’ mechanism against hyperglycaemia-
induced damage (Pacal et al., 2011). 
There are two distinct phases in the PPP. The first is the oxidative phase, in which NADPH is 
generated, and the second is the non-oxidative synthesis of 5-carbon sugars. Although the 
primary role of the PPP is anabolic rather than catabolic, it does still involve the oxidation of 
glucose. Both the process of glycolysis and the PPP appear to be highly conserved amongst 
species and have a very ancient evolutionary origin suggesting importance in function (Court 
et al., 2015, Stincone et al., 2015). One of the major uses of NADPH in the cell is to prevent 
oxidative stress. Oxidative stress can be defined as any “disturbance in the balance of 
antioxidants and pro-oxidants in favour of the later due to different factors such as aging, drug 
actions and toxicity and inflammation” (Rahal et al., 2014). Oxidative stress causes healthy 
cells of the body to lose their function and structure from oxygen free radical damage and 
when the antioxidant level is limited, this type of damage can become debilitating (Asmat et 
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al., 2016). Damage to DNA, proteins, and other macromolecules due to oxygen free radicals 
has been implicated in the pathogenesis of a wide variety of diseases, including diabetes 
(Asmat et al., 2016).  
Nicotinamide adenine dinucleotide phosphate (NADPH) reduces glutathione via glutathione 
reductase, which converts reactive H2O2 into H2O by glutathione peroxidase. If NADPH were 
absent, the H2O2 would be converted to hydroxyl free radicals which can cause irreversible 
cell damage. Cells generate a large amount of NADPH through the PPP to use in the reduction 
of glutathione. There are two routes for the disposal of H2O2: by catalase and by glutathione 
peroxidase (Gaetani et al., 1996). It is known that a defect in the catalase route for the disposal 
of peroxide can predispose individuals to developing diabetes. Therefore it is possible that it 
a defect in the glutathione peroxidase route (due to aberrant NADPH production) could have 
similar effects. It has been known for more than two decades that reactive oxygen species can 
cause diabetes in rodents (Bondeva and Wolf, 2014) and it is known that increased oxidative 
damage is found in both T1D and T2D (Giacco and Brownlee, 2010). Therefore, it has been 
suggested that oxidative stress is a significant cause of diabetes in human populations(Lappas 
et al., 2011, Matough et al., 2012). On the other hand, a number of studies have concluded 
that diabetes causes oxidative stress (Inoguchi et al., 2000) which may in turn cause the 
vascular and microvascular-complications that are characteristic of poorly controlled 
diabetes.    
Pathological pregnancies, including GDM, are associated with higher levels of oxidative stress 
which is the result of the overproduction of free radicals and/or a defect in the antioxidant 
defences (Lappas et al., 2011). In GDM pregnancies, glucose tolerance and metabolism as well 
as insulin resistance are altered, and although the pathophysiologic mechanisms underlying 
these changes are not completely understood, they are accompanied by oxidative stress (Zhu 
et al., 2015). 
In this study we see the significant under expression of five key enzymes that play a role in the 
PPP namely G6PD, TKT, PGLS, DCXR and ALDOA in the blood of women who develop GDM. 
Two of these genes, G6PD and TKT, were also found to be significantly under expressed in 
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exposed placenta. However, only G6PD was found to have significant promoter region 
methylation in both the blood of women who develop GDM as well as exposed placenta.  
Hyperglycaemia is the major feature of GDM. In theory, glucose is normally metabolized 
through the process of glycolysis but in the presence of abnormally high levels, some glucose 
is shunted to the PPP in an attempt to unburden glycolysis. In this way, the PPP acts as a 
protective mechanism to prevent the processing of glycolytic intermediates into toxic end 
products. One would therefore expect an increase in the action of the enzymes of this 
pathway in subjects with hyperglycaemia. However, in this study we observed a decrease in 
the expression of the enzymes in women who develop GDM (G6PD and TKT in exposed 
placenta as well). The reduced expression of key enzymes in the PPP (G6PD, TKT, ALDOA, PGLS 
and DCXR) should lead to  lower activity of the pathway. This will result in less NAPDH being 
produced in both the women and the placenta, putting them at risk for increased oxidative 
stress.  
Only a few studies have investigated the PPP in the human placenta. Glucose oxidation via the 
tricarboxylic acid (TCA) cycle and PPP, measured through the ratio of CO2 production from [1-
C]-glucose and [6-C]-glucose, have suggested that oxidation via the TCA cycle is higher than 
via the PPP in term placental slices, whereas in younger placentas (6-20 weeks) oxidation by 
the PPP is greater (Brekke et al., 2012). Different proportions of glucose utilisation via 
glycolysis and the TCA cycle or the PPP were found in another research study, but the PPP also 
accounted for higher portions of glucose utilisation (10 %) in early pregnancy (6-10 weeks) 
compared to term placentas (5 %)(Bertoldi Franco, 2015). In human trophoblast cultures from 
term placentas, the PPP accounted for less than 1% of the total glucose metabolised (Brekke 
et al., 2012). It is unknown whether glucose partitioning into the PPP increases with increasing 
glucose supply and whether a PPP functioning at a reduced rate is an adaptive mechanism in 
response to exposure to an adverse environment.  
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4.2.1 A significant decrease in the expression of the gene (G6PD) encoding the rate 
determining enzyme of the PPP 
The G6PD gene is an X-linked gene that maps to the Xq28 and is the rate-controlling enzyme 
of the PPP pathway. It is allosterically stimulated by NADP+ and strongly inhibited by NADPH 
(Patra and Hay, 2014). This cytoplasmic enzyme catalyses the rate-limiting step in the 
oxidative branch of the PPP that generates the first molecule of NADPH, therefore its 
expression and activity are tightly regulated (Jiang et al., 2014, Jin et al., 2014). A cell’s defence 
mechanism against oxidative damage is highly dependent on the activity of this enzyme 
because it is the main source of NADPH. The activity of G6PD is also post-translationally 
regulated by cytoplasmic deacetylase SIRT2. The SIRT2-mediated deacetylation and activation 
of G6PD stimulates the oxidative branch of the PPP to supply cytosolic NADPH to counteract 
oxidative damage (Xu et al., 2016b, Zhu et al., 2015). A study has shown that SIRT2 was not 
found to have significant differential expression in women with GDM and exposed placenta 
when compared to controls (Gui et al., 2015). It has been reported in a study by Zhang et al. 
(2010), that an increase in the concentration of maternal glucose resulted in the inhibition of 
G6PD and consequently a decrease in NADPH levels (Zhang et al., 2010). The data from this 
study supports this finding. We also observed a significant negative association between G6PD 
mRNA expression levels and maternal glucose levels. Hyperglycemia is known to elevate 
oxidative stress and also increase the activation of the hexosamine biosynthetic pathway, a 
secondary pathway of glucose metabolism. This pathway uses fructose-6-phosphate derived 
from glycolysis to produce glucosamine-6-phosphate which is a competitive inhibitor of G6PD. 
The inhibition or decrease in G6PD leads to decreased NAPDH concentrations and elevated 
oxidative stress. Numerous observations have demonstrated highly significant decreases in 
G6PD activity due to hyperglycemia or diabetes in liver, kidney, brain, endothelium, red blood 
cells and other cells and tissues (Stanton, 2012). Decreased G6PD activity has been observed 
in cells and tissues from diabetic animals. For example, neutrophils exposed to an increase in 
glucose levels had impaired neutrophil function associated with decreased G6PD function. 
This suggests that the glucose mediated decrease in G6PD led to a decrease in NADPH 
production that was needed for NAPDH oxidase activity in neutrophils (Perner et al., 2003, 
Stanton, 2012).  
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Human G6PD deficiency has mainly been studied in the context of the associated haemolysis 
or protection from malaria (Ouattara et al., 2014, Peters and Van Noorden, 2009, Valencia et 
al., 2016). However, some studies have reported an association between the activity of G6PD 
and other diseases. For example, a study performed in the Middle East demonstrated an 
increased frequency of diabetes in individual’s who were G6PD deficient (Pinna et al., 2013). 
Epidemiological data suggest that G6PD deficiency may be a risk factor for diabetes (Carette 
et al., 2011). Mutations in the G6PD gene results in protein variants with varying levels of 
enzyme activity accounting for a wide spectrum of clinical and biochemical phenotypes – 
although many individuals don’t display symptoms of G6PD deficiency. Deficiency of G6PD, 
also known as favism, can also be caused by an X-linked recessive genetic condition that 
predisposes those affected to developing haemolysis (Gaskin et al., 2011). Deficiency in G6PD 
is commonly found in people of Mediterranean and African origin due to its anti-malaria 
effects (Beutler et al., 2007).  
In our study we observe a significant negative correlation between the maternal glucose levels  
(at fasting and 1-hr post OGTT) and G6PD mRNA expression in both the mother and the 
placenta. Studies have found that high glucose levels have an inhibitory effect on the 
expression of G6PD (Zhang et al., 2000). Modest changes in G6PD activity have significant 
effects on cell growth and cell death in a variety of cell types (Tian et al., 1998), highlighting 
the importance of adequate functioning of G6PD. An association between high glucose levels 
and a decrease in G6PD expression and activity in human islets has been observed (Zhang et 
al., 2010). A high glucose level has been reported to suppress G6PD activity in endothelial cells, 
kidney, liver, and red blood cells resulting in oxidative damage, cellular dysfunction, and organ 
damage (Cheng et al., 2000, Xu et al., 2005). Gestational diabetes results in maternal 
hyperglycemia, which will untimely increase the flow of glucose from the mother, across the 
placenta, to the foetus. The foetus will be exposed to an in utero environment of 
hyperglycemia and hyperinsulemia. The significant reduction in the expression of G6PD in 
both blood from the mother and the placenta may be due to the inhibitory effects of high 
glucose levels.  
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Our data also showed a significant negative correlation between the promoter region 
methylation of the G6PD gene and G6PD gene expression in both the placenta and the 
maternal blood cells. It appears from these observations that the significant decrease in G6PD 
expression in a hyperglycemic environment may be due to increased promoter region 
methylation. In a recent study carried out by Xu et al. (2016), an association between low 
G6PD expression and increased promoter region methylation had been observed. This 
association was significant in females but not in males (Xu et al., 2016a). Our data did show a 
significant positive correlation between the promoter region methylation of G6PD in the blood 
and placenta with maternal glucose levels (at fasting and at 1-hr post OG). This may indicate 
that the expression of G6PD is inhibited by high glucose levels through an epigenetic 
mechanism, which is DNA methylation. The finding of reduced G6PD expression in the mother 
and placenta with hyperglycemia is potentially important. There seems to be a strong 
rationale for believing that high maternal glucose leads to methylation of the G6PD promoter, 
which in turn leads to decreased G6PD expression. Since G6PD expression levels may increase 
oxidative stress, this is likely a pathological rather than adaptive response.  
The same levels of G6PD promoter region methylation are observed in mothers and their 
fetuses and therefore, it becomes difficult to determine whether these methylation patterns 
were inherited or if they were directly caused by the hyperglycemic environment or if they 
were an adaptive response in both mother and foetus to the high glucose levels. From an 
adaptive perspective, the down-regulation of G6PD does not seem like an advantageous 
adaption for the survival of the developing foetus in a hyperglycemic environment. It has been 
extensively reported that G6PD is the principal source of NADPH and is critical for the defence 
against oxidative stress and a decrease in the expression of G6PD would result in a decrease 
in the production of NADPH. Given the evidence from the literature it is more likely that the 
high levels of glucose associated with GDM cause the reduction in the expression of G6PD in 
both maternal blood and the placenta. Therefore, we suggest that the significantly reduced 
expression of G6PD we observe in exposed placenta and maternal blood cells is due to the 
high glucose levels.  
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High glucose levels inhibit G6PD and therefore, in GDM, it may be possible that the PPP will 
be inhibited by increasing glucose metabolism by glycolysis. This will cause NADPH to drop 
(due to low G6PD activity) and oxygen free radical production to increase (due to higher flux 
through glycolysis). Both these events will contribute to increased oxidative stress. 
Furthermore, due to increased flux through glycolysis, the glycolytic pathway will become 
saturated leading to a plateau in glucose metabolism causing glucose levels to rise. Thus, the 
inhibition of G6PD by hyperglycaemia will indirectly worsen the hyperglycaemic state. The 
alternative hypothesis, for which there is less evidence, is that low G6PD activity is part of the 
aetiological pathway for GDM and diabetes. Low G6PD protein levels would push glucose into 
the glycolytic pathway increasing free radical output whilst NADPH would fall increasing 
oxidative stress. The glycolytic pathway may become saturated reducing glucose metabolism 
and causing blood glucose levels to increase. The high methylation levels in the GDM subjects 
may cause the reduced G6PD activity and one could hypothesise that this hypermethylation 
is due to other upstream factors including gene polymorphisms related to methylation at the 
G6PD locus. However, evidence from the literature to support this is sparse. One would 
assume that subjects with G6PD deficiency, which is quite common in African populations, 
may develop diabetes. Polymorphisms in the G6PD gene causing low levels of expression are 
quite common but none of them have been associated with diabetes in GWAS. GWAS studies 
cannot provide information about epigenetic effects, so the absence of a GWAS association 
between polymorphisms in G6PD and diabetes does not mean that there is no link between 
G6PD and epigenetic effects in GDM. Furthermore, there are studies associating diabetes with 
G6PD deficiency (Heymann et al., 2012, Pinna et al., 2013, Saeed et al., 1985) but none of 
these relate G6PD gene variants to diabetes but only measure G6PD activity. Therefore, these 
results could just as easily be interpreted as showing that diabetes causes lowered G6PD 
activity, as vice versa. 
Interestingly, studies have shown that in GDM the level of insulin output is lower than in 
mothers without GDM at each level of insulin resistance (Megia et al., 2008). Thus, in GDM 
the ß-cells fail to produce sufficient insulin in response to the rise in insulin resistance during 
pregnancy. It may be possible that the G6PD deficiency we see in GDM women could be 
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involved in this process, with excess oxidative stress causing ß-cell dysfunction in the GDM 
mothers. Thus the increase in glucose during GDM could lead to low G6PD mRNA expression 
and higher oxidative stress across the mother and the foetus. High glucose may also reduce 
G6PD in the ß-cells leading to cell death and reduced insulin output (Stanton, 2012).  Thus, 
G6PD deficiency may be a result of GDM but it may also enhance the pathological processes 
leading to eventual diabetes. These data suggest that G6PD deficiency on its own is not 
enough to cause diabetes but requires the presence of hyperglycaemia and insulin resistance 
before it will contribute to disease progression. 
4.2.2 A significant reduction in the expression of the reversible rate-limiting enzyme, 
Transketolase, of the non-oxidative branch of the PPP 
In mammals, transketolase (TKT) connects the PPP to glycolysis, feeding excess sugar 
phosphates into the main carbohydrate metabolic pathways. Functional TKT is also necessary 
for the production of NADPH which, as discussed above, is necessary to counteract oxidative 
stress.  
In this study, we observed a significant decrease in the expression of TKT mRNA in the women 
who develop GDM. This down regulation of the TKT gene in the blood samples was negatively 
correlated to maternal fasting glucose levels. These data indicate that high glucose levels in 
the mother are associated with decreased TKT expression in the blood. The promoter region 
of the gene was not significantly hypermethylated in the GDM cases and also there was no 
correlation between TKT promoter region methylation and maternal glucose levels. Therefore 
we can conclude that promoter region methylation is not the cause of the down regulation of 
TKT that we observe in GDM. One explanation could be that due to a decrease in the 
expression of G6PD, genes encoding enzymes further downstream in the pathway (PGLS, 
DCXR, ALDOA, TKT) may have a lower activity and expression due to a lower level of substrate. 
Thus, the decreased expression of G6PD will cause a so called “ripple effect” which will lead 
to a sequential decrease in the concentration of the downstream metabolites and their 
associated enzymes.  
In summary, our results suggest that high glucose levels that are characteristic of GDM, may 
result in the suppression of G6PD mRNA expression in both maternal blood and placental 
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tissue. We hypothesize that this suppression is mediated through increased DNA methylation 
of the G6PD gene. Our results also suggest that decreased IGFBP-1 expression in the placenta 
and in the mother in a GDM pregnancy, is implicated in the increased foetal growth which is 
characteristic of GDM.  
 
4.3 The limitations of this study 
One of the most apparent limitations of this study was the use of whole blood to identify gene 
expression and methylation changes in GDM cases and controls. Whole blood is made up of 
many different cell types, each of which may have a subtly different epigenetic pattern and 
gene expression profile. Performing DNA methylation analysis on a DNA sample that was 
obtained from a multicellular tissue will result in the average DNA methylation profile of that 
tissue. The varying levels of methylation in each cell type and the varying proportion in which 
each cell type is present in the tissue may mask significant methylation differences in a specific 
cell type that may be critical to disease in question.  
The question regarding which tissue is the most ideal in epigenetic studies is also of concern. 
The DNA methylation and gene expression patterns are tissue specific which imposes an issue 
when studying a disease which is known to act through perturbation of a specific cell or tissue 
type. The analysis of epigenetic patterns, in particular DNA methylation, of a surrogate non-
target tissue may not be informative.  The most appropriate tissue for studying GDM is the 
pancreas, but obtaining samples from this tissue is not possible. For ethical and practical 
reasons, the collection of human DNA samples must be as non-invasive as possible. Saliva, 
buccal swabs, blood samples or biopsies are the most common sources of DNA and RNA. DNA 
from peripheral blood and placental biopsies were used in this study, with the limitations 
recognised. More work needs to be done to determine whether these tissues are good 
surrogates for the specific diabetes relevant target tissue.  
The major limitation of this study is the small sample size. Determining the ideal sample size 
is important to ensure that you would be able to confidently observe a true effect or to 
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determine if there is sufficient power to detect a meaningful difference. The small sample size 
of the study limits the power of detection, therefore it is necessary to validate these finding 
in a larger cohort. The sample size should be increased to increase the statistical power of 
detecting true correlations in gene expression between the women with GDM and controls 
(Joehanes et al., 2013, Jones et al., 2015, Rapaport et al., 2013, Venet et al., 2011). To confirm 
that these changes are generally relevant would require a larger sample, as would the 
detection of more subtle gene expression shifts in GDM. However, although the samples size 
was small we did detect meaningful changes in gene expression and methylation in GDM-
relevant pathways that can be investigated in greater detail in future studies which use a much 
larger sample.  
Confounding is a key limitation of the work presented in this study, with specific reference to, 
but not restricted to, BMI.  The control group had a BMI that was on average 7kg/m2 higher 
than the case group. This is a marked difference and the results presented here could 
potentially and importantly be confounded by BMI. The lack of replication of the data 
presented in this study is also considered a limitation.    
 
4.4. Strengths of the study   
 
The biggest strength of this study is the homogeneous sample group of patients that was 
studied. All patients were of the same ethnicity and similar age. Gene expression and 
methylation patterns observed in the patients from this study are more likely to underlie 
disease aetiology than be confounded by heterogeneity arising from different ethnicities, ages 
and BMI of the patients. In addition, we only studied cases with female offspring. Another 
strength is that the methods used to detect (RNA-seq) and validate (qPCR) the significant gene 
expression differences between the cases and control groups were different, but the outcome 
was highly correlated. This promotes confidence in the results obtained. Despite the small 
sample size of the study, we did observe significant variation between the case and control 
groups in terms of gene expression and methylation. Also, we present strong correlations 
between the many variables analysed in this study. Another strength of this study is that we 
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investigated GDM in an under-studied population that has a high prevalence of obesity and 
type 2 diabetes and is therefore at high risk for GDM.  
 
4.5 Future work 
The search for candidate genes that predispose women to GDM is currently a very active field 
of research, and more and more genes associated with the development of the disease are 
being discovered. Before any further studies are done, there is a need for additional 
exploration to determine whether the results could be explained by confounding or by chance. 
A genome wide DNA methylation and transcriptomic analysis should be carried out on a larger 
cohort. 
In the future, it would be imperative to conduct an hypothesis driven study to further explore 
the role of the PPP in GDM and whether it is mediated by an essentially epigenetic mechanism, 
rather than genetic variation. Alternatively there may be a genetic susceptibility that drives 
the epigenetic modulation in the presence of an adverse environment.  Future studies should 
focus on G6PD and NADPH and their possible role in the development of adult onset diseases 
in foetuses exposed to hyperglycemia and these studies should be carried out in a larger 
cohort. It would also be of interest to include cord blood as an additional tissue to study as 
this will give a clearer idea of what is happening in the developing foetus when placental G6PD 
is suppressed and oxidative stress increases in the placenta. Likewise, studying the neonate, 
infant, child, adolescent and adult through their life time is enormously important in 
determining the trajectories of change that leads to adult onset disease. It may also be of 
interest to look at promoter region methylation in the other genes that make up the PPP, and 
NADPH levels in a variety of tissues and developmental time points.  
Future studies should focus on the precise mechanisms by which high maternal glucose levels 
observed in the GDM cases may cause a suppression in the expression of G6PD in maternal 
blood and placental tissue. We hypothesize that it may be due to promoter region methylation 
because our data indicated a significant correlation between expression of G6PD and 
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promoter region methylation in both tissues studied.  These studies could potentially focus on 
other epigenetic mechanisms such as histone modifications and gene-gene interactions 
through techniques such as CHiP-seq or ATAC-seq.  
It would be important to focus a larger study on the IGFBPs and other components of the IGF-
axis and examine their relative mRNA expression and protein levels in placenta and offspring 
exposed to GDM. The IGF-axis may be implicated in glucose homeostasis but its longitudinal 
profile across gestation in relation to the development of GDM is largely unknown. A critical 
unresolved question is whether or not the IGF-axis contributes to the pathophysiology of 
GDM. A key question in future studies would be whether DNA methylation at these loci is 
affected by early life exposures (such as the nutritional insult GDM imposes) and if so whether 
these methylation changes persist through early life and into adulthood. To investigate this 
DNA methylation analysis of the placental tissue would have to be undertaken at multiple time 
points including in utero, neonatal and later in life. This would allow the stability of epigenetic 
marks to be considered in light of the emergence of programmed phenotypic changes. 
Future studies could also include a more detailed testing and documentation of participant’s 
phenotypic data as this will allow robust and precise correlations between the clinical data 
and gene expression patterns. As mentioned, protein levels would be of interest in these 
future studies, therefore, since gene expression changes identified in the transcriptome do 
not always translate directly into changes in protein production, another validation approach 
that should accompany future studies is immunohistochemistry. This way, more accurate 
correlations between gene expression and phenotype (based on clinical data) can be 
generated.  
 
It would also be interesting to look at G6PD expression and methylation patterns in newly 
diagnosed type 2 diabetic and control subjects to determine if the observations in the current 
study are specific to GDM. The relationship between G6PD deficiency and T2D is not clear. 
Therefore a study should be undertaken where newly diagnosed type 2 diabetics are 
compared against a healthy control group in terms of G6PD activity levels in blood cells and 
the frequency of G6PD polymorphisms. A longitudinal study would also be useful to determine 
144 
 
 
 
whether G6PD deficiency and/or G6PD polymorphisms predict the future development of T2D 
in a population with a high risk of diabetes.  
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Chapter FIVE 
5. CONCLUSIONS 
The enzyme G6PD, is at the nexus of many important metabolic pathways and we are only at 
the beginning of understanding G6PD, NADPH and their interrelationships with cellular 
systems. A full understanding of G6PD, its role as a metabolic nexus for many cellular systems 
and how it is regulated should provide critical insights into many intracellular processes and 
disease mechanisms (Stanton, 2012).  
The high circulating glucose levels that are characteristic of GDM may have a suppressive 
effect on the expression of G6PD mRNA in the blood of affected women, however, further 
work would need to be carried out in order to determine a possible causative link. The 
developing foetus is also exposed to high levels of glucose, which cross the placenta via 
diffusion. This may result in the suppression of the expression of placental G6PD mRNA. This 
reduction of G6PD, the rate determining step of the pentose phosphate pathway, will affect 
the rate at which this pathway functions. The reaction catalyzed by G6PD gives rise to NADPH 
which plays a role in reducing oxidative stress by counteracting oxidative damage. Oxidative 
stress, which is known to play a role in the pathogenesis of diabetes and other adult disease, 
will increase in the presence or reduced levels of NADPH. We hypothesize that the mechanism 
by which high glucose suppresses G6PD expression is via DNA methylation. It is known that 
GDM is a transient condition, therefore after birth, the women’s glucose levels will return to 
normal but the methylation and reduced expression of G6PD may persist.  The suppression of 
G6PD and hence the reduction of NADPH may continue and increased cellular oxidative stress 
ensues. There is convincing experimental evidence that demonstrates that an increase in ROS 
increases in diabetes and oxidative stress is associated with the onset of diabetes (Matough 
et al., 2012). This may explain why women who develop GDM have a higher risk of developing 
T2D and other metabolic disorders later in life. The down-regulation of G6PD may also lead to 
the overloading of the glycolytic pathway with glucose, leading to reduced glucose uptake and 
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increased levels of blood glucose. It is possible that this, in combination with the insulin 
resistance of pregnancy uncovers an underlying problem in glucose metabolism and insulin 
secretory capacity resulting in GDM. However, with the increase in insulin sensitivity after 
birth, the metabolic pathways may be less stressed and euglycaemia is maintained but the 
underlying pathology may worsen over time leading to the development of T2D.  
It is possible that G6PD is an important component of the placental protection system. In this 
capacity, the optimal regulation of the gene encoding this enzyme is important for the health 
of the foetus. In terms of the developing foetus exposed to the adverse hyperglycemic in utero 
environment, the suppression of G6PD and NADPH will result in increased oxidative stress. 
This increase might interfere with the optimal functioning of the placenta. Oxidative stress has 
been observed in the placenta in preeclampsia and diabetes in association with altered 
placental function (Hanson and Mair, 2014, Myatt and Cui, 2004).  
This study provides evidence of aberrant regulation of IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-6) 
in the context of GDM exposure. Our data suggests that the suppression of gene expression 
of these three binding proteins in the placenta may partially account for the higher birth 
weight of the neonates born to women with GDM. We conclude that the foetal hyperglycemia 
and/or hyperinsulemia caused by maternal GDM, inhibits the expression of IGFBP-1 and 
IGFBP-2 ultimately affecting foetal growth through regulating the bioavailaibity of IGFs.  
It is now widely accepted that the development of chronic diseases in adulthood may have 
their origins in the womb. The development of GDM can exert both short and long term 
adverse effects on the health of the developing foetus (Brenseke et al., 2013). The challenges 
at present are to “identify common mechanisms and pathways involved in different perinatal 
malnutrition paradigms, deciphering physiological and/or pathological roles of specific 
nutrients, and to determine which components of the maternal diet may be best modified to 
optimize maternal health, placental integrity, birth outcome, and lifelong health of the 
offspring” (Brenseke, 2015).  
The role of early adverse life exposures in the developmental programming of adult onset 
diseases such as diabetes is well documented and it seems that DNA methylation may play a 
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key role in this process (Vaiserman et al., 2013; Lewis et al., 2014). However, it still remains 
unclear as to the precise moment during development where exposure to an adverse 
environment will have the greatest effect. Animal studies demonstrate that exposure to an 
adverse in utero environment programs the pattern of DNA methylation which persists 
throughout adulthood ultimately affecting gene expression levels and therefore the 
phenotype (Lee et al., 2015; Williams et al., 2014; Vaiserman et al., 2015). There has also been 
a suggestion that the pubertal period may be the critical window in development and that 
changes established at this particular stage may persist throughout the life course (Jasik and 
Lustig, 2008) and result in the development of disease. The Newcastle thousand family study 
suggests that influences in childhood are the most important determinants of disease risk in 
adulthood (Pearce et al., 2012). These studies highlight the importance of not only focusing 
on one particular developmental stage but rather assessing the role of epigenetic variation at 
many developmental stages. In addition, the possible role of genetic susceptibility in triggering 
DNA methylation changes or other epigenetic modulations in the presence of an adverse 
environment remains to be explored.  
The identification of genes linked to GDM will contribute to our understanding of the 
pathophysiology of the disease and to the development of prevention strategies. Identifying 
individuals who have a genetic predisposition to developing GDM may improve prevention of 
T2D through targeted interventions. These data provide an interesting starting point in the 
investigation of developmental programming in children exposed to GDM. Demonstrating a 
causal link between gene specific differential DNA methylation and gene expression is a 
promising target for future research. 
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APPENDIXES 
APPENDIX Ai: Patient and control informed consent sheet  
GENOME-WIDE GENE EXPRESSION ANALYSIS IN BLACK SOUTH AFRICAN WOMEN WHO DEVELOP GESTATIONAL 
DIABETES MELLITUS 
Consent to Participate in a Genetic Research Study  
By signing this form, you agree to participate in a research study that aims to identify genes involved in the 
development of gestational diabetes, This form is for you to give us permission to take two blood samples from 
you at your week 5 visit and a placental sample biopsy at delivery 
By signing this form, I agree that:  
 You have explained this study to me. You have answered all my questions 
YES    NO 
 
 You have explained the possible harms and benefits (if any) of this study.  
YES    NO 
 I understand that I have the right to refuse to take part in the study and the right to withdraw my 
participation at any time at no disadvantage to me.  
YES    NO 
 
 I understand that no information about who I am will be given to anyone.  
YES    NO 
 
 I will provide a blood sample for the genetic study and give permission for the use of a cord blood 
sample and placental biopsy as well.  
YES    NO 
 
 These samples will be used as a source of DNA and RNA and stored indefinitely for research purposes.  
YES    NO 
 
 I agree that a small bit of my DNA and RNA may be sent out of the country for research purposes. 
YES    NO 
 
 I understand that every time a new study is done on my DNA and RNA, permission will be obtained 
from the ethics committee for the study to make sure that it is used only for the purposes stated 
above.  
YES    NO 
I have read and understood the information sheet provided as well as this consent form. I agree, or consent, to 
take part in this study. 
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Full name of participant __________________________________________________________ 
 
_______________________                                                            ___________________ 
Signature of participant                                                                                       Date 
_______________________                                                           ___________________ 
Signature of witness (or person who explained study and consent)           Date 
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APPENDIX Aii: Patient and control information sheets 
 
CASE INDIVIDUAL 
GENOME-WIDE GENE EXPRESSION ANALYSIS IN BLACK SOUTH AFRICAN WOMEN WHO DEVELOP GESTATIONAL 
DIABETES MELLITUS 
Information Sheet  
Dear Potential Participant,  
My name is Angela Hobbs and I am a PhD student at the University of the Witwatersrand. The results from your 
Oral Glucose Tolerance Test (OGTT) showed that your blood glucose levels are higher than what we would 
expect during pregnancy. I would therefore like to invite you to participate in a genetics study aimed at finding 
out what causes an increase in glucose levels during pregnancy. 
 
 
Researchers Statement 
We are inviting you to participate in a research study called “Genome-wide analysis of black South African women 
who develop gestational diabetes mellitus (GDM)”. This study would like to examine which of our genes are 
involved in the development of this disease. The purpose of this information sheet is to provide you with the 
information you will need to make an informed decision about participating in this study. You may ask questions 
about the purpose of the study, what we require from you as a participant, the possible risks and benefits and 
anything else about the research project that may not be clear. 
Purpose of Research 
Genes are the parts of DNA which tell our bodies how to develop, grow and function. A change in the sequence 
of our DNA is called a mutation. Epigenetics is the study of changes in gene activity which are not caused by 
changes in the DNA sequence. The purpose of this study is to discover epigenetic changes that might cause 
gestational diabetes. When pregnant women show high blood glucose levels first seen during pregnancy, it is 
called gestational diabetes mellitus (GDM). This disease usually disappears after your baby has been born; 
however, it makes the mother and the fetus, more likely to develop Type 2 diabetes (T2D) later in life. Everyone 
has a number of epigenetic variations that result in the normal differences we expect to see between people, 
but some epigenetic changes lead to the development of diseases and problems with growth and development. 
We are trying to find out if there are epigenetic variations in specific genes in women who develop GDM in 
comparison to women who do not. This may help us better understand the role of genes in the development of 
GDM. 
 
Description of the Research 
You are already participating in a study investigating maternal factors associated with foetal growth and delivery 
outcomes. 
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 If you agree to participate in this genetics study, we would need to collect two blood samples from you at 
your week 5 visit.  
 If you agree to participate, we will also analyse the genetic material extracted from the cord blood sample 
and placental biopsy sample which was taken directly after delivery. 
Participation 
Participation in this study is entirely voluntary and you will not be disadvantaged in any way if you choose not to 
participate. You and your family will not benefit from participating in this study and will not receive any 
remuneration. Although you may not benefit directly from this study, results from the study will improve the 
understanding of gestational diabetes mellitus and may benefit pregnant women in the future. If at any time you 
decide to withdraw your genetic material from participation in the study, you can do so (you DNA and RNA 
sample will then be destroyed). 
Confidentiality 
We will respect your privacy. No information about you or who you are will be given to anyone or published 
without your permission. The data from this study will be stored in a secured location and only members of the 
research team will have access to the data. Published study results will not reveal your identity. In the laboratory, 
confidentiality will be maintained at all times by assigning lab codes to the DNA and RNA sample. The DNA and 
RNA isolated from your blood will be stored indefinitely with these lab codes. Your samples will be stored in a 
secure laboratory at the Sydney Brenner Institute for Molecular Bioscience.  
The test will involve no cost to the participant. Participation is completely voluntary and you will not be 
disadvantaged in any way if you decide not to participate. You may withdraw from the study at any time.  
Should you require any further information, please do not hesitate to contact:  
Mrs Angela Hobbs-Steyn or Professor Michele Ramsay  
Division of Human Genetics, National Health Laboratory Service (NHLS) and the University of the 
Witwatersrand 
(011) 489 9344 and (011) 489 9214 
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CONTROL INDIVIDUAL 
GENOME-WIDE GENE EXPRESSION ANALYSIS IN BLACK SOUTH AFRICAN WOMEN WHO DEVELOP GESTATIONAL 
DIABETES MELLITUS 
Information Sheet  
Dear Potential Participant,  
My name is Angela Hobbs and I am a PhD student at the University of the Witwatersrand. The results from your 
Oral Glucose Tolerance Test (OGTT) showed that your blood glucose levels are normal. We need control 
samples for a research study and would therefore like to invite you to participate.   
 
 
Researchers Statement 
We are inviting you to participate in a research study called “Genome-wide analysis of black South African women 
who develop gestational diabetes mellitus (GDM)”. This study would like to examine which of our genes are 
involved in the development of this disease. The purpose of this information sheet is to provide you with the 
information you will need to make an informed decision about participating in this study. You may ask questions 
about the purpose of the study, what we require from you as a participant, the possible risks and benefits and 
anything else about the research project that may not be clear. 
Purpose of Research 
Genes are the parts of DNA which tell our bodies how to develop, grow and function. A change in the sequence 
of our DNA is called a mutation. Epigenetics is the study of changes in gene activity which are not caused by 
changes in the DNA sequence. The purpose of this study is to discover epigenetic changes that might cause 
gestational diabetes. When pregnant women show high blood glucose levels first seen during pregnancy, it is 
called gestational diabetes mellitus (GDM). This disease usually disappears after your baby has been born; 
however, it makes the mother and the fetus, more likely to develop Type 2 diabetes (T2D) later in life. Everyone 
has a number of epigenetic variations that result in the normal differences we expect to see between people, 
but some epigenetic changes lead to the development of diseases and problems with growth and development. 
We are trying to find out if there are epigenetic variations in specific genes in women who develop GDM in 
comparison to women who do not. This may help us better understand the role of genes in the development of 
GDM. 
 
Description of the Research 
You are already participating in a study investigating maternal factors associated with foetal growth and delivery 
outcomes. 
 If you agree to participate in this genetics study, we would need to collect two blood samples from you at 
your week 5 visit.  
 If you agree to participate, we will also analyse the genetic material extracted from the cord blood sample 
and placental biopsy sample which was taken directly after delivery. 
Participation 
Participation in this study is entirely voluntary and you will not be disadvantaged in any way if you choose not to 
participate. You and your family will not benefit from participating in this study and will not receive any 
174 
 
 
 
remuneration. Although you may not benefit directly from this study, results from the study will improve the 
understanding of gestational diabetes mellitus and may benefit pregnant women in the future. If at any time you 
decide to withdraw your genetic material from participation in the study, you can do so (you DNA and RNA 
sample will then be destroyed). 
Confidentiality 
We will respect your privacy. No information about you or who you are will be given to anyone or published 
without your permission. The data from this study will be stored in a secured location and only members of the 
research team will have access to the data. Published study results will not reveal your identity. In the laboratory, 
confidentiality will be maintained at all times by assigning lab codes to the DNA and RNA sample. The DNA and 
RNA isolated from your blood will be stored indefinitely with these lab codes. Your samples will be stored in a 
secure laboratory at the Sydney Brenner Institute for Molecular Bioscience.  
The test will involve no cost to the participant. Participation is completely voluntary and you will not be 
disadvantaged in any way if you decide not to participate. You may withdraw from the study at any time.  
Should you require any further information, please do not hesitate to contact:  
Mrs Angela Hobbs-Steyn or Professor Michele Ramsay  
Division of Human Genetics, National Health Laboratory Service (NHLS) and the University of the 
Witwatersrand 
(011) 489 9344 and (011) 489 9214 
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APPENDIX Ci: Tempus™ Blood RNA Tube and Tempus™ Spin RNA Isolation Kit (Applied 
Biosystems) 
 
1. If the sample is frozen, thaw the sample in the Tempus tube at room temperature (18 to 25 °C). 
 
2. Remove the cap from the Tempus tube, then pour the contents of the tube into a clean 50-mL.  
 
3. Pipet 3 mL of 1✕ PBS (Ca2+/Mg2+-free) into the tube to bring the total volume to 12 mL. Note: If the 
initial blood sample was less than 3 mL, make up the difference by adding enough 1✕ PBS to bring the total 
volume to 12 mL. Otherwise, RNA yields decrease significantly.  
 
4. Replace the cap on the tube, then vortex the tube vigorously (at maximum vortex speed) for 30 seconds to 
ensure proper mixing of the contents. Note: To prevent the tube from leaking and spraying the sample during 
vortexing, make sure the tube is capped properly. Vortex the diluted sample for at least 30 seconds; vortexing 
for less than 30 seconds may cause clogging of the purification consumable. 
 
5. Centrifuge the tube at 4 °C at 3,000 x g (rcf) for 30 minutes. 
6. Carefully pour off the supernatant. Note: The RNA pellet is transparent and invisible, Handle the tube 
carefully so that you do not shake the RNA pellet off the bottom of the tube. 
 
7. Leave the tube inverted on absorbent paper for 1 to 2 minutes. 
 
8. Blot the remaining drops of liquid off the rim of the tube with clean absorbent paper. 
 
9. Pipet 400 μL of RNA Purification Resuspension Solution into the tube, then vortex briefly to resuspend the 
RNA pellet. Note: To prevent washing any blood residue down the inside of the tube, insert the pipet tip into 
the tube and add the resuspension solution to the bottom of the tube. 
 
10. The resuspended RNA can be kept on ice while preparing for the next steps: Proceed to “Performing the 
Purification Run”  
 
To perform the purification run: 
1. Label the RNA purification filter, then insert the filter into a waste collection tube.  
 
2. Pre-wet the filtration membrane by pipeting RNA Purification Wash Solution 1 into the purification filter. 
 
3. Pipet the resuspended RNA into the purification filter, then centrifuge. 
 
4. Remove the purification filter, discard the liquid waste collected in the waste tube, then re-insert the 
purification filter into the waste tube. Note: Each time you discard the liquid waste, instead of reusing the 
waste tube, you can transfer the purification filter into a new collection tube. 
 
5. Pipet RNA Purification Wash Solution 1 into the purification filter, then centrifuge. 
 
6. Remove the purification filter, discard the liquid waste collected in the waste tube, then re-insert the 
purification filter into the waste tube. Pipet RNA Purification Wash Solution 2 into the purification filter, then 
centrifuge. Note: When a DNase treatment is required, extend the centrifuge time to 1 minute to remove all 
wash solutions and dry the membrane completely. 
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8. Remove the purification filter, discard the liquid waste collected in the waste tube, then re-insert the 
purification filter into the waste tube. 
 
10. Pipet RNA Purification Wash Solution 2 into the purification filter, then centrifuge. 
 
11. Remove the purification filter, discard the liquid waste collected in the waste tube, then re-insert the 
purification filter into the waste tube. Centrifuge to dry the membrane. 
 
12. Transfer the purification filter to a new, labelled collection tube to collect the eluate. 
 
13. Pipet Nucleic Acid Purification Elution Solution into the purification filter, close the cap, incubate the 
entire tube, then centrifuge. 
 
14. Pipet the collected RNA eluate back into the purification filter, then centrifuge. No incubation is 
necessary. 
 
15. Discard the purification filter, then transfer approximately 90 μL of the RNA eluate to a new, labelled 
collection tube. Note: When transferring the RNA eluate, carefully pipet the liquid out of the collection tube 
starting from the top of the liquid to ensure that the pelleted particulates are not disturbed. 
 
16. Replace the cap on the new collection tube, then store the RNA at −20 ˚C, or −80 ˚C for long-term storage. 
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APPENDIX Cii: Salting out method (Miller et al., 1988) 
Equipment and Materials 
 Polypropylene tubes 15ml 
 Lysis buffer (10mM Tris-HCL,400mM NaCl, 2mM Na2EDTA, pH 8.2)  
 SDS 10% 
 Proteinase K solution (1 mg proteinase K in 1% SDS and 2 mM Na2 EDTA), 
 Centrifuge  
 Absolute ethanol 
 TE buffer (10mM Tris-HCL, 0.2mM Na2 EDTA, pH 7.5) 
 Disposable gloves 
 Gilson pipette 
Procedure 
1. Resuspend the buffy coats of nucleated cells obtained from blood with anticoagulents (ACD or EDTA) 
with 3ml of nuclear lysis buffer. 
2. Digest the cell lysates, with 0.2 ml of 10% SDS and 0.5 ml of proteinase K solution, overnight at 37 °C. 
3. Add 1ml of saturated NaCl (6M) to each tube and shake vigorously for 15 seconds. 
4. Centrifuge for 15 minutes at 2500 rpm, 4°C 
5. Transfer the supernatant containing the DNA to another 15ml polypropylene tube, the precipitated 
protein pellet is left behind at the bottom of the tube. 
6. Add 2 volumes of absolute ethanol and invert the tubes several times until the DNA precipitates. 
7. Remove the precipitated DNA with a plastic spatula or pipette and transfer to a 1.5ml microcentrifuge 
tube containing 100-200 µl TE buffer. 
8. Dissolve the DNA for 2 hours at 37°C. 
9. Store the tube at  +4 or –20°C. 
Check quantity/quality of DNA (see QUALITY CONTROL OF DNA protocol 
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APPENDIX Ciii: RNeasy Mini Kit (Qiagen)– Purification of Total RNA from Animal Tissues 
Procedure 
1. Remove the RNAlater stabilized tissue sample from the reagent using forceps. Weigh the tissue. Do not 
use more than 30 mg. 
 
2. Place the 30 mg tissue directly into a suitably sized vessel for disruption and homogenization. 
 
3. Disrupt the tissue and homogenize the lysate in 600 µl Buffer RLT (do not use more than 30 mg tissue) 
using a TissueLyser. 
 
4. Centrifuge the lysate for 3 min at full speed. Carefully remove the supernatant by pipetting, and transfer it 
to a new microcentrifuge tube (not supplied). Use only this supernatant (lysate) in subsequent steps. 
 
5. Add 1 volume of 70% ethanol to the cleared lysate, and mix immediately by pipetting. Do not centrifuge. 
Proceed immediately to step 6. 
Note: The volume of lysate may be less than 600 μl due to loss during homogenization and centrifugation in 
steps 3 and 4. 
 
6. Transfer up to 700 μl of the sample, including any precipitate that may have formed, to an RNeasy spin 
column placed in a 2 ml collection tube (supplied). Close the lid gently, and centrifuge for 15 s at ≥8000 x g 
(≥10.000 rpm). Discard the flow-through. 
 
7. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge for 15 s at ≥8000 x g 
(≥10.000 rpm) to wash the spin column membrane. Discard the flow-through. 
Note: After centrifugation, carefully remove the RNeasy spin column from the collection tube so that the 
column does not contact the flow-through. Be sure to empty the collection tube completely.  
 
8. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently and centrifuge for 15 s at ≥8000 x g 
(≥10.000 rpm) to wash the spin column membrane. Discard the flow-through. 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to Buffer RPE before use. 
 
9. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently. and centrifuge for 2min at ≥8000 x g 
(≥10.000 rpm) to wash the spin column membrane. 
The long centrifugation dries the spin column membrane ensuring that no ethanol is carried over during RNA 
elution. Residual ethanol may interfere with downstream reactions. Note: After centrifugation, carefully 
remove the RNeasy spin column from the collection tube so that the column does not contact the flow- 
through. Otherwise. carryover of ethanol will occur. 
 
10. Optional: Place the RNeasy spin column in a new 2 ml collection tube (supplied). and discard the old 
collection tube with the flow-through. Close the lid gently, and centrifuge at full speed for 1 min. 
Perform this step to eliminate any possible carryover of Buffer RPE, or if residual 
flow-through remains on the outside of the RNeasy spin column after step 9. 
 
11. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 μl RNase-free water 
directly to the spin column membrane. Close the lid gently, and centrifuge for 1 min at ≥8000 x g (≥10.000 
rpm) to elute the RNA. 
 
12. If the expected RNA yield is >30 μg, repeat step 11 using another 30–50 μl RNasefree water, or using the 
eluate from step 11 (if high RNA concentration is required). Reuse the collection tube from step 11. 
If using the eluate from step 11, the RNA yield will be 15–30% less than that obtained using a second volume of 
RNase-free water, but the final RNA concentration will be higher. 
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APPENDIX Civ: DNeasy Blood and Tissue kit (Qiagen) 
1. Tissue: Cut tissue ≤25 mg of the tissue into small pieces. and place in a 1.5 ml microcentrifuge tube.  
2. Add 200 μl Buffer AL. Mix thoroughly by vortexing and incubate the samples at 56°C for 10 min. 
3. Add 200 μl ethanol (96–100%). Mix thoroughly by vortexing and pipet the mixture into a DNeasy Mini spin 
column placed in a 2 ml collection tube. Centrifuge at ≥ 6000 x g (8000 rpm) for 1 min. Discard the flow-through 
and collection tube. Place the spin column in a new 2 ml collection tube.  
4. Add 500 μl Buffer AW1. Centrifuge for 1 min at ≥6000 x g. Discard the flow-through 
and collection tube. Place the spin column in a new 2 ml collection tube.  
5. Add 500 μl Buffer AW2, and centrifuge for 3 min at 20.000 x g (14.000 rpm). Discard 
the flow-through and collection tube. Transfer the spin column to a new 1.5 ml or 2 ml microcentrifuge tube. 
6. Elute the DNA by adding 200 μl Buffer AE to the centre of the spin column membrane. Incubate for 1 min at 
room temperature (15–25°C). Centrifuge for 1 min at ≥6000 x g. 
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APPENDIX D: GLOBINclear™ Kit (Ambion) 
1. Reagent Preparation 
Add 2 mL of 100% isopropanol to the RNA Binding Buffer Concentrate. Mix well and mark the label to indicate 
that the isopropanol was added. Store at room temperature. This mixture is referred to as RNA Binding Buffer.  
 
Add 4 mL of 100% ethanol to the RNA Wash Solution Concentrate. Mix well and indicate on the label that the 
ethanol was added. Store at room temperature. The resulting mixture is referred to as RNA Wash Solution in 
the instructions. 
 
Dilute the RNA Binding Beads in RNA Bead Buffer, and add isopropanol. In a 1.5 mL tube, combine RNA Bead 
Buffer (10 µl/sample) with RNA Binding Beads and mix briefly. Add the 100% isopropanol and mix thoroughly 
by vortexing. Store at room temperature. This mixture is the Bead Resuspension Mix  
2. Preparation of Streptavidin Magnetic Beads 
Set a dry incubator to 50°C and warm the 2X Hybridization Buffer and the Streptavidin Bead Buffer to 50°C for 
at least 15 min before starting the next procedure. Vortex well before use. 
 
a. Place 30 μL of Streptavidin Magnetic Beads per sample into a 1.5 mL tube  
i. Use 30 μL of Streptavidin Magnetic Beads for each sample; calculate the volume of beads needed for the 
samples being processed that day. When there are more than 2 samples, it is prudent to include 5–10% 
overage to cover pipetting error.  
ii. Vortex the tube of the Streptavidin Magnetic Beads to suspend the settled beads, and transfer the volume 
needed into a 1.5 mL Non-stick Tube  
iii. Briefly centrifuge (<2 sec) at low speed (<1000 x g) to collect the mixture at the bottom of the tube. 
 
b. Magnetically capture the beads and carefully remove and discard the supernatant 
i. Place the tube on a magnetic stand to capture the Streptavidin Magnetic Beads. Leave the tube on the 
magnetic stand until the mixture becomes transparent (~3–5 min). indicating that capture is complete.  
ii. Carefully aspirate the supernatant using a pipet without disturbing the Streptavidin Magnetic Beads. Discard 
the supernatant, and remove the tube from the magnetic stand 
 
c. Equilibrate the beads with an equal volume of Streptavidin Bead Buffer and place at 50°C 
i. Add Streptavidin Bead Buffer to the Streptavidin Magnetic Beads; use a volume equal to the original volume 
of Streptavidin Magnetic Beads. Vortex vigorously until the beads are resuspended.  
ii. Place the prepared Streptavidin Magnetic Beads at 50°C and immediately proceed to the next step. The 
beads should remain at 50°C for at least 15 min before they are used  
 
3. Hybridization of Globin mRNA and Globin Capture Oligonucleotides 
a. Combine 1–10 μg RNA and 1 μL Capture Oligo Mix 
Combine the following in a 1.5 mL Non-stick Tube provided with the kit:  1–10 μg human blood total RNA (in a 
maximum volume of 14 μL. i.e. the RNA concentration must ≥70 ng/μL) and add 1uL of Capture Oligo Mix 
 
b. Add Nuclease-free Water for a final volume of 15 μL 
If necessary, add Nuclease-free Water to the sample mixture from step 1 to a final volume of 15 μL. 
 
c. Add 15 μL 2X Hybridization Buffer 
a. Add 15 μL of 50°C 2X Hybridization Buffer to the sample. 
b. Vortex briefly to mix and centrifuge briefly at low speed to collect the contents in the bottom of the tube. 
 
4. Hybridize at 50°C for 15 min 
Place the sample in a prewarmed 50°C incubator and allow the Globin Capture Oligo Mix to hybridize to the 
globin mRNA for 15 min. 
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5. Removal of Globin mRNA 
a. Add 30 μL prepared Streptavidin Magnetic Beads to each sample 
i. Remove the prepared Steptavidin Magnetic Beads from the 50°C incubator, and resuspend them by gentle 
vortexing. Briefly centrifuge (<2 sec) at low speed (<1000 x g) to collect the mixture at the bottom of the tube. 
ii. Add 30 μL of prepared Streptavidin Magnetic Beads to each RNA sample.  
iii. Vortex to mix well and centrifuge briefly at low speed as in the previous steps to collect the contents in the 
bottom of the tube. 
iv. Flick the tube very gently to resuspend the beads, being careful to keep the contents at the bottom of the 
tube. 
 
b. Incubate 30 min at 50°C Place the RNA bead mixture at 50°C (hybridization oven or other fixed temperature 
air incubator recommended) and incubate for 30 min. 
 
c. Magnetically capture the beads 
i. Remove sample from the incubator, and vortex briefly to mix. Centrifuge briefly at low speed to collect the 
contents in the bottom of the tube. 
ii. Capture the Streptavidin Magnetic Beads on a magnetic stand. Leave the tube on the magnetic stand until 
the mixture becomes transparent (~3–5 min). indicating that capture is complete. 
 
d. Transfer the supernatant containing the RNA to a new tube 
Carefully draw up the supernatant. which contains the globin mRNA depleted RNA, using a pipet without 
disturbing the Streptavidin Magnetic Beads. Transfer the RNA to a new 1.5 mL Non-stick Tube supplied with the 
kit, and place on ice. The supernatant contains the GLOBINclear RNA; do not discard the supernatant. 
 
6. Purify the GLOBINclear RNA 
Warm the Elution Buffer to 58°C.  
a. Add 100 μL RNA Binding Buffer to each sample 
 
b. Add 20 μL Bead Resuspension Mix to each sample; mix for 10 sec 
i. Vortex the Bead Resuspension Mix. then immediately dispense 20 μL to each sample. It is important to 
resuspend the beads thoroughly before adding them to the samples. 
ii. Vigorously vortex the sample for 10 sec to fully mix the reagents, and to allow the RNA Binding Beads to bind 
the RNA.  
iii. Briefly centrifuge (<2 sec) at low speed (<1000 x g) to collect the mixture at the bottom of the tube. 
 
c. Magnetically capture the RNA Binding Beads and discard the supernatant 
i. Capture the RNA Binding Beads by placing the tube on a magnetic stand. Leave the tube on the magnetic 
stand until the mixture becomes transparent (~3–5 min), indicating that capture is complete. 
ii. Carefully aspirate the supernatant using a pipet without disturbing the RNA Binding Beads. Discard the 
supernatant. 
iii. Remove the tube from the magnetic stand. It is critical for effective washing to remove the tube from the 
magnetic stand before adding the RNA Wash Solution 
 
d. Wash the RNA Binding Beads with 200 μL RNA Wash Solution 
i. Add 200 μL RNA Wash Solution to each sample and vortex for 10 sec.  
ii. Briefly centrifuge (<2 sec) at low speed (<1000 x g) to collect the mixture at the bottom of the tube. 
iii. Capture the RNA Binding Beads on a magnetic stand as in the previous magnetic bead capture steps. 
iv. Carefully aspirate and discard the supernatant, and remove the tube from the magnetic stand. 
 
7. Purify the GLOBINclear RNA 
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a. Remove any remaining supernatant and leave the tube open for 5 min 
i. Briefly centrifuge the tube as in previous steps and place it back on the magnetic stand. 
ii. Remove any liquid in the tube with a small-bore pipet tip  
iii. Remove the tube from the magnetic stand and allow the beads to air-dry for 5 min with the caps left open. 
 
b. Add 30 μL Elution Buffer and incubate at 58°C for 5 min to elute the enriched RNA 
i. Add 30 μL warm (58°C) Elution Buffer to each sample, and vortex vigorously for ~10 sec to thoroughly 
resuspend the RNA Binding Beads. 
ii. Incubate the mixture at 58°C for 5 min. 
iii. Vortex the sample vigorously for ~10 sec to thoroughly resuspend the RNA Binding Beads and centrifuge 
briefly at low speed as in previous steps to collect the mixture at the bottom of the tube. 
 
8. Magnetically capture the RNA Binding Beads and transfer the GLOBINclear RNA to a new tube 
a. Capture the RNA Binding Beads on a magnetic stand as in the previous magnetic bead capture steps. Be 
especially careful at this step to avoid disturbing the RNA Binding Beads when collecting the supernatant. The 
purified RNA will be in the supernatant. 
b. Transfer the supernatant containing the RNA to a 1.5 mL Non-stick Tube (supplied). Store the purified RNA at 
–20°C. 
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APPENDIX E: TruSeq Stranded mRNA Preparation Protocol (Illumina) 
Purify and Fragment mRNA 
 Illumina recommends the use of 0.1-4ug RNA 
 Remove the following from the freezer and thaw at room temperature 
 Bead Binding Buffer (BBB) 
 Bead washing Buffer (BWB) 
 Elution buffer (ELB) 
 Fragment, Prime and Finish mix (FPF) 
 Resuspension Buffer (RSB) 
 Remove the RNA purification beads from the fridge and thaw to room temperature 
 Pre-program the PCR machine to the following programmes: 
o 65ºC 5 minutes, 4ºC hold (mRNA degradation) 
o 80ºC 2 minutes, 25ºC hold (mRNA elution 1) 
o 94ºC 8 minutes, 4ºC hold (Elution 2-Frag-Prime) 
 Centrifuge should be at 25ºC 
 Apply RBP barcode to plate 
Make RBP 
1. Dilute RNA in nuclease-free ultra pure water to 50ul in a 96-well plate. Vortex the RNA purification 
beads vigorously to resuspend 
2. Add 50ul RNA purification beads to each well, gently pipette up and down 6 times. Seal plate  
Incubate 1 RBP 
1. Place sealed plate into PCR machine, choose mRNA denaturation. Remove plate when it reached 4ºC 
2. Incubate plate at room temperature for 5 minutes 
Wash RBP 
1. Remove seal from plate. Place on magnetic stand for 5 minutes. Remove and discard all supernatant 
form each well. Remove plate from magnetic stand 
2. Wash beads with 200ul BWB, gently pipette up and down 6 times. Place plate on magnetic stand for 5 
minutes. Centrifuge thawed ELB to 600g for 5 seconds 
3. Remove and discard all supernatant from each well. Remove plate from magnetic stand 
4. Add 50ul ELB to each well, gently pipette up and down 6 times. Seal plate. Store ELB at 4ºC 
Incubate 2 RBP 
1. Place sealed plate in PCR machine, choose mRNA Elution 1. Remove plate when reached 25ºC 
2. Incubate at room temperature for 5 minutes. Remove seal 
Make RFP 
1. Centrifuge thawed BBB to 600g for 5 seconds. Add 50ul BBB to each well, gently pipette up and down 
6 times. Incubate at room temperature for 5 minutes, store BBB in the fridge 
2. Place plate on magnetic stand for 5 minutes. Remove and discard all the supernatant. Remove plate 
from magnetic stand 
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3. Wash beads with 200ul BWB, gently pipette up and down 6 times. Store BWB in the fridge. Place plate 
on magnetic stand for 5 minutes 
4. Remove and discard supernatant. Remove plate from magnetic stand. Add 19,5ul FPF, gently pipette 
up and down 6 times 
5. Seal plate, store FPF in feezer 
Incubate RFP 
1. Place plate in PR machine and choose Elution 2-Frag-Prime. Remove plate when reached 4ºC 
2. Proceed immediately to next step 
Synthesize First strand cDNA 
 Remove First Strand Synthesis Act D Mix (FSA) from freezer and thaw at room temperature 
 Programme PCR machine to the following: 
 Synthesize 1st Strand 
o Pre-heat lid to 100ºC 
o 25ºC for 10 minutes 
o 42ºC for 15 minutes 
o 70ºC for 15 minutes 
o Hold for 4ºC 
 Apply CDP barcode to new plate 
Make CDP 
1. Remove seal from RBP plate. Place plate on magnetic stand fro 5 minutes 
2. Transfer 17ul of supernatant from each well of plate to a new (CDP plate) . Centrifuge the FSA to 600g 
for 5 seconds 
3. Add 50ul SuperScript II to the FSA tube (otherwise add SuperScript II in a ratio of 1ul for each 9ul FSA) 
centrifuge briefly. Add 8ul of the mix to each well, gently pipette up and down 6 times 
4. Seal plate, centrifuge briefly. Store mix in the freezer 
Incubate 1 CDP 
1. Place plate in PCR, choose Synthesize 1st Strand. When plate reached 4ºC remove and proceed 
immediately to next step 
Synthesize Second Strand cDNA 
 Thaw these reagents at room temperature: End Pair Control (CTE) and Second Strand Marking Master 
Mix (SMM). Resuspention Buffer (RSB) from the fridge. AMPure XP beads from fridge  
 Pre-heat PCR machine to 16ºC 
 Choose the pre-heat lid to 30ºC 
 Apply ALP barcode to new PCR plate  
Add SMM 
1. Remove seal from CDP plate. Add 5ul RSB to each well. Centrifuge SMM to 600g for 5 seconds 
2. Add 20ul SMM, gently pipette up and down 6 times. Seal plate, return SMM to freezer 
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Incubate 2 CDP 
1. Place plate in PCR machine, incubate at 16ºC for 1 hour. Remove plate and place on bench, remove 
seal and bring plate to room temperature 
Purify CDP 
1. Vortex AMPure XP beads. Add 40ul AMPure XP beads, gently pipette up and down 10 times 
2. Incubate at room temperature for 15 minutes. Place plate on magnetic stand for 5 minutes 
3. Remove and discard 135ul supernatant 
4. Add 200ul 80% EtOH without disturbing beads. Incubate for 30 seconds and remove and discard 
supernatant. Repeat for a total of two ethanol washes 
5. Let the plate dry at room temperature for 15 minutes, remove plate from magnetic stand 
6. Centrifuge RSB to 600g for 5 seconds. Add 17,5ul RSB, gently pipette up and down 10 times 
7. Incubate plate at room temperature for 2 minutes. Place plate of magnetic stand for 5 minutes 
8. Transfer 15ul supernatant (ds cDNA) from the plate to new plate labeled ALP 
 
· SAFE STOPPING POINT : Store ALP plate at -15ºC to -25ºC for up to 7 days 
Adenylate 3’ ends 
 Remove the following and thaw at room temperature: 
o A-tailing control (CTA) 
o A-tailing mix (ATL) 
o Resuspension Buffer (RSB) from fridge 
o ALP plate, centrifuge once thawed 
 Programme PCR machine as ATAIL70: 
o  Pre-heat lid to 100ºC 
o 37ºC for 30 minutes 
o 70ºC for 5 minutes 
o Hold for 4ºC 
Add ATL 
1. Add 2.5ul RSB. Add 12.5ul ATL, gently pipette up and down 10 times. Seal the plate 
Incubate 1 ALP 
1. Place plate in PCR machine, choose ATAIL70.  When reached 4ºC remove plate and proceed 
immediately to next step 
Ligate Adapters 
 Remove the following and thaw at room temperature: 
o Appropriate RNA adapter tubes (adapter indices being used) 
o Stop Ligation Buffer (STL) 
o Ligation control (CTL) 
o Resuspension Buffer (RSB) 
o AMPure XP beads 
 Preheat PCR machine to 30ºC with preheat lid option to 100ºC 
 Apply CAP barcode to new plate 
 Apply PCR barcode to new plate 
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Add LIG 
1. Centrifuge RNA adapter tubes at 600g for 5 seconds. Centrifuge STL at 600g for 5 seconds 
2. Immediately before use remove Ligation Mix (LIG) from freezer. Remove seal from ALP plate 
3. Add 2.5ul RSB to each well. Add 2.5ul LIG to each well, return to freezer immediately. Add 2.5ul of 
RNA adapter index to each well, gently pipette up and down 10 times 
4. Seal the plate. Centrifuge ALP plate at 280g for 1 minute 
Incubate 2 ALP 
1. Place sealed ALP plate in PCR machine and incubate at 30ºC for 10 minutes. Remove plate from PCR 
machine 
Add STL 
1. Remove seal. Add 5ul STL to each well, seal plate 
2. Place on shaker for 2 minutes at 1800rpm. Centrifuge ALP plate at 280g for 1 minute 
Clean up ALP 
1. Vortex AMPure XP beads, remove seal from plate. Add 42ul AMPure XP beads, place on shaker for 2 
minutes at 1800rpm. Centrifuge ALP plate at 280g for 1 minute 
2. Incubate at room temperature for 15 minutes. Place ALP plate on magnetic stand for 5 minutes 
3. Remove and discard 79.5ul supernatant. Add 200ul 80% EtOH without disturbing the beads 
4. Incubate at room temperature for 30 seconds and remove the supernatant. Repeat for a total of two 
ethanol washes 
5. Let plate air dry for 15 minutes 
6. Remove the ALP plate from the magnetic stand. Add 52.5ul RSB, place on shaker for 2 minutes at 
1800rpm. Incubate at room temperature for 2 minutes 
7. Centrifuge ALP plate at 280g for 1 minute. Place plate on magnetic stand for 5 minutes 
8. Transfer 50ul of supernatant from ALP plate to CAP plate 
9. Vortex AMPure XP beads. Add 50ul AMPure XP beads to CAP plate. Incubate CAP plate for 15 
minutes. Centrifuge ALP plate at 280g for 1 minute 
10. Place CAP plate on magnetic stand for 5 minutes. Remove and discard the 95ul supernatant form the 
CAP plate. Add 200ul 80% EtOH, do not disturb the beads 
11. Incubate at room temperature for 30 seconds. Repeat for a total of two ethanol washes 
12. Let plate air dry for 15 minutes, remove plate from magnetic stand 
13. Add 22.5ul RSB. Incubate at room temperature for 2 minutes. Centrifuge ALP plate at 280g for 1 
minute. Place plate on magnetic stand for 5 minutes 
14. Transfer 20ul supernatant to PCR plate 
 
· SAFE STOPPING POINT : PCR plate can be stored at -15ºC to -25ºC for up to 7 days 
Enrich DNA Fragments 
 Remove and thaw at room temperature: 
o PCR Master Mix (PMM) and PCR Primer Cocktail (PPC) 
o Resuspension Buffer (RSB) 
o AMPure XP beads 
o Remove PCR plate if stored (centrifuge and remove seal) 
 Programme PCR machine store as PCR: 
o Preheat lid to 100ºC 
o 98ºC for 30 seconds 
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o 98ºC for 10 seconds 
o 60ºC for 30 seconds   15 cycles 
o 72ºC for 30 seconds 
o 72ºC for 5 minutes 
o 4ºC for hold 
 Apply TSP1 barcode to plate 
Make PCR 
1. Add 5ul PPC and 25ul PMM to each well, place on shaker for 2 minutes at 1800rpm. centrifuge PCR 
plate at 280g for 1 minute 
Amp PCR 
1. Place plate in PCR machine, choose PCR 
2. Vortex AMPure XP beads. Add 50ul AMPure XP beads to each well of the plate containing the library, 
place on shaker for 2 minutes at 1800rpm 
3. Incubate plate at room temperature for 15 minutes, centrifuge PCR plate at 280g for 1 minute 
4. Place plate on magnetic stand for 5 minutes. Remove and discard the 95ul supernatant 
5. Add 200ul 80% EtOH without disturbing beads. Incubate at room temperature for 30 seconds, remove 
and discard supernatant 
6. Repeat for a total of two ethanol washes and let the plate air dry for 15 minutes 
7. Add 32.5ul RSB, place on shaker for 2 minutes at 1800rpm. Incubate plate at room temperature for 2 
minutes. centrifuge PCR plate at 280g for 1 minute. Place plate on magnetic stand 
8. Transfer 30ul supernatant to TSP1 plate 
 
· SAFE STOPPING POINT : TSP1 plate can be stored at -15ºC to -25ºC for up to 7 days 
Validate Library 
 Illumina recommend quantifying the libraries using qPCR and to check quality using the Bioanalyser 
Normalise and Pool Libraries 
 Remove the TSP1 plate to thaw at room temperature and centrifuge 
 Apply DCT barcode to plate. apply PDP barcode to plate 
Make DCT 
1. Transfer 10ul sample from TSP1 plate to DCT plate 
2. Normalise concentration of each sample to 10nM using Tris-HCl 10mM, pH 8.5 with 0.1% Tween 20 
3. Gently pipette up and down 10 times 
4. For non-pooled libraries the protocol stops here. for pooled libraries proceed to next step 
Make PDP (Pooling only) 
1. Determine number of samples to be combined 
2. If pooling 2-24 samples: 
a. Transfer 10ul of normalized samples into PDP plate 
b. The volume in each well is 10x the number of sample there in (20-240ul) 
3. If pooling 25-96 samples: 
a. Transfer 5ul of normalized sample into PDP plate 
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b. Repeat for the number of samples 
4. Gently pipette up and down 10 times 
5. Proceed to cluster generation 
6. Seal the PDP plate 
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APPENDIX F: TaqMan Gene Expression Assays 
 
A. Prepare the cDNA sample with the High Capacity RNA to cDNA kit (Applied Biosystems) 
1. Use 250ng of total RNA 
2. Allow the kit components to thaw on ice 
3. Prepare a +RT and –RT reaction following the table below 
 
Component +RT reaction (ul) -RT reaction (ul) 
RNA sample Up to 9 Up to 9 
2x RT Buffer 10 10 
2x Enzyme mix 1  
Nuclease-free ddH20 Up to 20 Up to 20 
Total/reaction 20 20 
 
4. Aliquot reaction mix into a plate or tubes and seal properly 
5. Centrifuge briefly and put on ice 
6. Incubate at 37°C for 60 minutes; 95°C for 5 minutes; 4°C hold 
 
B. Setting up the Real-time PCR assay 
1. Thaw the reagents on ice (20X gene expression assay and cDNA samples (if frozen)) 
2. Mix the reagents by vortexing gently for a few seconds and centrifuge briefly 
3. Calculate the number of reaction to prepare (run each sample in triplicate; NTC and Housekeeping 
genes) 
4. For each sample, pipette the following into a 1.5ml Eppendorf tube 
 
 Volume per 20ul reaction (ul) 
PCR reaction mix component Single reaction Master mix (per 
assay)(80x) 
20X Taqman Gene Expression Assay 1 80 
2x Taqman GeneEx master mix 10 800 
cDNA (1 – 100ng) 1 80 
RNAse-free water 8 640 
 
5. Mix the master mix well by inverting and centrifuging briefly 
6. Add 1ul of cDNA to the 384 well plate followed by 19ul of the master mix (plate layout below) 
7. Seal the plate with an adhesive plate cover and centrifuge briefly 
8. Load the plate onto the real time instrument 
 
C. 384 Plate layout 
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D. Run the real-time PCR reaction on the 7900HT machine (Applied Biosystems) – FAST reaction 
 
Stage Temp (°C) Time (mm:ss) 
Hold 50 2:00 
Hold 95 0:20 
Cycle (40X) 95 
60 
0:01 
0:20 
 
E.  Analyze the results 
1. View the amplification plots for the entire plate 
2. Omit any failures or CT values within the triplicates that differ by more than 0.5 in value 
3. Export the data and calculate the relative quantification of the samples relative to the controls 
and normalized to three housekeeping genes. 
 
 
Gene name ThermoFisher Assay number Gene name ThermoFisher Assay number 
ALDOA Hs00605198_g1 CXCR1 Hs01921207_s1 
G6PD Hs0016169_m1 CXCR2 Hs01891184_s1 
DCXR Hs00212433_m1 IGFBP-1 Hs00236877_m1 
PGLS Hs00359986_m1 IGFBP-2 Hs01040719_m1 
TKT Hs01115545_m1 IGFBP-6 Hs00181853_m1 
C14ORF80 Hs00415039_m1 MMP12 Hs00159178_m1 
AKT2 Hs01086099_m1 GLT1D1 Hs01087581_m1 
GSK3A Hs00997938_m1 GGT3P Hs02387913_g1 
KCNQ1 Hs00923522_m1 RPLPO Hs00420895_gH 
SLC25A22 Hs00368705_m1 ACTB Hs01060665_g1 
HPRT1 Hs02800695_m1   
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APPENDIX G: EpiTech Methyl_II assay set up  
 
 
Procedure  
A. Restriction digestion  
 Perform the restriction digestions using the EpiTect Methyl II DNA Restriction Kit (cat. no. 335452).   
 Prepare a reaction mix without enzymes as indicated in Table 1 using 250 ng genomic DNA. 5x 
Restriction Digestion Buffer should be thawed and vortexed well before use 
Table 1. Reaction mix without enzymes 
Component Volume (μl) 
Genomic DNA (250ng) 3 
5x Restriction Digestion Buffer 26 
RNAse-free water 90 
Final volume 120 
  
 Add RNase-/DNase-free water to make the final volume 120 μl. Vortex to thoroughly mix the 
components and centrifuge briefly in a microcentrifuge.  
 Set up 4 digestion reactions (Mo, Ms, Md, and Msd) according to Table 2.  
IMPORTANT: All 4 tubes must contain equal amounts of genomic DNA.  
Table 2. Restriction digestion  
 
 
 
 
 
 Pipet up and down to gently, but thoroughly mix the components. Centrifuge the tubes briefly in a 
microcentrifuge.   
 Incubate all 4 tubes at 37°C for 6 h in a heating block or thermal cycler. The reaction can also be 
performed overnight.   
 After incubation, stop the reactions by heat-inactivating the enzymes at 65°C for 20 min.   
 Mix the samples thoroughly by vortexing before use. Centrifuge the samples briefly and proceed to step 
1 of “Setting up the PCR”.   
 
B. Setting up the PCR  
 Prepare individual reactions for each of the 4 digestions (Mo, Ms, Md, and Msd) in a 1.5 ml tube Table 
3. Repeat for each gene.  
Component Mo (μl) Ms (μl) Md (μl) Msd (μl) 
Reaction mix from step 3 28 28 28 28 
Methylation-sensitive enzyme A --- 1 --- 1 
Methylation-dependent enzyme B --- --- 1 1 
RNAse-free water 2 1 1 --- 
Final volume 30 30 30 30 
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Table 3: Setting up the PCR reaction 
 
 
 
 
 
 
 
 
 
 
 Mix tubes well by vortexing, and briefly centrifuge the contents to the bottom of the tube.  
 Add 25 μl of each reaction to the EpiTect Methyl II PCR Assay 384-well plate, as shown in Table 4.  
Table 4. Assay setup (384 well plate)  
 
 Seal or cap the wells of the plate. Centrifuge the plate for 1 min at 2000 rpm to remove any air bubbles.  
 
C. Running the PCR  
 Program the thermal cycler according to the manufacturer’s instructions, using the conditions outlined 
in Table 5. 
 
 
  
Component Mo (μl) Ms (μl) Md (μl) Msd (μl) 
PCR Master mix 5 5 5 5 
PCR primer mix 0.4 0.4 0.4 0.4 
Mo digest 2 --- --- --- 
Ms digest --- 2 --- --- 
Md digest --- --- 2 --- 
Msd digest --- --- --- 2 
RNAse-free water 2.6 2.6 2.6 2.6 
Final volume 10 10 10 10 
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Table 5: PCR cycling conditions  
Temperature (°C) Time (mm:ss) Number of cycles 
95 10:00 1 
99 
72 
00:30 
1:00 
3 
97 
72 
00:15 
1:00 
40 
Note: It is critical that the cycling conditions are followed exactly.  
 
D. Data analysis 
 Obtaining raw threshold cycle (CT) values  
After the cycling program has completed, obtain the CT values according to the instructions provided by the 
manufacturer of the real-time PCR instrument. We recommend manually setting the baseline and threshold 
values as follows.  
Baseline: Using the Linear View of the amplification plots, set the instrument to use the readings from cycle 
number 2 through the cycle just before the earliest visible amplification, usually between cycle 10 and 15.  
Threshold value: Using the Log View of the amplification plots, place the threshold above the background signal 
but within the lower third of the linear portion of the amplification curves.  
 Exporting CT values  
Export and/or copy/paste the CT values from the instrument software to a blank Microsoft Excel spreadsheet 
according the manufacturer’s instructions for the real-time PCR instrument.  
 Microsoft Excel based data analysis template  
Download the EpiTect Methyl II PCR Array Microsoft Excel based data analysis template, which is available at: 
www.sabiosciences.com/dna_methylation_data_analysis.php.  
Then, paste in the CT value data and analyze the automatically generated results by following the directions in 
the “Instructions” worksheet of the Excel file.  
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APPENDIX J: Resulting CT values from the Epitech Methyl II assay 
 
G6PD     TKT     
Blood 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Blood 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Case0 23.0292 24.0433 23.6153 33.5897 Case0 20.3782 25.0739 32.3435 35.1324 
Case1 22.1956 22.7787 22.5777 28.1372 Case1 19.2912 19.7321 22.1520 26.3178 
Case2 22.0966 22.4972 22.2787 28.3853 Case2 20.7312 22.7641 22.9049 25.7820 
Case3 22.4648 24.9069 24.4452 29.1643 Case3 19.9659 20.8063 21.9747 27.7124 
Case4 22.3247 33.3210 30.3704 35.0754 Case4 26.0000 38.0527 39.0826 38.4202 
Case5 23.6415 33.1804 32.9852 33.2952 Case5 26.1251 30.0000 38.4896 36.4781 
Control0 24.5362 33.3344 33.2832 34.3898 Control0 22.0145 35.0278 36.8130 38.2508 
Control1 22.9918 23.9057 23.3242 33.7548 Control1 17.5101 20.8728 22.0315 28.3264 
Control2 21.2924 23.5596 22.4729 25.6220 Control2 19.5590 21.0923 21.3141 29.4049 
Control3 21.8398 22.9625 22.1087 32.7061 Control3 19.3429 25.3278 26.8379 30.9245 
Control4 22.5291 35.2029 23.6402 35.5347 Control4 25.3424 31.0710 32.0930 34.8152 
Control5 22.2884 23.1966 22.4044 26.8826 Control5 19.4256 36.7978 37.5080 37.6495 
Placenta 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Placenta 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Case0 23.5185 30.3824 24.1697 33.8130 Case0 20.8103 26.8868 33.6914 34.9676 
Case1 22.7333 28.5713 23.1625 34.2896 Case1 21.7623 22.1052 23.1132 28.3534 
Case2 23.4623 24.9882 23.7616 29.5098 Case2 20.6610 26.5400 27.6126 28.8633 
Case3 22.4648 24.9069 24.4452 29.1643 Case3 22.2972 22.4398 23.1741 32.2610 
Case4 22.9744 23.6745 23.6765 33.7332 Case4 31.6102 34.6159 35.2930 38.7815 
Case5 22.4099 34.9445 34.2646 35.7005 Case5 26.9592 38.8447 39.0826 36.6354 
Control0 22.7333 28.5713 23.1625 34.2896 Control0 26.0184 34.2158 38.3675 36.7664 
Control1 22.7333 28.5713 23.1625 34.2896 Control1 20.0548 24.7201 25.1752 30.7946 
Control2 21.8445 28.7692 22.3988 34.1821 Control2 19.3336 19.8478 20.0709 27.3041 
Control3 23.1127 31.0337 23.7487 34.3981 Control3 19.8822 25.8907 29.7100 34.4500 
Control4 21.8367 31.2883 24.8550 34.2102 Control4 19.8598 25.2609 27.0382 36.5826 
Control5 23.5841 33.5329 33.3436 33.5988 Control5 18.2360 35.0639 36.2930 39.5400 
IGFBP-1     IGFBP-2     
Blood 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Blood 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Case0 20.6417 23.9191 25.6689 27.6247 Case0 26.7041 28.2084 31.0649 31.8627 
Case1 19.7566 23.0952 26.2773 32.2685 Case1 19.7770 20.1458 21.3701 25.9992 
Case2 19.7675 23.7134 25.3738 26.2900 Case2 18.5543 19.5624 20.4262 27.6179 
Case3 20.2615 23.8999 27.3709 29.8063 Case3 20.4370 20.5647 21.1352 28.1358 
Case4 17.9697 25.5424 27.2431 28.9455 Case4 27.8283 28.0829 28.2460 29.3471 
Case5 19.5513 29.7438 30.7026 31.4737 Case5 27.4314 28.1975 28.8338 28.7243 
Control0 24.2778 26.7620 29.5070 37.1891 Control0 21.6200 28.5066 28.8265 28.8388 
Control1 21.2226 24.2624 25.5230 27.4402 Control1 23.1669 27.4318 27.8651 32.1460 
Control2 19.1912 22.3788 24.9256 26.1503 Control2 19.6661 20.4275 21.1349 27.7121 
Control3 19.6499 22.6375 26.0441 29.2666 Control3 19.3867 27.7932 27.9959 29.5384 
Control4 20.7377 26.6046 28.9234 28.9913 Control4 27.6373 28.5171 28.5687 29.4155 
Control5 20.4633 25.1450 28.2292 28.4545 Control5 19.4914 27.5329 27.8754 29.7569 
Placenta 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Placenta 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
Case0 19.9844 21.4869 21.8496 27.7701 Case0 21.5004 21.9148 21.9764 27.9325 
Case1 21.3511 22.6944 24.3268 24.5046 Case1 20.7277 20.9449 21.7231 26.8116 
Case2 20.2566 22.5040 22.6131 23.6095 Case2 20.7465 22.1768 22.2566 28.6351 
Case3 21.6278 23.5710 25.6661 29.0029 Case3 26.9010 27.9419 28.2689 30.5213 
Case4 22.5923 25.2584 25.5377 29.9465 Case4 27.4668 28.8268 28.9425 30.0289 
Case5 20.5979 22.5487 24.0191 28.7715 Case5 19.8941 27.6681 27.6911 29.2139 
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Control0 24.0458 24.5533 29.4086 30.2717 Control0 26.0763 27.4079 27.8693 28.4594 
Control1 17.5101 20.8728 22.0315 28.3264 Control1 20.0545 20.5441 20.8426 27.3665 
Control2 19.8316 21.3249 22.1925 23.2579 Control2 20.5209 27.1854 27.5687 29.2093 
Control3 19.9947 21.4134 22.8886 28.6740 Control3 20.7044 28.2878 28.4094 29.2762 
Control4 21.6587 22.2174 24.2676 28.2867 Control4 21.0751 28.1524 28.7982 29.3413 
Control5 19.1415 22.9440 28.3721 33.2693 Control5 20.7044 28.2878 28.4094 29.2762 
IGFBP-6           
Blood 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
      
Case0 20.3782 25.0739 32.3435 35.1324       
Case1 19.2912 19.7321 22.1520 26.3178       
Case2 20.7312 22.7641 22.9049 25.7820       
Case3 19.9659 20.8063 21.9747 27.7124       
Case4 26.0000 38.0527 39.0826 38.4202       
Case5 26.1251 29.0000 35.4896 36.4781       
Control0 22.0145 35.0278 36.8130 38.2508       
Control1 17.5101 20.8728 22.0315 28.3264       
Control2 19.5590 21.0923 21.3141 29.4049       
Control3 19.3429 25.3278 26.8379 30.9245       
Control4 25.3424 31.0710 32.0930 34.8152       
Control5 19.4256 36.7978 37.5080 37.6495       
Placenta 
samples 
Ct 
mock 
Ct dependent Ct sensitive Ct double 
      
Case0 20.8103 26.8868 33.6914 34.9676       
Case1 21.7623 22.1052 23.1132 28.3534       
Case2 20.6610 26.5400 27.6126 28.8633       
Case3 22.2972 22.4398 23.1741 32.2610       
Case4 26.6102 30.6159 31.2930 36.7815       
Case5 26.9592 35.8447 35.0826 36.6354       
Control0 32.0184 34.2158 38.3675 39.7664       
Control1 20.0548 24.7201 25.1752 30.7946       
Control2 19.3336 19.8478 20.0709 27.3041       
Control3 19.8822 25.8907 29.7100 34.4500       
Control4 19.8598 25.2609 27.0382 36.5826       
Control5 18.2360 35.0639 36.2930 39.5400       
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APPENDIX K: Review article published in the journal of Epigenomics titled “Epigenetics and 
the burden of noncommunicable disease: a paucity for research in Africa” 
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